Updated on 2026/03/05

All information, except for affiliations, is reprinted from the information registered on researchmap.

写真a

 
Shin Fujisawa
 
Organization
YCU Medical Center Hematology Associate Professor
Title
Associate Professor
Homepage
http://www.yokohama-cu.ac.jp/urahp/section/blood/index.html
Profile
＜経歴＞1988年 東京医科大学 卒業
2003年5月～ 横浜市立大学附属市民総合医療センター 血液内科部長・准教授
＜研究分野＞血液造血器腫瘍に対する化学療法・造血幹細胞移植療法
＜資格＞医学博士
内科学会認定内科医・指導医
日本血液学会認定専門医・指導医・代議員
日本造血細胞移植学会認定医・評議員
日本臨床腫瘍学会暫定指導医
日本輸血細胞治療学会認定医
External link

Degree

  • 博士（医学）

Research Interests

  • 血液腫瘍学

Research Areas

  • Life Science / Hematology and medical oncology

Papers

  • Survival impact of response within the first year in a multicenter prospective observational study of chronic GVHD in a Japanese cohort.

    Chikako Ohwada, Emiko Sakaida, Yusuke Takeda, Noriko Doki, Aiko Igarashi, Makoto Onizuka, Masako Toyosaki, Masatsugu Tanaka, Takayoshi Tachibana, Keisuke Kataoka, Jun Kato, Shin Fujisawa, Seiko Kato, Hideki Nakasone, Ken Naganuma, Takayuki Saitoh, Katsuhiro Shono, Maki Hagihara, Takeshi Saito, Kensuke Usuki, Takehiko Mori, Chiaki Nakaseko, Shinichiro Okamoto, Yoshinobu Kanda

    International journal of hematology   120 ( 3 )   347 - 355   2024.9

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    A prospective multicenter observational study of organ response was conducted in patients with chronic GVHD diagnosed by the NIH criteria. When response was assessed at 12 months (12 M) in 118 patients, 74.6% were classified as responders and 25.4% as non-responders. The skin and oral cavity were the most frequent organs used as the basis for determining overall response. The lungs, liver, and eyes were also used in 20% of patients. Non-response decisions at 12 M were most frequent in the lungs. A significantly higher percentage of responders than non-responders completed systemic treatment (24.3% vs. 3.3%, P = 0.02). Global scoring showed significant changes, with improvement in responders and worsening in non-responders throughout the observation period. Two-year transplant-related mortality, using the 12 M assessment as the landmark, was significantly worse in non-responders (28.5% vs. 2,7%, P = 0.0001), while the 2-year recurrence rate was equivalent (5.4% vs. 4.8%, P = 0.78). Consequently, the 2-year overall survival rate from the 12 M assessment was significantly better in responders than non-responders (95% vs. 65.3%, P = 0.0001). Our data suggests that patients who do not achieve a response within the first year should be candidates for clinical studies on chronic GVHD.

    DOI： 10.1007/s12185-024-03813-0

    PubMed

    researchmap

  • Utility of allogeneic stem cell transplantation for adult Ph+ALL with complete molecular remission. International journal

    Satoshi Nishiwaki, Isamu Sugiura, Shin Fujisawa, Yoshihiro Hatta, Yoshiko Atsuta, Noriko Doki, Shingo Kurahashi, Yasunori Ueda, Nobuaki Dobashi, Tomoya Maeda, Itaru Matsumura, Masatsugu Tanaka, Shinichi Kako, Tatsuo Ichinohe, Takahiro Fukuda, Shigeki Ohtake, Yuichi Ishikawa, Yasushi Miyazaki, Hitoshi Kiyoi

    American journal of hematology   99 ( 5 )   806 - 815   2024.5

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    This study aimed to investigate the usefulness of allogeneic stem cell transplantation (allo-SCT) for Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) in the first complete remission (CR1) with complete molecular remission (CMR). We compared the outcomes between Ph+ALL patients who did or did not undergo allo-SCT in CR1. We included patients enrolled in the prospective clinical studies in the tyrosine kinase inhibitor era conducted by the Japan Adult Leukemia Study Group, who achieved CMR within 3 months. A total of 147 patients (allo-SCT: 101; non-SCT: 46) were eligible for this analysis. In the multivariate analyses, allo-SCT was significantly associated with both superior overall survival (OS) (adjusted hazard ratio (aHR): 0.54; 95% CI: 0.30-0.97; p = .04) and relapse-free survival (RFS) (aHR: 0.21; 95% CI: 0.12-0.38; p < .001). The 5-year adjusted OS and RFS were 73% and 70% in the allo-SCT cohort, whereas they were 50% and 20% in the non-SCT cohort. Despite the higher non-relapse mortality (aHR: 3.49; 95% CI: 1.17-10.4; p = .03), allo-SCT was significantly associated with a lower relapse rate (aHR: 0.10; 95% CI: 0.05-0.20; p < .001). In addition, allo-SCT was also associated with superior graft-versus-host disease-free, relapse-free survival (aHR: 0.43; 95% CI: 0.25-0.74; p = .002). Propensity score-matched analyses confirmed the results of the multivariate analyses. In patients who achieved CMR within 3 months, allo-SCT in CR1 had superior survival and lower relapse compared with the non-SCT cohort.

    DOI： 10.1002/ajh.27237

    PubMed

    researchmap

  • Investigation of biomarkers to predict outcomes in allogeneic hematopoietic stem cell transplantation. International journal

    Takayoshi Tachibana, Takuya Miyazaki, Ayako Matsumura, Maki Hagihara, Masatsugu Tanaka, Satoshi Koyama, Eriko Ogusa, Jun Aoki, Yuki Nakajima, Hiroyuki Takahashi, Taisei Suzuki, Yoshimi Ishii, Haruka Teshigawara, Kenji Matsumoto, Mayumi Hatayama, Akihiko Izumi, Katsuya Ikuta, Koji Yamamoto, Heiwa Kanamori, Shin Fujisawa, Hideaki Nakajima

    Cytotherapy   2024.3

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    BACKGROUND: Various biomarkers have been developed and evaluated to predict the prognosis and complications of allogeneic hematopoietic cell transplantation (HCT). Most previous studies conducted on different biomarkers evaluated single effects such as those associated with inflammation, immunology, iron metabolism, and nutrition, and only a few studies have comprehensively analyzed markers. OBJECTIVE: The study aimed to survey comprehensive multiple markers prior to HCT and extract those that significantly predict the outcomes. STUDY DESIGN: A prospective multicenter observational study was performed. (UMIN000013506) Patients undergoing HCT for hematologic diseases were consecutively enrolled. Besides the usual clinical biomarkers, serum samples for extra-clinical biomarkers were collected and cryopreserved before starting the conditioning regimen. A total of 32 candidate biomarkers were selected, 23 from hematology, biochemistry, immunology, nutrition, and iron metabolism, and 9 from composite markers. Based on the area under the curve (AUC) values for survival, promising biomarkers was extracted. Internal validation for these markers was applied based on bootstrap methods. Setting the cut-off values for them, log-rank test was applied and outcomes including overall survival (OS), relapse, and non-relapse mortality (NRM) were evaluated using multivariate analyses. Furthermore, detailed analysis including transplant-related complications and external validation were conducted focusing on C-reactive protein (CRP) to platelet (Plt) ratio. RESULTS: A total of 152 patients with hematologic malignancies were enrolled from April 2014 to March 2017. CRP, soluble interleukin-2 receptor (IL2R), CRP to albumin (Alb) ratio, CRP to Plt ratio, Plt to IL2R ratio, and IL2R to Alb ratio were identified as promising markers. Internal validation successfully confirmed their reliability of AUC and multivariate analysis demonstrated the statistical significance between the higher and the lower markers. Above all, a higher CRP to Plt ratio was significantly associated with a lower OS (hazard ratio [HR] 2.77; 95% confidence interval [CI] 1.30-5.91; P = 0.008) and higher non-relapse mortality rates (HR 2.79; 95%CI 1.14-6.80; P = 0.024) at 180 days. Furthermore, univariate analysis showed that a higher CRP to Plt ratio was significantly associated with a higher incidence of sinusoidal obstructive syndrome (P < 0.001) and bloodstream infection (P = 0.027). An external validation test confirmed the significance of the CRP to Plt ratio for these outcomes. CONCLUSION: The multicenter prospective observational study successfully identified significant biomarkers in patients with hematologic malignancies who received HCT. In particular, CRP to Plt ratio was identified as a novel and useful biomarker for predicting transplant outcomes. Further investigations are needed to validate the novel markers, analysis of the pathophysiology, and application to treatment settings other than HCT.

    DOI： 10.1016/j.jcyt.2024.03.490

    PubMed

    researchmap

  • Comparison of standardized prophylactic high-dose and intrathecal methotrexate for DLBCL with a high risk of CNS relapse

    Masahiro Akimoto, Takuya Miyazaki, Hiroyuki Takahashi, Yusuke Saigusa, Takaaki Takeda, Yuto Hibino, Mayumi Tokunaga, Takuma Ohashi, Ayako Matsumura, Haruka Teshigawara, Taisei Suzuki, Hiroshi Teranaka, Yuki Nakajima, Kenji Matsumoto, Chizuko Hashimoto, Katsumichi Fujimaki, Hiroyuki Fujita, Rika Sakai, Shin Fujisawa, Hideaki Nakajima

    International Journal of Hematology   119 ( 2 )   164 - 172   2024.1

    　More details

    Publishing type：Research paper (scientific journal)   Publisher：Springer Science and Business Media LLC  

    DOI： 10.1007/s12185-023-03700-0

    researchmap

    Other Link： https://link.springer.com/article/10.1007/s12185-023-03700-0/fulltext.html

  • Clinical significance of total nucleated cell count in bone marrow of patients with acute lymphoblastic leukemia who underwent allogeneic hematopoietic stem cell transplantation.

    Jun Nukui, Takayoshi Tachibana, Takuya Miyazaki, Masatsugu Tanaka, Kenji Matsumoto, Yoshimi Ishii, Ayumi Numata, Yuki Nakajima, Ayako Matsumura, Taisei Suzuki, Akihiko Izumi, Natsuki Hirose, Koji Yamamoto, Maki Hagihara, Shin Fujisawa, Heiwa Kanamori, Hideaki Nakajima

    International journal of hematology   119 ( 1 )   62 - 70   2024.1

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    The clinical implications of recipient bone marrow nucleated cell count (NCC) prior to allogeneic hematopoietic stem cell transplantation (allo-HSCT) remain unknown. We conducted a multicenter retrospective study to evaluate the clinical significance of bone marrow NCC prior to allo-HSCT in patients with acute lymphoblastic leukemia. Patients who were in remission and underwent the initial allo-HSCT were included and stratified into high- and low-NCC groups using an NCC of 10 × 104/µL as the cut-off. The 3-year overall survival (OS), non-relapse mortality (NRM), and relapse rates for the high- and low-NCC groups were 51.2 vs. 84.5% (p < 0.001), 27.5 vs. 6.5% (p < 0.001), and 31.1 vs. 24.4% (p = 0.322), respectively. The high-NCC group had significantly poorer OS and higher NRM when compared with the low-NCC group. In summary, high recipient bone marrow NCC is associated with higher NRM and lower OS following allo-HSCT.

    DOI： 10.1007/s12185-023-03688-7

    PubMed

    researchmap

  • Clinical significance of late CMV disease in adult patients who underwent allogeneic stem cell transplant. International journal

    Hiroaki Shimizu, Yuho Najima, Shinichi Kako, Masatsugu Tanaka, Shin-Ichiro Fujiwara, Takehiko Mori, Kensuke Usuki, Moritaka Gotoh, Maki Hagihara, Nobuhiro Tsukada, Makoto Oniduka, Satoru Takada, Emiko Sakaida, Shin Fujisawa, Masahiro Onoda, Nobuyuki Aotsuka, Shingo Yano, Kazuteru Ohashi, Satoshi Takahashi, Shinichiro Okamoto, Yoshinobu Kanda

    Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy   2023.8

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    INTRODUCTION: Late cytomegalovirus (CMV) disease, which was defined as CMV disease occurring >100 days post-transplant, remains an important complication among allogeneic stem cell transplant recipients, even now that the prophylactic strategy using ganciclovir preemptive therapy has been established. Due to the recent expansion of donor sources and conditioning regimens, it is therefore appropriate to reevaluate the incidence, risk factors, and clinical impacts of late CMV disease. METHODS: This study included the 1295 adult patients, who underwent transplant for the first time from 2008 to 2015, without underlying disease relapse or CMV disease within 100 days post-transplant. There were no restrictions on underlying diseases or transplant procedures. RESULTS: During the median follow-up period of 48.4 months, 21 patients developed late CMV disease and the 5-year cumulative incidence of late CMV disease was 1.6%. By multivariate analysis, haploidentical related donor, adult T-cell leukemia lymphoma, and preemptive therapy before 100 days post-transplant were extracted as independent risk factors. Late CMV disease negatively affected transplant outcomes, and was identified as an independent risk factor for the non-relapse mortality rate (hazard ratio 3.83, p < 0.001) and overall survival rate (hazard ratio 4.01, p < 0.001). Although 17 of 21 patients with late CMV disease died, the main causes of death were not related to CMV, except in three patients with CMV pneumonia. CONCLUSIONS: Although the incidence of late CMV disease is low in transplant recipients, this complication negatively affects clinical courses. Therefore, transplant recipients with these risk factors should be more carefully managed.

    DOI： 10.1016/j.jiac.2023.07.015

    PubMed

    researchmap

  • High-risk Combinations of Additional Chromosomal Abnormalities in Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia: JALSG Ph+ALL TKI-SCT Study. International journal

    Satoshi Nishiwaki, Isamu Sugiura, Shin Fujisawa, Yoshihiro Hatta, Yoshiko Atsuta, Noriko Doki, Shingo Kurahashi, Yasunori Ueda, Nobuaki Dobashi, Tomoya Maeda, Yasuhiro Taniguchi, Masatsugu Tanaka, Shinichi Kako, Tatsuo Ichinohe, Takahiro Fukuda, Shigeki Ohtake, Yuichi Ishikawa, Hitoshi Kiyoi, Itaru Matsumura, Yasushi Miyazaki

    HemaSphere   7 ( 6 )   e899   2023.6

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1097/HS9.0000000000000899

    PubMed

    researchmap

  • Clinical risk factors for patients with myelodysplastic syndromes undergoing allogeneic hematopoietic stem cell transplantation

    Haruka Teshigawara-Tanabe, Maki Hagihara, Jun Aoki, Satoshi Koyama, Hiroyuki Takahashi, Yuki Nakajima, Hiroyoshi Kunimoto, Takayoshi Tachibana, Takuya Miyazaki, Kenji Matsumoto, Masatsugu Tanaka, Etsuko Yamazaki, Shin Fujisawa, Heiwa Kanamori, Masataka Taguri, Hideaki Nakajima

    Hematology   27 ( 1 )   620 - 628   2022.12

    　More details

    Publishing type：Research paper (scientific journal)   Publisher：Informa UK Limited  

    DOI： 10.1080/16078454.2022.2052601

    researchmap

  • Clinical impact of cigarette smoking on the outcomes of allogeneic hematopoietic stem cell transplantation: a multicenter retrospective study. International journal

    Takuma Ohashi, Jun Aoki, Taiki Ando, Yasufumi Ishiyama, Yoshimi Ishii, Kazuho Miyashita, Yuki Nakajima, Takayoshi Tachibana, Maki Hagihara, Kenji Matsumoto, Masatsugu Tanaka, Heiwa Kanamori, Shin Fujisawa, Hideaki Nakajima

    Bone marrow transplantation   57 ( 7 )   1124 - 1132   2022.7

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    Smoking is associated with a high risk for different diseases including respiratory tract infections in immunocompetent patients. However, data about the effects of cigarette smoking on the outcomes of allogeneic hematopoietic stem cell transplantation (allo-HSCT) are limited. Therefore, we retrospectively investigated 608 patients aged ≥20 years with hematological disorders who received their first allo-HSCT at our group of hospitals between 2000 and 2015, and evaluated the impact of cigarette smoking before allo-HSCT on clinical outcomes by dividing patients into two groups according to the Brinkman index (BI) (nonsmokers or light smokers [BI: 0-500] and heavy smokers [BI: ≥ 500]). Multivariate analyses showed that heavy smoking was associated with a high 5-year cumulative incidence of chronic graft-versus-host disease (cGVHD) (hazard ratio [HR]: 1.73, 95% confidence interval [CI]: 1.15-2.61, p < 0.01). The 5-year overall survival (HR: 1.16, 95% CI: 0.86-1.58, p = 0.33) and disease-free survival (HR: 1.12, 95% CI: 0.83-1.52, p = 0.45) were similar between the two groups. Hence, cigarette smoking is correlated with cGVHD, although prospective studies must be conducted to further verify this result.

    DOI： 10.1038/s41409-022-01678-7

    PubMed

    researchmap

  • Pre-conditioning intervention in patients with relapsed or refractory acute lymphoblastic leukemia who underwent allogeneic hematopoietic cell transplantation: a KSGCT multicenter retrospective analysis. International journal

    Takayoshi Tachibana, Junya Kanda, Takuma Ishizaki, Yuho Najima, Masatsugu Tanaka, Noriko Doki, Shin-Ichiro Fujiwara, Shun-Ichi Kimura, Makoto Onizuka, Satoshi Takahashi, Takeshi Saito, Takehiko Mori, Shin Fujisawa, Emiko Sakaida, Takuya Miyazaki, Nobuyuki Aotsuka, Moritaka Gotoh, Reiko Watanabe, Katsuhiro Shono, Heiwa Kanamori, Yoshinobu Kanda, Shinichiro Okamoto

    Annals of hematology   100 ( 11 )   2763 - 2771   2021.11

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    The efficacy and clinical significance of pre-conditioning intervention (PCI) before allogeneic hematopoietic cell transplantation (HCT) in patients with acute lymphoblastic leukemia (ALL) not in remission remain inconclusive. The purpose of this multicenter retrospective study was to clarify the clinical significance of PCI before HCT in patients with non-remission ALL. Patients with non-remission ALL who received HCT between 2005 and 2015 at 16 institutions were included. PCI was objectively defined and classified to three groups according to the intensity of PCI (no, intensive, or moderate). The study cohort consisted of 104 patients with a median age of 38 (range 17-68). A significant decrease of blast percentage in the peripheral blood (PB) was confirmed in both PCI groups, suggesting that PCIs were effective to stabilize the disease activity. The group with moderate PCI had higher nucleated cell count in the BM compared to the group with intensive PCI or the group without PCI. The overall survival (OS) rates of groups with intensive and no PCI showed comparable and significantly better compared to the group with moderate PCI (P = 0.009). Multivariate analysis demonstrated that the OS of moderate PCI group was significantly worse compared to that of intensive PCI group (HR = 2.43, 95% CI: 1.32-4.14, P = 0.004), while the OS of intensive PCI group was comparable to that of the group without PCI. These results suggest that the intensity of PCI rather than the response to PCI may contribute to improve the transplant outcome in patients with ALL not in remission.

    DOI： 10.1007/s00277-021-04607-8

    PubMed

    researchmap

  • Compromised anti-tumor-immune features of myeloid cell components in chronic myeloid leukemia patients. International journal

    Ibuki Harada, Haruka Sasaki, Koichi Murakami, Akira Nishiyama, Jun Nakabayashi, Motohide Ichino, Takuya Miyazaki, Ken Kumagai, Kenji Matsumoto, Maki Hagihara, Wataru Kawase, Takayoshi Tachibana, Masatsugu Tanaka, Tomoyuki Saito, Heiwa Kanamori, Hiroyuki Fujita, Shin Fujisawa, Hideaki Nakajima, Tomohiko Tamura

    Scientific reports   11 ( 1 )   18046 - 18046   2021.9

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    Chronic myeloid leukemia (CML) is a form of myeloproliferative neoplasm caused by the oncogenic tyrosine kinase BCR-ABL. Although tyrosine kinase inhibitors have dramatically improved the prognosis of patients with CML, several problems such as resistance and recurrence still exist. Immunological control may contribute to solving these problems, and it is important to understand why CML patients fail to spontaneously develop anti-tumor immunity. Here, we show that differentiation of conventional dendritic cells (cDCs), which are vital for anti-tumor immunity, is restricted from an early stage of hematopoiesis in CML. In addition, we found that monocytes and basophils, which are increased in CML patients, express high levels of PD-L1, an immune checkpoint molecule that inhibits T cell responses. Moreover, RNA-sequencing analysis revealed that basophils express genes related to poor prognosis in CML. Our data suggest that BCR-ABL not only disrupts the "accelerator" (i.e., cDCs) but also applies the "brake" (i.e., monocytes and basophils) of anti-tumor immunity, compromising the defense against CML cells.

    DOI： 10.1038/s41598-021-97371-8

    PubMed

    researchmap

  • Novel Indicators of Transplant Outcomes for PhALL: Current Molecular-Relapse-Free Survival. International journal

    Hideki Nakasone, Shinichi Kako, Takayoshi Tachibana, Masatsugu Tanaka, Makoto Onizuka, Satoshi Takahashi, Akira Yokota, Shin-Ichiro Fujiwara, Toru Sakura, Emiko Sakaida, Shin Fujisawa, Rie Yamazaki, Moritaka Gotoh, Maki Hagihara, Nobuyuki Aotsuka, Nobuhiro Tsukada, Yoshihiro Hatta, Hiroaki Shimizu, Kensuke Usuki, Reiko Watanabe, Takehiko Mori, Shingo Yano, Heiwa Kanamori, Yoshinobu Kanda

    Transplantation and cellular therapy   27 ( 9 )   800.e1-800.e8   2021.9

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    Molecular relapse after allogeneic hematopoietic cell transplantation (allo-HCT) has been thought to predict clinical relapse in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (PhALL). Tyrosine kinase inhibitor (TKI) administration after allo-HCT may dynamically change the status from molecular relapse to molecular remission, but these state changes cannot be accurately represented by conventional survival indicators such as relapse-free survival, where events are usually considered irreversible. We aimed to develop novel indicators of transplant outcomes for allo-HCT recipients with PhALL and to visualize current molecular-relapse-free survival (CMRFS) and current on-TKI status (CTKI), treating molecular relapse or TKI administration after allo-HCT as a reversible event. We retrospectively analyzed 286 patients with PhALL who received allo-HCT between 2000 and 2016 in order to develop the indicators. CMRFS was defined as the probability of molecular remission without clinical relapse or death at any time after allo-HCT. Similarly, CTKI was defined as the probability of TKI administration without clinical relapse or death at any time after allo-HCT. The 1- and 5-year CMRFS rates were 67% and 59%, respectively, whereas the 1- and 5-year conventional molecular relapse-free survival rates were 42% and 37%. The 1- and 5-year CTKI rates were 14% and 8%, respectively. In a post hoc analysis focusing on patients who had achieved a molecular complete remission within 6 weeks (n = 201), the 5-year CMRFS rate (71%) was similar to the 5-year conventional molecular relapse-free survival (molRFS) rate (70%) in the non-TKI group. On the other hand, the 5-year CMRFS rate in the TKI group was 61%, whereas the 5-year conventional molRFS rate was only 38%. CMRFS and CTKI might become useful indicators of transplant success in terms of survival, leukemia-free status, and treatment-free status at any time point. Future extension of these survival models to other clinical situations is warranted.

    DOI： 10.1016/j.jtct.2021.06.020

    PubMed

    researchmap

  • Minimal residual disease (MRD) positivity at allogeneic hematopoietic cell transplantation, not the quantity of MRD, is a risk factor for relapse of Philadelphia chromosome-positive acute lymphoblastic leukemia.

    Yu Akahoshi, Yasuyuki Arai, Satoshi Nishiwaki, Shuichi Mizuta, Atsushi Marumo, Naoyuki Uchida, Yoshinobu Kanda, Hitoshi Sakai, Satoru Takada, Takahiro Fukuda, Shin Fujisawa, Takashi Ashida, Junji Tanaka, Yoshiko Atsuta, Shinichi Kako

    International journal of hematology   113 ( 6 )   832 - 839   2021.6

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    Minimal residual disease (MRD) monitoring by quantitative real-time reverse transcription PCR (qRT-PCR) is the standard of care in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph-positive ALL). We evaluated the impact of MRD status at hematopoietic cell transplantation (HCT) on relapse, as measured by a unified protocol at a central laboratory. Only patients with Ph-positive ALL who had minor transcripts (e1a2) and who underwent allogeneic HCT in first complete remission between 2008 and 2017 were included. First, patients with negative-MRD (n = 196) and positive-MRD (n = 61) at HCT were analyzed. As expected, MRD positivity at HCT was significantly associated with an increased risk of hematological relapse (hazard ratio [HR], 2.91; 95% CI 1.67-5.08; P < 0.001) in the multivariate analysis. Next, patients with positive-MRD were divided into low-MRD (n = 39) and high-MRD (n = 22) groups. In the multivariate analysis, high-MRD at HCT was not significantly associated with an increased risk of hematological relapse compared to the low-MRD group (HR 1.10; 95% CI 0.54-2.83; P = 0.620). These results indicate that the therapeutic decisions should be made based on MRD positivity, rather than on the MRD level, at HCT.

    DOI： 10.1007/s12185-021-03094-x

    PubMed

    researchmap

  • Stopping tyrosine kinase inhibitors started after allogeneic HCT in patients with Philadelphia chromosome-positive leukemia. International journal

    Hideki Nakasone, Shinichi Kako, Takehiko Mori, Satoshi Takahashi, Makoto Onizuka, Shin-Ichiro Fujiwara, Toru Sakura, Emiko Sakaida, Akira Yokota, Nobuyuki Aotsuka, Maki Hagihara, Nobuhiro Tsukada, Yoshihiro Hatta, Kensuke Usuki, Reiko Watanabe, Moritaka Gotoh, Shin Fujisawa, Shingo Yano, Heiwa Kanamori, Shinichiro Okamoto, Yoshinobu Kanda

    Bone marrow transplantation   56 ( 6 )   1402 - 1412   2021.6

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    For patients with Philadelphia chromosome (Ph)-positive leukemia, there is no consensus regarding how long tyrosine kinase inhibitors (TKI) should be given or whether TKI could be stopped if TKI is administrated after allogeneic hematopoietic cell transplantation (allo-HCT). We analyzed relapse-free survival (RFS) in 92 allo-HCT patients who received TKI for >3 months after allo-HCT, and aimed to develop a novel indicator, called as current TKI- & relapse-free (cTRFree) achievement. TKI after allo-HCT was started as planned in 39 patients, based on measurable residual disease (MRD) in 53 at a median of 152 days after allo-HCT. There was no difference in post-TKI RFS between the planned and MRD-based starting groups (P = 0.69). Second-generation TKIs were associated with superior RFS in Ph-positive acute leukemia (HR 2.71, P = 0.031). TKI was stopped before relapse in 48 patients. Stopping TKI as a time-dependent covariate was not associated with subsequent hematological relapse (HR 1.18, P = 0.72). In the TKI-stop group, TKI administration for >6 months tended to be associated with superior RFS (HR = 0.30, P = 0.08). As an indicator of transplant success, cTRFree was 35% 5 years after starting TKI. TKI could be stopped for recipients with sustained undetectable MRD. However, further prospective studies will be required to establish clinical recommendations.

    DOI： 10.1038/s41409-020-01206-5

    PubMed

    researchmap

  • Clinical Benefits of Preconditioning Intervention in Patients with Relapsed or Refractory Acute Myelogenous Leukemia Who Underwent Allogeneic Hematopoietic Cell Transplantation: A Kanto Study of Group for Cell Therapy Multicenter Analysis. International journal

    Takayoshi Tachibana, Junya Kanda, Takuma Ishizaki, Yuho Najima, Masatsugu Tanaka, Noriko Doki, Shin-Ichiro Fujiwara, Shun-Ichi Kimura, Makoto Onizuka, Satoshi Takahashi, Takeshi Saito, Takehiko Mori, Shin Fujisawa, Emiko Sakaida, Takuya Miyazaki, Nobuyuki Aotsuka, Moritaka Gotoh, Reiko Watanabe, Katsuhiro Shono, Kensuke Usuki, Nobuhiro Tsukada, Heiwa Kanamori, Yoshinobu Kanda, Shinichiro Okamoto

    Transplantation and cellular therapy   27 ( 1 )   70.e1-70.e8   2021.1

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    A multicenter retrospective study was conducted to evaluate the clinical significance of preconditioning intervention (PCI) before allogeneic hematopoietic cell transplantation (HCT) in patients with acute myelogenous leukemia (AML) not in remission. The study cohort consisted of 519 patients classified according to the intensity (intensive/moderate) of PCI and their response to PCI. The group treated with PCI had higher blast counts in the peripheral blood (PB) and had a lower overall survival (OS) rate (P < .001) and higher nonrelapse mortality (NRM) rate (P = .035) compared with those without PCI (no PCI group). Approximately 40% of the patients (68 of 236) achieved a good response to PCI (good PCI group), and those patients had lower blast counts in the PB compared with the group with poor response to PCI (poor PCI group). OS in the good PCI group was comparable to that in the no PCI group and significantly better than that in the poor PCI group (hazard ratio, .54; 95% confidence interval, .39 to .77; P < .001). However, OS was significantly lower in patients with intensive/moderate PCI compared with the no PCI group. These results suggest that PCI increases NRM without decreasing the post-transplantation relapse rate, but may be beneficial for patients with lower blast counts in PB irrespective of its intensity.

    DOI： 10.1016/j.bbmt.2020.09.025

    PubMed

    researchmap

  • Computed tomography-defined sarcopenia: prognostic predictor of nonrelapse mortality after allogeneic hematopoietic stem cell transplantation: a multicenter retrospective study.

    Taiki Ando, Shin Fujisawa, Haruka Teshigawara, Ayako Matsumura, Takayuki Sakuma, Taisei Suzuki, Hiroshi Teranaka, Eriko Ogusa, Yoshimi Ishii, Kazuho Miyashita, Hiroyuki Takahashi, Yuki Nakajima, Takuya Miyazaki, Maki Hagihara, Kenji Matsumoto, Etsuko Yamazaki, Hideaki Nakajima

    International journal of hematology   112 ( 1 )   46 - 56   2020.7

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    We analyzed clinical cutoffs for defining computed tomography (CT) methods for sarcopenia and examined the prognostic value of CT for allogeneic hematopoietic stem cell transplantation (allo-HCST) outcomes of patients with myeloid malignancy. One hundred twenty-five adult patients with acute myeloid leukemia and myelodysplastic syndrome who underwent first allo-HSCT between 2000 and 2017 were included. Sarcopenia was assessed using CT-based skeletal muscle index (SMI) and mean muscle attenuation at L3. A statistical difference in SMI was confirmed between sarcopenia (n = 52) and nonsarcopenia (n = 73) patients. There were no significant correlations of muscularity with age, performance status, or other characteristics of HSCT. After 2 years, overall survival (OS) was 43.5% and 70.1%, disease-free survival was 52.9% and 68.6%, nonrelapse mortality (NRM) was 20.8% and 8.4%, incidence of acute GVHD (≥ grade 2) was 38.8% and 39.1%, that of chronic GVHD was 53.2% and 37.3%, and median duration of hospitalization was 88 days and 74 days (P = 0.026), respectively, in the sarcopenia and nonsarcopenia groups. Multivariate analysis showed that presence of sarcopenia is a novel adverse factor for high NRM and poor OS. Pretransplant CT-defined sarcopenia is correlated with decreased OS, increased NRM, and prolonged hospitalization.

    DOI： 10.1007/s12185-020-02870-5

    PubMed

    researchmap

  • Outcomes and Prognostic Factors for Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia Who Underwent Allogeneic Hematopoietic Cell Transplantation: A KSGCT Multicenter Analysis. Reviewed International journal

    Takayoshi Tachibana, Junya Kanda, Takuma Ishizaki, Yuho Najima, Masatsugu Tanaka, Noriko Doki, Shin-Ichiro Fujiwara, Shun-Ichi Kimura, Makoto Onizuka, Satoshi Takahashi, Takeshi Saito, Takehiko Mori, Shin Fujisawa, Emiko Sakaida, Kenji Matsumoto, Nobuyuki Aotsuka, Moritaka Gotoh, Reiko Watanabe, Katsuhiro Shono, Kensuke Usuki, Nobuhiro Tsukada, Heiwa Kanamori, Yoshinobu Kanda, Shinichiro Okamoto

    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation   26 ( 5 )   998 - 1004   2020.5

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    A multicenter retrospective study was performed to evaluate the prognostic factors in 104 patients with relapsed or refractory acute lymphoblastic leukemia (ALL), who underwent allogeneic hematopoietic cell transplantation (HCT) between 2005 and 2015. The median age was 38 (range, 17 to 68), and the median blast fraction in peripheral blood and bone marrow was 1% (range, 0 to 99%) and 52% (range, 0 to 100%), respectively. With a median follow-up of 47 months (range, 8.3 to 105 months), overall survival (OS), nonrelapse mortality, and relapse mortality at 1 year were 25%, 44%, and 31%, respectively. Multivariate analysis demonstrated independent predictors for poor OS, including nuclear cell count in the bone marrow ≥10 × 104/μL (hazard ratio [HR], 2.14; 95% confidence interval [CI], 1.33 to 3.43; P = .002), elevated lactate dehydrogenase level (HR, 1.66; 95% CI, 1.05 to 2.62; P = .031), and no primary induction failure (HR, 2.05; 95% CI, 1.11 to 3.78; P = .022). A prognostic scoring index was designed based on these survival predictors. At 2 years, OS was 28%, 14%, and 0% for good (score 0 or 1; n = 47), intermediate (score 2; n = 40), and poor (score 3; n = 17), respectively (P < .001). This scoring system may be useful in identifying the patient population for which allogeneic HCT is least beneficial in advanced stages of ALL.

    DOI： 10.1016/j.bbmt.2020.01.007

    PubMed

    researchmap

  • Hematopoietic Stem Cell Transplantation From a Related Donor with Human Leukocyte Antigen 1-Antigen Mismatch in the Graft-Versus-Host Direction Using Low-dose Anti-thymocyte Globulin

    Junya Kanda, Toshihiko Ando, Shun-ichi Kimura, Shin-ichiro Fujiwara, Kazunori Imada, Shin Fujisawa, Takayoshi Tachibana, Yoshiko Atsuta, Yoshinobu Kanda

    Cell Transplantation   2020.1

    　More details

    Publishing type：Research paper (scientific journal)  

    DOI： 10.1177/0963689720976567

    researchmap

  • A Prospective, Longitudinal Observation of the Incidence, Treatment, and Survival of Late Acute and Chronic Graft-versus-Host Disease by National Institutes of Health Criteria in a Japanese Cohort. International journal

    Chikako Ohwada, Emiko Sakaida, Aiko Igarashi, Takeshi Kobayashi, Noriko Doki, Takehiko Mori, Jun Kato, Yuya Koda, Heiwa Kanamori, Masatsugu Tanaka, Takayoshi Tachibana, Shin Fujisawa, Yuki Nakajima, Ayumi Numata, Masako Toyosaki, Yasuyuki Aoyama, Makoto Onizuka, Maki Hagihara, Satoshi Koyama, Yoshinobu Kanda, Hideki Nakasone, Hiroaki Shimizu, Seiko Kato, Reiko Watanabe, Katsuhiro Shono, Rika Sakai, Takeshi Saito, Chiaki Nakaseko, Shinichiro Okamoto

    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation   26 ( 1 )   162 - 170   2020.1

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    To prospectively validate the incidence, manifestations, and outcomes of graft-versus-host disease (GVHD) by National Institutes of Health criteria, we recruited 406 hematopoietic stem cell transplantation recipients at 16 transplant centers in Japan from May 2012 to June 2014. The 2-year cumulative incidence of late acute and chronic GVHD was 3.2% (n = 13) and 35.4% (n = 145), with a median onset of 3.6 and 4.7 months after transplant, respectively. The global severity at onset was mild in 30.3%, moderate in 43.5%, and severe in 26.2%. Eighty-two patients were followed up for 2 years, with 79.3% still manifesting GVHD symptoms, and 80.6% (n = 117) of the patients received systemic immunosuppressive treatment (IST), with a 2-year cumulative incidence of IST termination of 33.1%. Severe patients showed a significantly lower rate of IST termination than those with mild and moderate severities (mild, 38.5%; moderate, 40.9%; and severe, 17.2%). The 2-year incidence of nonrelapse mortality (NRM) and relapse was not significantly different according to the severity at onset (NRM: mild [16.6%] versus moderate [8.7%] versus severe [16.1%]; relapse: mild [14.9%] versus moderate [14.7%] versus severe [5.3%]). As a result, 2-year overall survival (OS) and GVHD-specific survival (GSS) were equivalent according to the severity at onset (mild: OS = 81.0%, GSS = 85.7%; moderate: OS = 84.2%, GSS = 92.5%; severe: OS = 83.9%, GSS = 89.2%). Our study helped identify the characteristics of late acute and chronic GVHD in Japanese patients. Further investigation is needed to identify an optimal endpoint for survival prediction.

    DOI： 10.1016/j.bbmt.2019.09.016

    PubMed

    researchmap

  • Prognostic impact of cytogenetic abnormalities in adult patients with Philadelphia chromosome-negative ALL who underwent an allogeneic transplant. Reviewed International journal

    Hiroaki Shimizu, Noriko Doki, Heiwa Kanamori, Toru Sakura, Takehiko Mori, Shinichiro Machida, Satoshi Takahashi, Chikako Ohwada, Shin Fujisawa, Shingo Yano, Maki Hagihara, Yoshinobu Kanda, Masahiro Onoda, Moritaka Gotoh, Shinichi Kako, Jun Taguchi, Kensuke Usuki, Nobutaka Kawai, Nobuyuki Aotsuka, Shinichiro Okamoto

    Bone marrow transplantation   54 ( 12 )   2020 - 2026   2019.12

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    Although cytogenetic abnormalities at diagnosis are recognized as an important prognostic factor in patients with Philadelphia chromosome (Ph)-negative acute lymphoblastic leukemia (ALL), the prognostic impact has not been evaluated in allogeneic stem cell transplant (allo-SCT) recipients. Thus, we assessed 373 Ph-negative ALL patients who underwent allo-SCT. The high-risk (HR) group included those with t(4;11), t(8;14), low hypodiploidy, and complex karyotype, and the standard risk (SR) group included all other karyotypes. Among the 204 patients who underwent a transplant during the first remission (167 in the SR group and 37 in the HR group), the overall survival (OS) rates were similar between these groups (64.1% vs. 80.0% at 5 years, respectively; p = 0.12). Conversely, among the 106 patients who underwent a transplant while not in remission (84 in the SR group and 22 in the HR group), patients in the SR group showed a significantly superior OS rate compared to the HR group (15.4% vs. 4.5% at 5 years, respectively; p = 0.022). These results suggested that treatment outcomes of Ph-negative ALL patients with HR cytogenetic abnormalities may improve following allo-SCT, especially in the first remission. Innovative transplant approaches are warranted in patients who are not in remission.

    DOI： 10.1038/s41409-019-0585-2

    PubMed

    researchmap

  • Allogeneic hematopoietic cell transplantation in patients with untreated acute myeloid leukemia: a KSGCT multicenter retrospective analysis. Reviewed International journal

    Tachibana T, Ishizaki T, Takahashi S, Najima Y, Kimura SI, Sakaida E, Onizuka M, Mori T, Fujisawa S, Fujiwara SI, Saito T, Hagihara M, Aotsuka N, Gotoh M, Usuki K, Tsukada N, Kanda J, Kanamori H, Kanda Y, Okamoto S, Kanto Study, Group for Cell Therapy, KSGCT

    Bone marrow transplantation   55 ( 7 )   1497 - 1501   2019.9

    　More details

  • Predictive values of early suppression of tumorigenicity 2 for acute GVHD and transplant-related complications after allogeneic stem cell transplantation: prospective observational study

    Ayako Matsumura, Takuya Miyazaki, Takayoshi Tachibana, Taiki Ando, Megumi Koyama, Satoshi Koyama, Yoshimi Ishii, Hiroyuki Takahashi, Yuki Nakajima, Ayumi Numata, Wataru Yamamoto, Kenji Motohashi, Maki Hagihara, Kenji Matsumoto, Shin Fujisawa, Hideaki Nakajima

    Turkish Journal of Hematology   2019.8

    　More details

    Publishing type：Research paper (scientific journal)   Publisher：Galenos Yayinevi  

    DOI： 10.4274/tjh.galenos.2019.2019.0139

    researchmap

  • Efficacy and safety of oral deferasirox treatment for transfusional iron overload in pure red cell aplasia patients after allogeneic stem cell transplantation. Reviewed International journal

    Ryo Shimizu, Masahiro Takeuchi, Emiko Sakaida, Chikako Ohwada, Masako Toyosaki, Shinichiro Machida, Makoto Onizuka, Katsuhiro Shono, Masahiro Onoda, Takeshi Saito, Shingo Yano, Masatsugu Tanaka, Shin Fujisawa, Takehiko Mori, Kensuke Usuki, Satoshi Takahashi, Heiwa Kanamori, Chiaki Nakaseko, Shinichiro Okamoto

    Annals of hematology   98 ( 7 )   1781 - 1783   2019.7

    　More details

  • Impact of treatment-related weight changes from diagnosis to hematopoietic stem-cell transplantation on clinical outcome of acute myeloid leukemia.

    Taiki Ando, Shin Fujisawa, Haruka Teshigawara, Eriko Ogusa, Yoshimi Ishii, Kazuho Miyashita, Kenji Motohashi, Takuya Miyazaki, Takayoshi Tachibana, Maki Hagihara, Kenji Matsumoto, Masatsugu Tanaka, Chizuko Hashimoto, Hideyuki Koharazawa, Katsumichi Fujimaki, Jun Taguchi, Hiroyuki Fujita, Heiwa Kanamori, Etsuko Yamazaki, Hideaki Nakajima

    International journal of hematology   109 ( 6 )   673 - 683   2019.6

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    We hypothesized that treatment-related weight loss is associated with worse outcomes following HSCT. Overall, 184 patients with AML who underwent induction therapy were classified according to d-BMI (BMI at transplant minus BMI at diagnosis) (kg/m2) as < -2, - 2 to + 2, and > + 2. At 1 year, OS was 67.9% (95% CI, 60.7-74.2), DFS was 64.1% (95% CI, 56.7-70.6), and GRFS was 40.2% (95% CI, 33.1-47.2). For d-BMI groups < - 2, - 2 to + 2, and > + 2, GRFS at 1 year was 16.1% (95% CI, 5.1-31.4), 45.4% (95% CI, 36.4-53.7), and 41.7% (95% CI, 22.2-60.1), respectively (P = 0.0067). Multivariate analysis showed that both worse OS (HR, 1.78; 95% CI, 1.02-3.14; P = 0.007) and GRFS (HR, 2.34; 95% CI, 1.26-4.35; P = 0.007) were associated with reduced BMI (d-BMI < - 2). Treatment-related weight reduction in AML was associated with poor outcome after HSCT.

    DOI： 10.1007/s12185-019-02647-5

    PubMed

    researchmap

  • Prognostic index for patients with relapsed or refractory acute myeloid leukemia who underwent hematopoietic cell transplantation: a KSGCT multicenter analysis. Reviewed International journal

    Tachibana T, Kanda J, Ishizaki T, Najima Y, Tanaka M, Doki N, Fujiwara SI, Kimura SI, Onizuka M, Takahashi S, Saito T, Mori T, Fujisawa S, Sakaida E, Matsumoto K, Aotsuka N, Goto M, Watanabe R, Shono K, Usuki K, Tsukada N, Kanamori H, Kanda Y, Okamoto S, Kanto Study, Group for Cell Therapy, KSGCT

    Leukemia   33 ( 11 )   2610 - 2618   2019.5

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    A multicenter retrospective study was performed to explore a prognostic scoring index in order to identify a population who are least likely to benefit from allogeneic hematopoietic cell transplantation (HCT) in patients with relapsed or refractory acute myeloid leukemia (AML). The cohort included 519 patients with AML, who received HCT between 2005 and 2015 at a status of relapse or primary induction failure. Multivariate analysis demonstrated five independent predictors for OS, including C-reactive protein ≥ 1 mg/dL, peripheral blood blast fraction ≥ 20%, poor-risk karyotype, performance status ≥ 2, and bone marrow unrelated donor as a stem cell source. A prognostic scoring index was explored based on these predictors, and successfully separated the cohort into four groups. At 2 years, OS was 47%, 24%, 8%, and 0% for Good (Score 0, 1: n = 118), Intermediate-1 (Score 2: n = 75), Intermediate-2 (Score 3: n = 39), and Poor (Score 4: n = 24), respectively (P < 0.001). The predicting value of the index was confirmed in a validation cohort. Although a further validation study is warranted, the scoring index may be useful to predict survival and to identify the population with the lowest survival prior to HCT in patients with relapsed or refractory AML.

    DOI： 10.1038/s41375-019-0494-9

    PubMed

    researchmap

  • Employment status was highly associated with quality of life after allogeneic hematopoietic cell transplantation, and the association may differ according to patient age and graft-versus-host disease status: analysis of a nationwide QOL survey. International journal

    Saiko Kurosawa, Takuhiro Yamaguchi, Kumi Oshima, Atsumi Yanagisawa, Takahiro Fukuda, Heiwa Kanamori, Takehiko Mori, Satoshi Takahashi, Tadakazu Kondo, Shin Fujisawa, Yasushi Onishi, Shingo Yano, Makoto Onizuka, Yoshinobu Kanda, Ishikazu Mizuno, Shuichi Taniguchi, Takuya Yamashita, Yoshihiro Inamoto, Shinichiro Okamoto, Yoshiko Atsuta

    Bone marrow transplantation   54 ( 4 )   611 - 615   2019.4

    　More details

  • Feasibility of the imatinib stop study in the Japanese clinical setting: delightedly overcome CML expert stop TKI trial (DOMEST Trial)

    Shin Fujisawa, Yasunori Ueda, Kensuke Usuki, Hajime Kobayashi, Eisei Kondo, Noriko Doki, Takafumi Nakao, Yoshinobu Kanda, Nobuharu Kosugi, Hiroshi Kosugi, Takashi Kumagai, Hiroshi Harada, Masato Shikami, Yasuhiro Maeda, Toru Sakura, Koiti Inokuchi, Akio Saito, Yuichiro Nawa, Masahiro Ogasawara, Junji Nishida, Takeshi Kondo, Chikashi Yoshida, Hiroyuki Kuroda, Yoko Tabe, Yoshinobu Maeda, Kenji Imajo, Kensuke Kojima, Satoshi Morita, Sho Komukai, Atsushi Kawaguchi, Junichi Sakamoto, Shinya Kimura

    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY   24 ( 4 )   445 - 453   2019.4

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1007/s10147-018-1368-2

    Web of Science

    researchmap

  • Primary uterine lymphoma: The Yokohama Cooperative Study Group for Hematology (YACHT) study. International journal

    Yoshimi Ishii, Shin Fujisawa, Taiki Ando, Taisei Suzuki, Yasufumi Ishiyama, Kumiko Kishimoto, Yukako Hattori, Yuki Nakajima, Takuya Miyazaki, Hirotaka Takasaki, Kenji Matsumoto, Hideyuki Koharazawa, Jun Taguchi, Katsumichi Fujimaki, Rika Sakai, Hideaki Nakajima

    Asia-Pacific journal of clinical oncology   14 ( 5 )   e455-e459   2018.10

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    AIM: Primary malignant lymphomas arising from the female genital tract are very rare, with an incidence rate of 0.5%. Because of its rarity, its clinical characteristics, prognosis and optimal treatment are still unclear. Here, we retrospectively evaluated female patients with uterine lymphoma. METHODS: Between January 2000 and October 2016, 4362 patients were newly diagnosed with malignant lymphoma by the participating institutions of YACHT. Among these 4362 patients, we retrospectively evaluated 14 adult patients with primary uterine lymphoma. RESULTS: The median follow up time was 41 months. The median age at diagnosis was 68 years. Of 14 patients, 10 (72%) were diagnosed with diffuse large B-cell lymphoma. Seven patients presented with vaginal bleeding and three with abdominal pain. Eleven patients (79%) had advanced stages at diagnosis. Three patients (21%) had ovarian involvement and 2 (14%) had vaginal involvement. Induction chemotherapy regimens were R-CHOP in seven patients (50%), CHOP in three (21%) and other regimens in four (29%). Among 14 patients, 12 patients (86%) achieved a complete response and 2 (14%) experienced disease progression. Three patients (21%) showed relapse. Five patients (36%) died because of malignant lymphoma. The 3-year overall survival rate was 57.9%. Soluble interleukin-2 receptor levels > 5000 U/mL, anemia, a bulky mass and the presence of > 1 extranodal sites, B symptom at diagnosis were associated with a poor prognosis. CONCLUSION: Female genital lymphoma is very rare, and further study of more cases is warranted.

    DOI： 10.1111/ajco.13049

    PubMed

    researchmap

  • t(4;11)(q21;q23)を伴う急性リンパ性白血病に対する同種造血幹細胞移植(Allogeneic hematopoietic stem cell transplantation in patients with B-ALL with t(4;11)(q21;q23))

    青木 淳, 藤澤 信, 水田 秀一, 小澤 幸泰, 大橋 一輝, 太田 秀一, 小川 啓恭, 福田 隆浩, 内田 直之, 田中 淳司, 熱田 由子, 賀古 真一

    臨床血液   59 ( 9 )   1553 - 1553   2018.9

    　More details

    Language：English   Publisher：(一社)日本血液学会-東京事務局  

    researchmap

  • 同種造血幹細胞移植におけるNTBIの臨床的有用性(Clinical role of NTBI during allogeneic hematopoietic stem cell transplantation)

    松村 彩子, 宮崎 拓也, 立花 崇孝, 畑山 真弓, 安藤 太基, 小山 めぐみ, 小山 哲, 石井 好美, 高橋 寛行, 中嶋 ゆき, 沼田 歩, 山本 渉, 本橋 賢治, 萩原 真紀, 松本 憲二, 生田 克哉, 藤澤 信, 中島 秀明

    臨床血液   59 ( 9 )   1812 - 1812   2018.9

    　More details

    Language：English   Publisher：(一社)日本血液学会-東京事務局  

    researchmap

  • 診断後1年の治療効果は2005年NIH診断基準による慢性GVHDにおける予後予測因子となりうる(A prognostic impact of complete or partial response at 1 year after onset in 2005 NIH chronic GVHD)

    大和田 千桂子, 堺田 惠美子, 五十嵐 愛子, 土岐 典子, 森 毅彦, 加藤 淳, 金森 平和, 田中 正嗣, 藤澤 信, 大草 恵理子, 豊崎 誠子, 青山 泰之, 神田 善伸, 仲宗根 秀樹, 萩原 真紀, 清水 啓明, 加藤 せい子, 渡部 玲子, 鐘野 勝洋, 酒井 リカ, 齋藤 健, 臼杵 憲祐, 中世古 知昭, 岡本 真一郎

    臨床血液   59 ( 9 )   1584 - 1584   2018.9

    　More details

    Language：English   Publisher：(一社)日本血液学会-東京事務局  

    researchmap

  • Anemia Associated with Worse Outcome in Diffuse Large B-Cell Lymphoma Patients: A Single-Center Retrospective Study International journal

    Kenji Matsumoto, Shin Fujisawa, Taiki Ando, Megumi Koyama, Satoshi Koyama, Yoshimi Ishii, Ayumi Numata, Wataru Yamamoto, Kenji Motohashi, Maki Hagihara, Hideaki Nakajima

    Turkish journal of haematology : official journal of Turkish Society of Haematology   35 ( 3 )   181 - 184   2018.8

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    Objective: Useful prognostic biomarkers for diffuse large B-cell lymphoma (DLBCL) patients have been reported. To determine the prognostic value of hemoglobin (Hb) level in DLBCL patients, we performed a retrospective study. Materials and Methods: We evaluated disease outcome, progression-free survival (PFS), overall survival as the endpoint, and clinical and laboratory factors affecting the outcome of 185 DLBCL patients who had received rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone therapy during 2004-2014. Results: The study group included 121 men and 64 women with a median age of 66 years minimum-maximum: 21-83 years. In univariate analysis, factors independently associated with worse PFS were Eastern Cooperative Oncology Group performance status ≥2, Ann Arbor stage III or IV, anemia with Hb levels of <10 g/dL, and serum albumin of <3.5 g/dL. In multivariate analysis, anemia with Hb levels of <10 g/dL and Ann Arbor stage III or IV were found to be international index-independent prognostic factors (hazard ratio: 2.4; p=0.04). Conclusion: Anemia is an independent prognostic marker of poor outcome in DLBCL patients. Hb can be an easily available prognostic marker for risk stratification in these patients.

    DOI： 10.4274/tjh.2017.0437

    PubMed

    researchmap

  • Clinical Significance of Serum Ferritin at Diagnosis in Patients With Acute Myeloid Leukemia: A YACHT Multicenter Retrospective Study. International journal

    Takayoshi Tachibana, Taiki Andou, Masatsugu Tanaka, Satomi Ito, Takuya Miyazaki, Yoshimi Ishii, Eriko Ogusa, Hideyuki Koharazawa, Hiroyuki Takahashi, Kenji Motohashi, Jun Aoki, Yuki Nakajima, Kenji Matsumoto, Maki Hagihara, Chizuko Hashimoto, Jun Taguchi, Katsumichi Fujimaki, Hiroyuki Fujita, Shin Fujisawa, Heiwa Kanamori, Hideaki Nakajima

    Clinical lymphoma, myeloma & leukemia   18 ( 6 )   415 - 421   2018.6

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    PURPOSE: A multicenter retrospective analysis was performed to evaluate the clinical significance of serum ferritin at diagnosis in patients with acute myeloid leukemia (AML). METHODS: The study cohort included 305 patients who were newly diagnosed with AML from 2000 to 2015 and received standard induction chemotherapy. Transplantation was performed in 168 patients. RESULTS: The median ferritin value was 512 ng/mL (range, 8-9475 ng/mL). Ferritin correlated with lactate dehydrogenase, C-reactive protein, white blood cell count, and blast count, and elevation of ferritin was associated with poor performance status. The median follow-up period was 58 months (range, 4-187 months) among survivors. The high ferritin group (≥ 400 ng/mL) demonstrated inferior event-free survival (EFS) at the 5-year interval (30% vs. 40%; P = .033) compared to the low ferritin group. Multivariate analysis in the high-risk karyotype revealed that high ferritin levels predicted worse EFS (hazard ratio = 2.07; 95% confidence interval, 1.28-3.33; P = .003). CONCLUSION: Elevated ferritin at diagnosis may indicate tumor burden in patients with AML and predict worse EFS in the high-risk group.

    DOI： 10.1016/j.clml.2018.03.009

    PubMed

    researchmap

  • Cytogenetic risk stratification may predict allogeneic hematopoietic stem cell transplantation outcomes for chronic myelomonocytic leukemia. Reviewed International journal

    Kenji Motohashi, Shin Fujisawa, Noriko Doki, Takeshi Kobayashi, Takehiko Mori, Kensuke Usuki, Masatsugu Tanaka, Shinichiro Fujiwara, Shinichi Kako, Yasuyuki Aoyama, Masahiro Onoda, Shingo Yano, Moritaka Gotoh, Heiwa Kanamori, Satoshi Takahashi, Shinichiro Okamoto

    Leukemia & lymphoma   59 ( 6 )   1332 - 1337   2018.6

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only curative treatment for chronic myelomonocytic leukemia (CMML); however, factors predicting allo-HSCT outcomes for CMML have not been well defined. This study assessed whether the existing five scoring systems for CMML prognosis could be applied for predicting allo-HSCT outcomes. We retrospectively evaluated 38 patients who underwent allo-HSCT for CMML from 2000 to 2014. At 3 years, overall survival (OS) and disease-free survival were 34.6 and 24.7%, respectively. According to the risk stratification at the time of transplantation, only the CMML-specific cytogenetic risk scoring system could successfully predict transplantation outcomes. At 3 years, OS was 56.7, 12.5, and 0% (p = .01) in the low, intermediate, and high-risk groups. Our data suggest that the CMML-specific cytogenetic risk stratification at transplant may be useful for identifying patients with CMML who may benefit from HSCT. However, further studies are warranted to confirm this observation.

    DOI： 10.1080/10428194.2017.1387913

    PubMed

    researchmap

  • Peripheral Blood Monocyte Count is a Predictor of Successful Peripheral Blood Stem Cell Harvest After Chemo-Mobilization in Patients with Malignant Lymphoma. International journal

    Yoshimi Ishii, Shin Fujisawa, Chika Nigauri, Taiki Ando, Taisei Suzuki, Eriko Ogusa, Kazuho Miyashita, Kenji Motohashi, Hideaki Nakajima

    Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion   34 ( 2 )   347 - 349   2018.4

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1007/s12288-017-0848-2

    PubMed

    researchmap

  • Regulatory T cell inhibition by dasatinib is associated with natural killer cell differentiation and a favorable molecular response-The final results of the D-first study. International journal

    Yuho Najima, Chikashi Yoshida, Noriyoshi Iriyama, Shin Fujisawa, Hisashi Wakita, Shigeru Chiba, Shinichiro Okamoto, Kimihiro Kawakami, Naoki Takezako, Takashi Kumagai, Kazuma Ohyashiki, Jun Taguchi, Shingo Yano, Tadahiko Igarashi, Yasuji Kouzai, Satoshi Morita, Junichi Sakamoto, Hisashi Sakamaki, Koiti Inokuchi

    Leukemia research   66   66 - 72   2018.3

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    We evaluated the effects of regulatory T cell (Treg) inhibition during dasatinib treatment on the anticancer immune response, particularly on natural killer (NK) cells and cytotoxic T lymphocytes (CTLs). Fifty-two newly diagnosed Japanese patients with chronic myeloid leukemia (CML) in the chronic phase were enrolled in the D-first study; all received 100 mg of dasatinib once daily and were followed for at least 36 months. The cumulative deep molecular response (DMR, MR4) rate was 65% by 36 months; the 3-year overall survival was 96%. CD4+ T cell counts were stable, whereas the proportion of CD4+CD25+CD127low (Treg) cells decreased in a time-dependent manner. The DMR rate by18 months was significantly better in low Treg patients (<5.7% at 12 months) compared to the remaining patients (odds ratio 4.07). NK cell and CTL counts at several time points were inversely correlated with Treg counts. Furthermore, the degree of NK cell differentiation (CD3-CD57+/CD3-CD56+) was closely and inversely correlated with the proportion of Treg cells throughout the observation period, and showed a gradually increasing trend. In conclusion, our results demonstrate that Treg inhibition by dasatinib contributes to better treatment response through enhancement of the immune system, particularly via NK cell differentiation.

    DOI： 10.1016/j.leukres.2018.01.010

    PubMed

    researchmap

  • Outcome and prognostic factors among patients who underwent a second transplantation for disease relapse post the first allogeneic cell transplantation Reviewed

    Takayoshi Tachibana, Kenji Matsumoto, Masatsugu Tanaka, Maki Hagihara, Kenji Motohashi, Wataru Yamamoto, Eriko Ogusa, Satoshi Koyama, Ayumi Numata, Naoto Tomita, Jun Taguchi, Shin Fujisawa, Heiwa Kanamori, Hideaki Nakajima

    LEUKEMIA & LYMPHOMA   58 ( 6 )   1403 - 1411   2017.6

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1080/10428194.2016.1243678

    Web of Science

    researchmap

  • Dasatinib versus imatinib in Japanese patients with newly diagnosed chronic phase chronic myeloid leukemia: a subanalysis of the DASISION 5-year final report Reviewed

    Hirohisa Nakamae, Shin Fujisawa, Michinori Ogura, Toshiki Uchida, Yasushi Onishi, Masafumi Taniwaki, Atae Utsunomiya, Kosei Matsue, Yasushi Takamatsu, Kensuke Usuki, Mitsune Tanimoto, Yoji Ishida, Kazuteru Ohashi, Li Li, Masafumi Miyoshi

    INTERNATIONAL JOURNAL OF HEMATOLOGY   105 ( 6 )   792 - 804   2017.6

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1007/s12185-017-2208-2

    Web of Science

    PubMed

    researchmap

  • Body mass index is a prognostic factor in adult patients with acute myeloid leukemia Reviewed

    Taiki Ando, Etsuko Yamazaki, Eriko Ogusa, Yoshimi Ishii, Wataru Yamamoto, Kenji Motohashi, Takayoshi Tachibana, Maki Hagihara, Kenji Matsumoto, Masatsugu Tanaka, Chizuko Hashimoto, Hideyuki Koharazawa, Katsumichi Fujimaki, Jun Taguchi, Hiroyuki Fujita, Heiwa Kanamori, Shin Fujisawa, Hideaki Nakajima

    INTERNATIONAL JOURNAL OF HEMATOLOGY   105 ( 5 )   623 - 630   2017.5

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1007/s12185-017-2183-7

    Web of Science

    researchmap

  • Phase II study of imatinib-based chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia Reviewed

    Shin Fujisawa, Shuichi Mizuta, Hideki Akiyama, Yasunori Ueda, Yasutaka Aoyama, Yoshihiro Hatta, Kazuhiko Kakihana, Nobuaki Dobashi, Isamu Sugiura, Yasushi Onishi, Tomoya Maeda, Kiyotoshi Imai, Shigeki Ohtake, Yasushi Miyazaki, Kazunori Ohnishi, Keitaro Matsuo, Tomoki Naoe

    AMERICAN JOURNAL OF HEMATOLOGY   92 ( 4 )   367 - 374   2017.4

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1002/ajh.24653

    Web of Science

    PubMed

    researchmap

  • Current treatment of adult acute lymphoblastic leukemia

    FUJISAWA Shin

    Rinsho Ketsueki   58 ( 10 )   1983 - 1994   2017

    　More details

    Language：Japanese   Publisher：The Japanese Society of Hematology  

    <p>The survival outcomes for children with acute lymphoblastic leukemia (ALL) have dramatically improved over recent years, and improved outcomes in adolescents and young adults patients have been achieved by applying regimens based on pediatric protocols. The treatment strategies for adult ALL are similar to those for pediatric ALL. T-cell ALL is less common than B-cell ALL. Therefore, there are only few reports of investigations in a large group of adult T-ALL patients. In Japan, nelarabine-combined chemotherapy has been tested in a phase II study in patients with newly diagnosed T-ALL. Patients with Philadelphia chromosome-positive ALL had a poor prognosis. However, the introduction of a tyrosine kinase inhibitor (TKI) has dramatically altered treatment strategies, resulting in complete remission in virtually all patients and an increased proportion of patients who undergo allogeneic stem cell transplantation. The prognosis of adults with relapsed and refractory ALL is extremely poor, and some novel agents are currently under development for relapsed and refractory ALL. This article describes the current treatment strategy and future perspectives for adult ALL.</p>

    DOI： 10.11406/rinketsu.58.1983

    CiNii Books

    researchmap

  • Hyper-recovery of platelets after induction therapy is a predictor of relapse-free survival in acute myeloid leukemia Reviewed

    Etsuko Yamazaki, Heiwa Kanamori, Megumi Itabashi, Eriko Ogusa, Ayumi Numata, Wataru Yamamoto, Satomi Ito, Takayoshi Tachibana, Maki Hagihara, Kenji Matsumoto, Hideyuki Koharazawa, Jun Taguchi, Naoto Tomita, Katsumichi Fujimaki, Hiroyuki Fujita, Shin Fujisawa, Koji Ogawa, Yoshiaki Ishigatsubo

    LEUKEMIA & LYMPHOMA   58 ( 1 )   104 - 109   2017

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1080/10428194.2016.1190969

    Web of Science

    researchmap

  • The SIL index is a simple and objective prognostic indicator in diffuse large B-cell lymphoma Reviewed

    Naoto Tomita, Taisei Suzuki, Kazuho Miyashita, Wataru Yamamoto, Kenji Motohashi, Takayoshi Tachibana, Hirotaka Takasaki, Rika Kawasaki, Maki Hagihara, Chizuko Hashimoto, Sachiya Takemura, Hideyuki Koharazawa, Etsuko Yamazaki, Jun Taguchi, Katsumichi Fujimaki, Hiroyuki Fujita, Rika Sakai, Shin Fujisawa, Shigeki Motomura, Keisuke Kawamoto, Hirohito Sone, Jun Takizawa

    LEUKEMIA & LYMPHOMA   57 ( 12 )   2763 - 2770   2016.12

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1080/10428194.2016.1195498

    Web of Science

    PubMed

    researchmap

  • Residual Blast Cells in Bone Marrow on Day 15 Following Remission Induction Therapy for Acute Myeloid Leukemia Is Associated with Long-Term Prognosis: A Retrospective Analysis of the JALSG AML201 Study Reviewed

    Maki Hagihara, Shin Fujisawa, Sumihisa Honda, Shigeki Ohtake, Shuichi Miyawaki, Nobuaki Dobashi, Toru Sakura, Yukiyasu Ozawa, Yoshikazu Ito, Katsumichi Fujimaki, Asao Hirose, Hiroyuki Fujita, Kinya Ohata, Tomoya Maeda, Toshi Imai, Hitoshi Kiyoi, Yasushi Miyazaki, Kazunori Ohnishi, Tomoki Naoe, Hideaki Nakajima

    BLOOD   128 ( 22 )   2016.12

    　More details

  • Outcome of Newly Diagnosed Acute Myeloid Leukemia with Hyperleukocytosis: Retrospective Study of JALSG AML201 Reviewed

    Kenji Matsumoto, Shin Fujisawa, Maki Hagihara, Sumihisa Honda, Shigeki Ohtake, Shuichi Miyawaki, Toru Sakura, Dobashi Nobuaki, Kinya Ohata, Yukiyasu Ozawa, Iekuni Ou, Asao Hirose, Tomoya Maeda, Yoshikazu Ito, Noriko Doki, Hitoshi Kiyoi, Kazunori Ohnishi, Tomoki Naoe, Yasushi Miyazaki, Hideaki Nakajima

    BLOOD   128 ( 22 )   2016.12

    　More details

  • Favorable prognosis in Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia patients following hematopoietic stem cell transplantation. Reviewed International journal

    Numata A, Fujisawa S, Itabashi M, Ishii Y, Yamamoto W, Motohashi K, Matsumoto K, Hagihara M, Nakajima H

    Clinical transplantation   30 ( 5 )   485 - 486   2016.5

    　More details

    Language：English  

    DOI： 10.1111/ctr.12702

    PubMed

    researchmap

  • Allogeneic Hematopoietic Stem Cell Transplantation after Conditioning Regimens with Fludarabine/melphalan or Fludarabine/busulfan for Patients with Hematological Malignancies: A Single-center Analysis Reviewed

    Wataru Yamamoto, Taiki Andou, Megumi Itabashi, Satoshi Koyama, Yoshimi Ishii, Ayumi Numata, Kenji Motohashi, Maki Hagihara, Kenji Matsumoto, Shin Fujisawa

    INTERNAL MEDICINE   55 ( 13 )   1721 - 1727   2016

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.2169/internalmedicine.55.6094

    Web of Science

    researchmap

  • Cytomegalovirus Pneumonia after Anti-CC-chemokine Receptor 4 Monoclonal Antibody (Mogamulizumab) Therapy in an Angioimmunoblastic T-cell Lymphoma Patient Reviewed

    Yoshimi Ishii, Megumi Itabashi, Ayumi Numata, Wataru Yamamoto, Kenji Motohashi, Maki Hagihara, Kenji Matsumoto, Shin Fujisawa

    INTERNAL MEDICINE   55 ( 6 )   673 - 675   2016

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.2169/internalmedicine.55.5644

    Web of Science

    researchmap

  • Effectiveness of High-Dose MTX Therapy for Adult Ph-Negative ALL By Randomized Trial: JALSG ALL202-O Reviewed

    Toru Sakura, Fumihiko Hayakawa, Isamu Sugiura, Kiyotoshi Imai, Noriko Usui, Shin Fujisawa, Tohru Murayama, Toshiaki Yujiri, Hitoshi Kiyoi, Kazunori Ohnishi, Yasushi Miyazaki, Shigeki Ohtake, Yukio Kobayashi, Keitaro Matsuo, Tomoki Naoe

    BLOOD   126 ( 23 )   2015.12

    　More details

    Language：English  

    Web of Science

    researchmap

  • Clinical significance of the administration of cytarabine or thiotepa in addition to total body irradiation and cyclophosphamide for allogeneic hematopoietic cell transplantation in patients with acute leukemia Reviewed

    Takayoshi Tachibana, Masatsugu Tanaka, Maki Hagihara, Rika Kawasaki, Etsuko Yamazaki, Hideyuki Koharazawa, Jun Taguchi, Naoto Tomita, Katsumichi Fujimaki, Rika Sakai, Hiroyuki Fujita, Shin Fujisawa, Atsuo Maruta, Yoshiaki Ishigatsubo, Heiwa Kanamori

    INTERNATIONAL JOURNAL OF HEMATOLOGY   102 ( 4 )   451 - 459   2015.10

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1007/s12185-015-1836-7

    Web of Science

    researchmap

  • Patient-reported quality of life after allogeneic hematopoietic cell transplantation or chemotherapy for acute leukemia Reviewed

    S. Kurosawa, T. Yamaguchi, T. Mori, H. Kanamori, Y. Onishi, N. Emi, S. Fujisawa, A. Kohno, C. Nakaseko, B. Saito, T. Kondo, M. Hino, Y. Nawa, S. Kato, A. Hashimoto, T. Fukuda

    BONE MARROW TRANSPLANTATION   50 ( 9 )   1241 - 1249   2015.9

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1038/bmt.2015.137

    Web of Science

    PubMed

    researchmap

  • Clinical significance of pretransplant serum ferritin on the outcome of allogeneic hematopoietic SCT: A prospective cohort study by the Kanto Study Group for Cell Therapy

    M. Tanaka, H. Kanamori, K. Matsumoto, T. Tachibana, A. Numata, K. Ohashi, T. Kobayashi, C. Nakaseko, Y. Kanda, E. Yamazaki, S. Fujisawa, J. Ooi, T. Sakura, N. Aotsuka, M. Onoda, S. Machida, J. Kato, K. Usuki, R. Watanabe, J. Taguchi, S. Yano, T. Saito, S. Takahashi, H. Sakamaki, S. Okamoto

    Bone Marrow Transplantation   50 ( 5 )   727 - 733   2015.5

    　More details

    Publishing type：Research paper (scientific journal)  

    DOI： 10.1038/bmt.2015.17

    Scopus

    PubMed

    researchmap

  • [Analysis of prognostic factors in transplant-eligeble newly diagnosed myeloma patients treated with bortezomib plus dexamethasone as induction therapy]. Reviewed

    Koharazawa H, Watanabe R, Hattori Y, Numata A, Kawasaki R, Kuwabara H, Hagihara M, Matsumoto K, Tanaka M, Hashimoto C, Takemura S, Yamazaki E, Fujimaki K, Taguchi J, Tomita N, Fujita H, Sakai R, Harano H, Ishigatsubo Y, Fujisawa S

    [Rinsho ketsueki] The Japanese journal of clinical hematology   56 ( 4 )   392 - 399   2015.4

    　More details

  • ボルテゾミブとデキサメタゾンの併用による寛解導入療法を施行した移植適応新規骨髄腫症例における予後規定因子の検討

    小原澤 英之, 渡邊 玲奈, 服部 友歌子, 沼田 歩, 川崎 理加, 桑原 英幸, 萩原 真紀, 松本 憲二, 田中 正嗣, 橋本 千寿子, 竹村 佐千哉, 山崎 悦子, 藤巻 克通, 田口 淳, 富田 直人, 藤田 浩之, 酒井 リカ, 原野 浩, 石ヶ坪 良明, 藤澤 信

    臨床血液   56 ( 4 )   392 - 399   2015.4

    　More details

  • Shorter halving time of BCR-ABL1 transcripts is a novel predictor for achievement of molecular responses in newly diagnosed chronic-phase chronic myeloid leukemia treated with dasatinib: Results of the D-first study of Kanto CML study group Reviewed

    Iriyama, Noriyoshi, Fujisawa, Shin, Yoshida, Chikashi, Wakita, Hisashi, Chiba, Shigeru, Okamoto, Shinichiro, Kawakami, Kimihiro, Takezako, Naoki, Kumagai, Takashi, Inokuchi, Koiti, Ohyashiki, Kazuma, Taguchi, Jun, Yano, Shingo, Igarashi, Tadahiko, Kouzai, Yasuji, Morita, Satoshi, Sakamoto, Junichi, Sakamaki, Hisashi

    AMERICAN JOURNAL OF HEMATOLOGY   90 ( 4 )   282 - 287   2015.4

    　More details

    Language：English   Publishing type：Research paper (scientific journal)   Publisher：WILEY-BLACKWELL  

    DOI： 10.1002/ajh.23923

    researchmap

  • A Safety and Efficacy Study of Medium-Dose Etoposide, Cyclophosphamide and Total Body Irradiation Conditioning Before Allogeneic Stem Cell Transplantation for Acute Lymphoblastic Leukemia. International journal

    Akio Shigematsu, Yukiyasu Ozawa, Makoto Onizuka, Shin Fujisawa, Ritsuro Suzuki, Yoshiko Atsuta, Kazuo Hatanaka, Masayoshi Masuko, Toshiro Ito, Naoki Kobayashi, Jun Kato, Koichi Miyamura, Takahiro Fukuda, Yasuo Morishima, Masahiro Imamura

    Transplantation direct   1 ( 2 )   e8   2015.3

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    UNLABELLED: Prognosis for adult patients with acute lymphoblastic leukemia (ALL) has been reported to be approximately 35% to 50%, even after allogeneic stem cell transplantation (allo-SCT). We previously reported retrospective analyses of a conditioning regimen of medium-dose etoposide, cyclophosphamide (CY), and total body irradiation (TBI) before allo-SCT for ALL. To prospectively analyze the efficacy of this conditioning regimen, we conducted a trial prospectively. METHODS: The eligibility criteria of this study were as follows: diagnosis of ALL, aged between 15 and 50 years, in complete remission, and first SCT from HLA serologically matched donor. The primary endpoint of this study was event-free survival at 1 year after SCT, and the events were defined as death and relapse. RESULTS: Fifty eligible patients were treated, and the median age of the patients was 33.5 years. Nineteen patients were Philadelphia chromosome-positive, and 47 were in first complete remission at SCT. All patients achieved neutrophil engraftment. Grade 3 to 4 acute graft-versus-host disease and extensive chronic graft-versus-host disease developed in 4 patients and 18 patients, respectively. No patient died within 100 days after SCT. One-year event-free survival was 76.0%, and 1-year overall survival was 80.0%. The cumulative incidences of relapse and non-relapse mortality at 1-year after SCT were 10.0% and 14.0%, respectively. CONCLUSIONS: Medium-dose etoposide + CY + TBI is an effective conditioning before allo-SCT for adult patients with ALL, enabling good disease control without an increase in nonrelapse mortality. A phase 3 trial comparing this regimen with the standard CY + TBI regimen for adult patients with ALL is warranted.

    DOI： 10.1097/TXD.0000000000000514

    PubMed

    researchmap

  • Post-therapy ¹⁸F-fluorodeoxyglucose positron emission tomography for predicting outcome in patients with peripheral T cell lymphoma. International journal

    Naoto Tomita, Yukako Hattori, Shin Fujisawa, Chizuko Hashimoto, Jun Taguchi, Hirotaka Takasaki, Rika Sakai, Ukihide Tateishi, Yoshiaki Ishigatsubo

    Annals of hematology   94 ( 3 )   431 - 6   2015.3

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    The International Harmonization Project on Lymphoma recommends (18)F-fluorodeoxyglucose (FDG)-positron emission tomography (PET) for the routine assessment of treatment efficacy in patients with FDG-avid lymphomas such as Hodgkin's and diffuse large B cell lymphomas. The utility of FDG-PET in predicting outcomes in patients with peripheral T cell lymphomas (PTCL) has not been fully elucidated. We retrospectively determined the predictive value of FDG-PET after first-line treatment (post-PET) for outcome in PTCL. Of the 36 patients enrolled, 16 were histologically diagnosed with PTCL not otherwise specified and 20 were diagnosed with angioimmunoblastic T cell lymphoma. All patients received curative-intent anthracycline-containing chemotherapy regimens. Post-PET images were visually evaluated by local nuclear medicine physicians. The median observation period for the surviving patients was 44 months. Positive and negative post-PET results were obtained in 31 % (11/36) and 69 % (25/36) of patients, respectively. The 3-year progression-free survival rates in the positive and negative post-PET result groups were 18 % and 62 %, respectively (P < 0.001). Nine of the 11 patients in the positive post-PET result group experienced progressive disease (PD) (positive predictive value, 82 %), whereas 16 of the 25 patients in the negative post-PET result group did not experience PD (negative predictive value, 64 %). The 3-year overall survival rates in the positive and negative post-PET result groups were 44 % and 84 %, respectively (P = 0.03). Our findings indicate that post-PET is predictive of outcome in patients with PTCL.

    DOI： 10.1007/s00277-014-2227-5

    PubMed

    researchmap

  • Analysis of outcomes in patients with supra-diaphragmatic vs infra-diaphragmatic diffuse large B cell lymphoma treated with R-CHOP therapy Reviewed

    Yuki Nakajima, Naoto Tomita, Megumi Itabashi, Kazuho Miyashita, Reina Watanabe, Takuya Miyazaki, Takayoshi Tachibana, Hirotaka Takasaki, Rika Kawasaki, Masatsugu Tanaka, Chizuko Hashimoto, Etsuko Yamazaki, Jun Taguchi, Katsumichi Fujimaki, Rika Sakai, Hiroyuki Fujita, Shin Fujisawa, Hiroshi Harano, Shigeki Motomura, Yoshiaki Ishigatsubo

    LEUKEMIA RESEARCH   39 ( 2 )   198 - 203   2015.2

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1016/j.leukres.2014.11.030

    Web of Science

    researchmap

  • Does the Hematopoietic Cell Transplantation Specific Comorbidity Index (HCT-CI) Predict Transplantation Outcomes? A Prospective Multicenter Validation Study of the Kanto Study Group for Cell Therapy Reviewed

    Nakaya, Aya, Mori, Takehiko, Tanaka, Masatsugu, Tomita, Naoto, Nakaseko, Chiaki, Yano, Shingo, Fujisawa, Shin, Sakamaki, Hisashi, Aotsuka, Nobuyuki, Yokota, Akira, Kanda, Yoshinobu, Sakura, Toru, Nanya, Yasuhito, Saitoh, Takayuki, Kanamori, Heiwa, Taka

    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION   20 ( 10 )   1553 - 1559   2014.10

    　More details

    Publishing type：Research paper (scientific journal)  

    DOI： 10.1016/j.bbmt.2014.06.005

    Scopus

    PubMed

    researchmap

  • Serum ferritin level is prognostic of patient outcome in extranodal NK/T cell lymphoma, nasal type

    Etsuko Yamazaki, Naoto Tomita, Satoshi Koyama, Eriko Ogusa, Yoshimi Ishii, Hiroyuki Takahashi, Kazuho Miyashita, Shiro Matsuura, Takayoshi Tachibana, Hirotaka Takasaki, Sachiya Takemura, Katsumichi Fujimaki, Rika Sakai, Shin Fujisawa, Yoshiaki Ishigatsubo

    Medical Oncology   31 ( 9 )   1 - 7   2014.9

    　More details

    Language：English   Publishing type：Research paper (scientific journal)   Publisher：Humana Press Inc.  

    DOI： 10.1007/s12032-014-0149-7

    Scopus

    PubMed

    researchmap

  • Efficacy and safety of dasatinib versus imatinib in Japanese patients with newly diagnosed chronic-phase chronic myeloid leukemia (CML-CP): Subset analysis of the DASISION trial with 2-year follow-up Reviewed

    Shin Fujisawa, Hirohisa Nakamae, Michinori Ogura, Ken-ichi Ishizawa, Masafumi Taniwaki, Atae Utsunomiya, Kosei Matsue, Yasushi Takamatsu, Kensuke Usuki, Mitsune Tanimoto, Yoji Ishida, Hideki Akiyama, Shintaro Onishi

    INTERNATIONAL JOURNAL OF HEMATOLOGY   99 ( 2 )   141 - 153   2014.2

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1007/s12185-013-1470-1

    Web of Science

    PubMed

    researchmap

  • Relative increase in lymphocytes from as early as 1 month predicts improved response to dasatinib in chronic-phase chronic myelogenous leukemia. Reviewed

    Takashi Kumagai, Eri Matsuki, Koiti Inokuchi, Kazuteru Ohashi, Atsushi Shinagawa, Jin Takeuchi, Chikashi Yoshida, Shinichiro Okamoto, Hisashi Wakita, Yasuji Kozai, Yukari Shirasugi, Shin Fujisawa, Osamu Iwase, Shingo Yano, Kaichi Nishiwaki, Koji Oba, Junichi Sakamoto, Hisashi Sakamaki

    International journal of hematology   99 ( 1 )   41 - 52   2014.1

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1007/s12185-013-1483-9

    Web of Science

    PubMed

    researchmap

  • European Treatment and Outcome Study score does not predict imatinib treatment response and outcome in chronic myeloid leukemia patients. International journal

    Eri Yamamoto, Shin Fujisawa, Maki Hagihara, Masatsugu Tanaka, Katsumichi Fujimaki, Kumiko Kishimoto, Chizuko Hashimoto, Megumi Itabashi, Daisuke Ishibashi, Yuki Nakajima, Takayoshi Tachibana, Rika Kawasaki, Hideyuki Kuwabara, Hideyuki Koharazawa, Etsuko Yamazaki, Naoto Tomita, Rika Sakai, Hiroyuki Fujita, Heiwa Kanamori, Yoshiaki Ishigatsubo

    Cancer science   105 ( 1 )   105 - 9   2014.1

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    The Sokal and Hasford scores were developed in the chemotherapy and interferon era and are widely used as prognostic indicators in patients with chronic myeloid leukemia (CML). Recently, a new European Treatment and Outcome Study (EUTOS) scoring system was developed. We performed a multicenter retrospective study to validate the effectiveness of each of the three scoring systems. The study cohort included 145 patients diagnosed with CML in chronic phase who were treated with imatinib. In the EUTOS low- and high-risk groups, the cumulative incidence of complete cytogenetic response (CCyR) at 18 months was 86.9% and 87.5% (P = 0.797) and the 5-year overall survival rate was 92.6% and 93.3% (P = 0.871), respectively. The cumulative incidence of CCyR at 12 months, 5-year event-free survival and 5-year progression-free survival were not predicted using the EUTOS scoring system. However, there were significant differences in both the Sokal score and Hasford score risk groups. In our retrospective validation study, the EUTOS score did not predict the prognosis of patients with CML in chronic phase treated with imatinib.

    DOI： 10.1111/cas.12321

    PubMed

    researchmap

  • Cord colitis syndromeを合併した急性骨髄性白血病

    田中 正嗣, 桑原 英幸, 立花 崇孝, 本橋 賢治, 中嶋 ゆき, 沼田 歩, 岸本 久美子, 藤澤 信, 大島 理加, 石ヶ坪 良明

    神奈川医学会雑誌   41 ( 1 )   112 - 113   2014.1

    　More details

    Language：Japanese   Publisher：(公社)神奈川県医師会  

    researchmap

  • Clinical significance of pre- and 1-year post-transplant serum ferritin among adult transplant recipients

    Takayoshi Tachibana, Masatsugu Tanaka, Ayumi Numata, Kenji Matsumoto, Naoto Tomita, Katsumichi Fujimaki, Jun Taguchi, Rika Sakai, Hiroyuki Fujita, Shin Fujisawa, Atsuo Maruta, Yoshiaki Ishigatsubo, Heiwa Kanamori

    Leukemia and Lymphoma   55 ( 6 )   1350 - 1356   2014

    　More details

    Language：English   Publishing type：Research paper (scientific journal)   Publisher：Informa Healthcare  

    DOI： 10.3109/10428194.2013.842981

    Scopus

    PubMed

    researchmap

  • Validation of the European Group for Blood and Marrow Transplantation (EBMT) risk score in patients receiving allogeneic hematopoietic stem cell transplantation at a single center in Japan

    Ayumi Numata, Masatsugu Tanaka, Kenji Matsumoto, Hirotaka Takasaki, Takayoshi Tachibana, Katsumichi Fujimaki, Rika Sakai, Shin Fujisawa, Naoto Tomita, Hiroyuki Fujita, Atsuo Maruta, Yoshiaki Ishigatsubo, Heiwa Kanamori

    Clinical Transplantation   28 ( 4 )   403 - 409   2014

    　More details

    Language：English   Publishing type：Research paper (scientific journal)   Publisher：Blackwell Publishing Ltd  

    DOI： 10.1111/ctr.12324

    Scopus

    PubMed

    researchmap

  • Efficacy of molecular response at 1 or 3 months after the initiation of dasatinib treatment can predict an improved response to dasatinib in imatinib-resistant or imatinib-intolerant Japanese patients with chronic myelogenous leukemia during the chronic phase.

    Koiti Inokuchi, Takashi Kumagai, Eri Matsuki, Kazuteru Ohashi, Atsushi Shinagawa, Yoshihiro Hatta, Jin Takeuchi, Chikashi Yoshida, Hisashi Wakita, Yasuji Kozai, Yukari Shirasugi, Shin Fujisawa, Osamu Iwase, Shingo Yano, Shinichiro Okamoto, Koji Oba, Junichi Sakamoto, Hisashi Sakamaki

    Journal of clinical and experimental hematopathology : JCEH   54 ( 3 )   197 - 204   2014

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    Dasatinib is a BCR-ABL kinase inhibitor with improved potency compared with imatinib, for which efficacy and safety in imatinib-resistant and imatinib-intolerant patients with chronic myelogenous leukemia (CML) have been established. Here, an open-label phase II study evaluated the efficacy and safety of dasatinib in 50 Japanese patients with imatinib-resistant or imatinib-intolerant CML during the chronic phase (CML-CP). Dasatinib was effective in imatinib-resistant and imatinib-intolerant patients. After 12 months of dasatinib therapy, 35 patients (70%) had achieved a major molecular response (MMR) and 16 patients (32%) had achieved a complete molecular response (CMR). Among the imatinib-resistant CML-CP cohort, 21 and 8 patients had achieved an MMR and a CMR after 12 months of dasatinib therapy, respectively. Among the imatinib-intolerant CML-CP cohort, 14 and 8 patients had achieved an MMR and a CMR after 12 months of dasatinib therapy, respectively. After 18 months of dasatinib therapy, 38 out of 50 patients (76.0%) had achieved an MMR and 19 patients (38.0%) had achieved a CMR. A lower level of BCR-ABL transcript at 1 or 3 months after the initiation of dasatinib treatment was more strongly correlated with the BCR-ABL transcript level at 12 and 18 months (p ＜ 0.001) than a higher level of BCR-ABL. The T315I mutation was identified in two patients receiving dasatinib therapy. Dasatinib was generally well tolerated, with only 3 patients (5%) having treatment discontinuation as a result of adverse hematologic events (thrombocytopenia, anemia, neutropenia) and/or non-hematologic events at a 12-month follow-up evaluation. Dasatinib was a safe and effective treatment for Japanese patients with imatinib-resistant or imatinib-intolerant CML. In addition, the molecular response at 1 or 3 months predicted a response to dasatinib at 12 or 18 months.

    PubMed

    researchmap

  • The Transcription Factor IRF8 Counteracts BCR-ABL to Rescue Dendritic Cell Development in Chronic Myelogenous Leukemia Reviewed

    Tomoya Watanabe, Chie Hotta, Shin-ichi Koizumi, Kazuho Miyashita, Jun Nakabayashi, Daisuke Kurotaki, Go R. Sato, Michio Yamamoto, Masatoshi Nakazawa, Hiroyuki Fujita, Rika Sakai, Shin Fujisawa, Akira Nishiyama, Zenro Ikezawa, Michiko Aihara, Yoshiaki Ishigatsubo, Tomohiko Tamura

    CANCER RESEARCH   73 ( 22 )   6642 - 6653   2013.11

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1158/0008-5472.CAN-13-0802

    Web of Science

    researchmap

  • Concentrated ascites reinfusion therapy for sinusoidal obstructive syndrome after hematopoietic stem cell transplantation. International journal

    Hiroyuki Takahashi, Rika Sakai, Atsuko Fujita, Hideyuki Kuwabara, Yukako Hattori, Shiro Matsuura, Rika Ohshima, Maki Hagihara, Naoto Tomita, Yoshiaki Ishigatsubo, Shin Fujisawa

    Artificial organs   37 ( 10 )   932 - 6   2013.10

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    Sinusoidal obstruction syndrome (SOS) is one of the severe complications of hematopoietic stem cell transplantation (HSCT). Systemic management including respiratory and circulatory support is necessary. In addition, abdominal paracentesis is often needed for pain relief and to reduce the pressure of tense ascites. Concentrated ascites reinfusion therapy (CART) involves the filtration, concentration, and reinfusion of drained ascites, which contributes to reuse of autologous proteins. CART has been reported as supportive therapy for patients with liver cirrhosis and cancer. We retrospectively reviewed the efficacy and safety of CART in three patients (two with acute myelogenous leukemia and one with chronic myeloid leukemia) who developed SOS after allo-HSCT. They all had symptomatic, tense, and diuretic-refractory ascites with right costal pain and marked weight gain. Two patients showed immediate improvement after CART. However, one patient experienced four CARTs with slow recovery. All patients are now alive and are being monitored as outpatients over 2 years with remission. No severe adverse event was observed related to CART, and 25.2-98.0 (median 30.2) grams of albumin was collected and reinfused. CART after paracentesis reduces protein loss in ascites by reinfusion of autologous protein instead of exogenous albumin preparations. Although transient fever is reported as a frequent adverse event, no events like severe bleeding or infection were observed. While its safety has not been fully established in patients with hematological disease after HSCT, CART may be a considerable supportive therapy for SOS with tense ascites.

    DOI： 10.1111/aor.12080

    PubMed

    researchmap

  • Absolute monocyte count in follicular lymphoma patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone Reviewed

    Reina Watanabe, Naoto Tomita, Kumiko Kishimoto, Satoshi Koyama, Eriko Ogusa, Yoshimi Ishii, Kazuho Miyashita, Shiro Matsuura, Shin Fujisawa, Yukako Hattori, Hirotaka Takasaki, Atsuko Fujita, Rika Ohshima, Hideyuki Kuwabara, Chizuko Hashimoto, Katsumichi Fujimaki, Rika Sakai, Yoshiaki Ishigatsubo

    LEUKEMIA RESEARCH   37 ( 10 )   1208 - 1212   2013.10

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1016/j.leukres.2013.07.015

    Web of Science

    researchmap

  • Prognosis of patients with core binding factor acute myeloid leukemia after first relapse. International journal

    Saiko Kurosawa, Shuichi Miyawaki, Takuhiro Yamaguchi, Heiwa Kanamori, Toru Sakura, Yukiyoshi Moriuchi, Fumiaki Sano, Takeshi Kobayashi, Atsushi Yasumoto, Kazuo Hatanaka, Masamitsu Yanada, Yuichiro Nawa, Jin Takeuchi, Yukinori Nakamura, Shin Fujisawa, Hirohiko Shibayama, Ikuo Miura, Takahiro Fukuda

    Haematologica   98 ( 10 )   1525 - 31   2013.10

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    Core binding factor acute myeloid leukemia is known to have a favorable prognosis, however, there have been no detailed analyses on prognostic factors after first relapse. Using a nationwide database, we retrospectively analyzed core binding factor acute myeloid leukemia patients who relapsed after being treated with chemotherapy alone during their first complete remission. Of a total of 397 patients who were diagnosed with core binding factor acute myeloid leukemia, 208 experienced a first relapse, and analyses were performed in 139 patients for whom additional data were available. In the entire cohort, the overall survival rate after relapse was 48% at 3 years. By multivariate analysis, younger age at diagnosis, a longer interval before relapse, and inv(16) were shown to be independently associated with better survival after relapse. Although there was no significant difference in survival after relapse between patients who underwent allogeneic hematopoietic cell transplantation and those who did not in the overall series of relapsed patients, we found that transplantation significantly improved survival among patients who had t(8;21) (54% versus 26% at 3 years, P=0.002). In addition, among patients with t(8;21), those who had different cytogenetics at relapse had a significantly improved survival after transplantation, while those who had same cytogenetics did not. We showed that the prognosis differs significantly and optimal treatment strategies may vary between groups of patients with core binding factor acute myeloid leukemia with different cytogenetic profiles at relapse. These findings may help to guide therapeutic decisions after first relapse.

    DOI： 10.3324/haematol.2012.078030

    PubMed

    researchmap

  • Drug-induced liver injury after allogeneic bone marrow transplantation Reviewed

    Takayoshi Tachibana, Akito Nozaki, Makiko Enaka, Eri Yamamoto, Rika Kawasaki, Hideyuki Koharazawa, Maki Hagihara, Daisuke Ishibashi, Yuki Nakajima, Hideyuki Kuwabara, Naoto Tomita, Yoshiaki Ishigatsubo, Shin Fujisawa

    INTERNATIONAL JOURNAL OF HEMATOLOGY   98 ( 4 )   499 - 503   2013.10

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1007/s12185-013-1434-5

    Web of Science

    PubMed

    researchmap

  • Standard R-CHOP Therapy in Follicular Lymphoma and Diffuse Large B-Cell Lymphoma

    TOMITA Naoto, TAKASAKI Hirotaka, FUJISAWA SHIN, MIYASHITA Kazuho, OGUSA Eriko, KISHIMOTO Kumiko, MATSUURA Shiro, SAKAI Rika, KOHARAZAWA Hideyuki, YAMAMOTO Wataru, FUJIMAKI Katsumichi, FUJITA Hiroyuki, ISHII Yoshimi, TAGUCHI Jun, KUWABARA Hideyuki, MOTOMURA Shigeki, ISHIGATSUBO Yoshiaki

    The journal of the Japanese Society of Lymphoreticular Tissue research   53 ( 2 )   121 - 125   2013.8

    　More details

    Language：English   Publisher：The Japanese Society for Lymphoreticular Tissue Research  

    The introduction of rituximab (R) has measurably improved the outcome of patients with follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL). To evaluate the outcome of patients with FL and DLBCL under R plus CHOP therapy, we performed a retrospective analysis in Yokohama City University Hematology Group in Japan. Five hundred and twenty-six patients (158, FL ; 368, DLBCL) were scheduled to undergo primary therapy with 6 cycles of full-dose R-CHOP therapy with curative intent. The median observation periods in livingpatients with FL and DLBCL were 45 months and 43 months, respectively. The complete response, 5-year progression-free survival (PFS), and 5-year overall survival (OS) rates were 86%, 50%, and 92% in the FL group, and 89%, 72%, and 80% in the DLBCL group, respectively. Although PFS was significantly better in the DLBCL group than in the FL group, OS was significantly better in FL patients. We also found that the OS and PFS of grade 3 FL patients were not statistically different from those with grade 1-2. These findings indicate that all grades of FL should be categorized simply as "FL" with regard to R-CHOP therapy. Our results also demonstrate the incurability of FL (grade 1-3B), even with R-CHOP therapy. [<I>J Clin Exp Hematop 53(2) : 121-125, 2013</I>]

    DOI： 10.3960/jslrt.53.121

    CiNii Books

    researchmap

    Other Link： http://search.jamas.or.jp/link/ui/2014164063

  • Upfront Autologous Stem Cell Transplantation for Untreated High-Risk Diffuse Large B-Cell Lymphoma in Patients Up to 60 Years of Age Reviewed

    Hirotaka Takasaki, Chizuko Hashimoto, Atsuko Fujita, Kenji Matsumoto, Jun Taguchi, Hideyuki Kuwabara, Etsuko Yamazaki, Hideyuki Koharazawa, Hiroyuki Fujita, Shin Fujisawa, Yoshimi Ishii, Wataru Yamamoto, Shigeki Motomura, Naoto Tomita, Yoshiaki Ishigatsubo, Rika Sakai

    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA   13 ( 4 )   404 - 409   2013.8

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1016/j.clml.2013.03.003

    Web of Science

    researchmap

  • Cord colitis syndromeを合併した急性骨髄性白血病

    田中 正嗣, 桑原 英幸, 立花 崇孝, 本橋 賢治, 中嶋 ゆき, 沼田 歩, 岸本 久美子, 藤澤 信, 大島 理加, 石ヶ坪 良明

    神奈川医学会雑誌   40 ( 2 )   319 - 319   2013.7

    　More details

    Language：Japanese   Publisher：(公社)神奈川県医師会  

    researchmap

  • R-CHOP therapy alone in limited stage diffuse large B-cell lymphoma. International journal

    Naoto Tomita, Hirotaka Takasaki, Kazuho Miyashita, Shin Fujisawa, Eriko Ogusa, Shiro Matsuura, Kumiko Kishimoto, Ayumi Numata, Atsuko Fujita, Rika Ohshima, Hideyuki Kuwabara, Maki Hagihara, Chizuko Hashimoto, Sachiya Takemura, Hideyuki Koharazawa, Etsuko Yamazaki, Katsumichi Fujimaki, Jun Taguchi, Rika Sakai, Yoshiaki Ishigatsubo

    British journal of haematology   161 ( 3 )   383 - 8   2013.5

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    Long-term observation has identified a pattern of continuing relapse in limited stage diffuse large B-cell lymphoma (DLBCL) treated by three cycles of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) plus involved-field irradiation. We retrospectively analysed 190 untreated patients with limited stage DLBCL treated by R-CHOP alone. All the patients were scheduled to undergo primary therapy with six cycles of full-dose R-CHOP. Cases with a dose reduction of more than 20% were excluded from the study. Additional local irradiation was allowed in patients with partial response (PR). Five patients received additional local irradiation after PR at the end of the R-CHOP therapy. The median observation period was 52 months. Median age at diagnosis was 63 years. The responses to therapy were 180 complete responses, eight PR, and two progression of disease (PD). The 5-year progression-free survival and 5-year overall survival rates were 84% and 90%, respectively, both in plateau. During the observation period, 29 patients experienced PD. The progression sites were the primary sites in 15 patients, outside the primary sites in 10, and undetermined in four patients. These results suggest that the 'standard' strategy of three cycles of R-CHOP followed by involved-field radiotherapy for limited stage DLBCL could be effectively replaced by six cycles of R-CHOP alone.

    DOI： 10.1111/bjh.12281

    PubMed

    researchmap

  • Phase 2 study of arsenic trioxide followed by autologous hematopoietic cell transplantation for relapsed acute promyelocytic leukemia. International journal

    Masamitsu Yanada, Motohiro Tsuzuki, Hiroyuki Fujita, Katsumichi Fujimaki, Shin Fujisawa, Kazutaka Sunami, Masafumi Taniwaki, Akira Ohwada, Kosuke Tsuboi, Akio Maeda, Akihiro Takeshita, Shigeki Ohtake, Yasushi Miyazaki, Yoshiko Atsuta, Yukio Kobayashi, Tomoki Naoe, Nobuhiko Emi

    Blood   121 ( 16 )   3095 - 102   2013.4

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    The optimal treatments for relapsed acute promyelocytic leukemia (APL) remain equivocal. We conducted a phase 2 study to evaluate the efficacy and feasibility of a sequential treatment consisting of induction and consolidation with arsenic trioxide (ATO), peripheral blood stem cell (PBSC) harvest after high-dose cytarabine chemotherapy, and autologous hematopoietic cell transplantation (HCT). Between 2005 and 2009, 35 patients (26 with hematologic and 9 with molecular relapse) were enrolled. Induction therapy resulted in complete remission in 81% of those with hematologic relapse, and most patients became negative for PML-RARα after the first ATO consolidation course, but 4 remained positive. Administration of the second ATO consolidation course further decreased the transcript levels in 3 patients. In total, 25 patients proceeded to PBSC harvest, all of whom successfully achieved the target CD34+ cell doses, and 23 underwent autologous HCT with PML-RARα-negative PBSC graft. Posttransplant relapse occurred in 3 patients, and there was no transplant-related mortality. With a median follow-up of 4.9 years, the 5-year event-free and overall survival rates were 65% and 77%, respectively. These findings demonstrate the outstanding efficacy and feasibility of the sequential treatment featuring ATO and autologous HCT for relapsed APL. This study was registered at http://www.umin.ac.jp/ctr/ as #C000000302.

    DOI： 10.1182/blood-2012-11-466862

    PubMed

    researchmap

  • Prospective multicenter study of single-unit cord blood transplantation with myeloablative conditioning for adult patients with high-risk hematologic malignancies. International journal

    Takehiko Mori, Masatsugu Tanaka, Takeshi Kobayashi, Kazuteru Ohashi, Shin Fujisawa, Akira Yokota, Hiroyuki Fujita, Chiaki Nakaseko, Toru Sakura, Yasuhito Nannya, Satoshi Takahashi, Heiwa Kanamori, Yoshinobu Kanda, Hisashi Sakamaki, Shinichiro Okamoto

    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation   19 ( 3 )   486 - 91   2013.3

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    Although the use of cord blood transplantation (CBT) is increasing, the optimal methods for conditioning and graft-versus-host disease (GVHD) prophylaxis remain to be established. Among previous reports, the Institute of Medical Science, University of Tokyo (IMSUT) has reported remarkably favorable results of CBT for hematologic malignancies as a single-institute experience. The aim of the present multicenter prospective study was to assess the safety and efficacy of CBT performed precisely according to IMSUT transplantation procedures. Thirty-three adult patients with hematologic malignancies, such as acute leukemia, chronic myelogenous leukemia, or myelodysplastic syndrome, either lacking an HLA-identical sibling/HLA-matched unrelated donor or requiring urgent transplantation were enrolled. Conditioning consisted of total body irradiation (12 Gy), cytarabine, and cyclophosphamide. Cyclosporine A and methotrexate were used for GVHD prophylaxis. Diagnoses were acute leukemia in 26 patients, chronic myelogenous leukemia in 4, and myelodysplastic syndrome in 3; 12 patients were in first complete remission, and the others were in advanced stages at the time of CBT. Thirty-one patients achieved engraftment, and the cumulative incidence of grade II-IV acute GVHD was 45% (95% confidence interval, 28%-62%). With a median follow-up of 46.2 months in 16 surviving patients, the 1-year cumulative incidence of nonrelapse mortality was 15% (95% confidence interval, 5%-30%). Causes of nonrelapse mortality were infection (n = 4) and graft failure (n = 1). The overall and disease-free survival rates were 51% (95% CI, 34%-68%) and 42% (95% CI, 26%-59%), respectively. These results suggest that the IMSUT CBT procedures can safely provide a high disease-free survival rate in patients with high-risk hematologic malignancies.

    DOI： 10.1016/j.bbmt.2012.12.007

    PubMed

    researchmap

  • Successful disease control with L-asparaginase monotherapy for aggressive natural killer cell leukemia with severe hepatic failure. International journal

    Hiroyuki Takahashi, Rika Sakai, Yukako Hattori, Rika Ohshima, Hideyuki Kuwabara, Maki Hagihara, Makiko Enaka, Akinori Nozawa, Naoto Tomita, Yoshiaki Ishigatsubo, Shin Fujisawa

    Leukemia & lymphoma   54 ( 3 )   662 - 4   2013.3

    　More details

  • Allogeneic hematopoietic stem cell transplantation for patients with mildly reduced renal function as defined based on creatinine clearance before transplantation. International journal

    Kumi Oshima, Yoshinobu Kanda, Yasuhito Nanya, Masatsugu Tanaka, Chiaki Nakaseko, Shingo Yano, Shin Fujisawa, Hiroyuki Fujita, Akira Yokota, Satoshi Takahashi, Heiwa Kanamori, Shinichiro Okamoto

    Annals of hematology   92 ( 2 )   255 - 60   2013.1

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    While renal comorbidity is generally defined by the serum creatinine level, the creatinine clearance rate (Ccr) is a more accurate indicator of renal function. Therefore, we retrospectively assessed how mildly reduced renal function as defined based on Ccr affects the outcome after allogeneic hematopoietic stem cell transplantation (HSCT). Patients who underwent allogeneic HSCT at the eight institutes of the Kanto Study Group for Cell Therapy were included in this study. Based on the corrected Ccr, patients were classified into group 0 (n = 440,  ≥ 90 mL/min/1.73 m(2)), group 1 (n = 56, 60-89 mL/min/1.73 m(2)), or group 2 (n = 11, 30-59 mL/min/1.73 m(2)). Therefore, 67 patients were considered to have mild renal impairment, whereas only 2 had a serum creatinine level higher than 1.2 mg/dL. Twenty-eight patients required hemodialysis after HSCT, with 5.5, 5.4, and 9.1 % in groups 0, 1, and 2, respectively (p = 0.65). The incidence of non-relapse mortality (NRM) was higher in group 2, although these differences were not statistically significant probably due to the small sample size (23.7, 28.2, and 47.2 % at 3 years, p = 0.20). In conclusion, NRM may be associated with mildly reduced renal function before allogeneic HSCT, which cannot be detected by measurement of the serum creatinine level alone.

    DOI： 10.1007/s00277-012-1584-1

    PubMed

    researchmap

  • Twenty-eight cases of relapsed or refractory multiple myeloma treated with lenalidomide

    Yukako Hattori, Katsumichi Fujimaki, Yoshimi Ishii, Satomi Itoh, Rika Ohshima, Maki Hagihara, Kenji Matsumoto, Hideyuki Koharazawa, Chizuko Hashimoto, Rika Sakai, Hiroyuki Fujrra, Hiroshi Haran, Koji Ogawa, Naoto Tomita, Shin Fujisawa, Yoshiaki Ishigatsubo

    Yokohama Medical Journal   64 ( 2 )   39 - 43   2013

    　More details

    Language：Japanese   Publishing type：Research paper (scientific journal)   Publisher：Medical Association of Yokohama City University  

    Scopus

    researchmap

  • POEMS syndrome treated with lenalidomide plus high-dose dexamethasone as a pre-transplant induction therapy

    MATSUURA Shiro, OGUSA Eriko, TAGUCHI Jun, IMAI Noboru, FUJITA Hiroyuki, TOMITA Naoto, ISHIGATSUBO Yoshiaki, FUJISAWA Shin

    Rinsho Ketsueki   53 ( 12 )   2025 - 2028   2012.12

    　More details

    Language：Japanese   Publisher：The Japanese Society of Hematology  

    A 60-year-old male with POEMS syndrome received lenalidomide and high-dose dexamethasone combination therapy as an initial treatment, with no severe adverse events occurring during the treatment. Two cycles of the therapy led to significantly decreased serum VEGF level, and IgA-λ type M-protein was not detected by immunofixation electrophoresis. We next performed autologous stem cell transplantation, without severe complications such as engraftment syndrome. He improved enough to walk independently and now is being followed up without treatment. This case suggests that lenalidomide-dexamethasone therapy is highly effective and can be a good option for pre-transplant treatment for POEMS syndrome.

    DOI： 10.11406/rinketsu.53.2025

    CiNii Books

    researchmap

    Other Link： https://jlc.jst.go.jp/DN/JALC/10013528958?from=CiNii

  • Allogeneic hematopoietic stem cell transplantation for adult AML patients with granulocytic sarcoma Reviewed

    H. Shimizu, T. Saitoh, M. Tanaka, T. Mori, T. Sakura, N. Kawai, Y. Kanda, C. Nakaseko, S. Yano, H. Fujita, S. Fujisawa, S. Miyawaki, H. Kanamori, S. Okamoto

    LEUKEMIA   26 ( 12 )   2469 - 2473   2012.12

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1038/leu.2012.156

    Web of Science

    researchmap

  • SIL index, comprising stage, soluble interleukin-2 receptor, and lactate dehydrogenase, is a useful prognostic predictor in diffuse large B-cell lymphoma Reviewed

    Naoto Tomita, Rika Sakai, Shin Fujisawa, Katsumichi Fujimaki, Jun Taguchi, Chizuko Hashimoto, Koji Ogawa, Etsuko Yamazaki, Yoshiaki Ishigatsubo

    CANCER SCIENCE   103 ( 8 )   1518 - 1523   2012.8

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1111/j.1349-7006.2012.02331.x

    Web of Science

    researchmap

  • [Retrospective analysis of treatment outcomes in 70 patients with t(8;21) acute myeloid leukemia].

    Ayumi Numata, Katsumichi Fujimaki, Tomohiro Aoshima, Makoto Onizuka, Maki Hagihara, Koji Miyazaki, Hiroyuki Fujita, Rika Sakai, Shinichiro Machida, Eri Tanaka, Yuki Nakajima, Yukako Hattori, Masatsugu Tanaka, Etsuko Yamazaki, Yukari Shirasugi, Yasuyuki Inoue, Shigeki Watanabe, Shin Fujisawa

    [Rinsho ketsueki] The Japanese journal of clinical hematology   53 ( 7 )   698 - 704   2012.7

    　More details

    Language：Japanese   Publishing type：Research paper (scientific journal)  

    We conducted a retrospective study to evaluate outcomes and prognostic factors of newly diagnosed patients with t(8;21) acute myeloid leukemia (AML). There were 70 patients (43 men and 27 women) with a median age of 48 years old (range, 17∼76 years old). Sixty-five patients achieved complete remission (CR) after induction chemotherapy. Fifty-seven patients received consolidation chemotherapy based on the policy of not performing allogeneic hematopoietic stem cell transplantation (allo-HSCT) at the time of first CR. Twenty-seven of the 57 patients relapsed (relapse rate, 47%). The median time from the achievement of the first CR to relapse was 307 days (96∼1,256 days). A white blood cell count of more than 25,400/μl at diagnosis was associated with a higher relapse rate than a white blood cell count of less than or equal to 25,400/μl (75% vs. 43%, P=0.04). Nineteen of the 25 relapsed patients who received re-induction therapy experienced a second CR (second CR rate, 76%). Twenty-six patients (5 with first CR, 12 with second CR, and 9 without remission) received allo-HSCT. The five-year overall survival and disease-free survival rates were 61% and 45%, respectively. Patients with t(8;21) AML had a high CR rate, but about half of them relapsed. However, this report could not show prognostic factors for the identification of patients who should receive allo-HSCT at the time of their first CR.

    PubMed

    researchmap

  • Long-term outcome following imatinib therapy for chronic myelogenous leukemia, with assessment of dosage and blood levels: the JALSG CML202 study Reviewed

    Kazunori Ohnishi, Chiaki Nakaseko, Jin Takeuchi, Shin Fujisawa, Tadashi Nagai, Hirohito Yamazaki, Tetsuzo Tauchi, Kiyotoshi Imai, Naoki Mori, Fumiharu Yagasaki, Yasuhiro Maeda, Noriko Usui, Yasushi Miyazaki, Koichi Miyamura, Hitoshi Kiyoi, Shigeki Ohtake, Tomoki Naoe

    CANCER SCIENCE   103 ( 6 )   1071 - 1078   2012.6

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1111/j.1349-7006.2012.02253.x

    Web of Science

    PubMed

    researchmap

  • Pretransplant serum ferritin has a prognostic influence on allogeneic transplant regardless of disease risk. International journal

    Takayoshi Tachibana, Masatsugu Tanaka, Ayumi Numata, Hirotaka Takasaki, Satomi Ito, Rika Ohshima, Maki Hagihara, Etsuko Yamazaki, Naoto Tomita, Katsumichi Fujimaki, Jun Taguchi, Rika Sakai, Hiroyuki Fujita, Shin Fujisawa, Atsuo Maruta, Yoshiaki Ishigatsubo, Heiwa Kanamori

    Leukemia & lymphoma   53 ( 3 )   456 - 61   2012.3

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    A multicenter retrospective analysis of the influence of pretransplant serum ferritin (SF) was performed in 261 adult recipients of allogeneic hematopoietic stem cell transplant (allo-HSCT), including 159 patients with acute myeloid leukemia (AML), 66 with acute lymphoid leukemia (ALL) and 36 with myelodysplastic syndrome (MDS). Patients were divided into subgroups according to the pretransplant SF level [< 1000 ng/mL (low) vs. ≥ 1000 ng/mL (high)] and disease status at transplant. A high SF level was significantly associated with high disease risk (p = 0.041), but pretransplant SF and disease risk were independent significant prognostic factors for overall survival (OS), disease-free survival (DFS) and non-relapse mortality rate (NRM) on multivariate analysis. The high-SF group showed a worse outcome than the low-SF group among both standard-risk patients (OS: 54% vs. 64%, p = 0.043; DFS: 46% vs. 57%, p = 0.031) and high-risk patients (OS: 16% vs. 35%, p = 0.001; DFS: 15% vs. 34%, p = 0.001). In conclusion, a high SF at transplant adversely influences the outcome of allo-HSCT regardless of disease risk in patients with acute leukemia and MDS.

    DOI： 10.3109/10428194.2011.619607

    PubMed

    researchmap

  • Clinical efficacy of carbapenems on hospital-acquired pneumonia in accordance with the Japanese Respiratory Society Guidelines for management of HAP Reviewed

    Masaru Ito, Takeshi Kaneko, Hideto Goto, Nobuhiro Yamaguchi, Shin Fujisawa, Shigeru Ono, Satoshi Morita, Naoki Miyazawa, Heiwa Kanamori, Yuji Watanuki, Yoshiaki Ishigatsubo

    JOURNAL OF INFECTION AND CHEMOTHERAPY   17 ( 6 )   770 - 775   2011.12

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1007/s10156-011-0253-y

    Web of Science

    researchmap

  • Long-term outcome of human herpesvirus-6 encephalitis after allogeneic stem cell transplantation. International journal

    Rika Sakai, Heiwa Kanamori, Kenji Motohashi, Wataru Yamamoto, Shiro Matsuura, Atsuko Fujita, Rika Ohshima, Hideyuki Kuwabara, Masatsugu Tanaka, Hiroyuki Fujita, Atsuo Maruta, Yoshiaki Ishigatsubo, Shin Fujisawa

    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation   17 ( 9 )   1389 - 94   2011.9

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    Human herpesvirus-6 (HHV-6) encephalitis is recognized as a relatively rare, but sometimes lethal, complication of allogeneic hematopoietic stem cell transplantation (HSCT). Although the development of new diagnostic techniques and antiviral therapy has improved, the prognosis of encephalitis is still unclear. We surveyed 197 patients who underwent allogeneic HSCT between January 2004 and March 2008 at our institution, and 8 (4.0%) were diagnosed as having HHV-6 encephalitis. Five were male and 3 were female, with a median age of 40.5 years. The median onset of HHV-6 encephalitis was 18 days after HSCT, and the median duration of antiviral therapy was 41 days. The median survival time from the onset of encephalitis was 23.1 months (range: 2.7-66.7), and 3 patients died of unrelated causes (sepsis in 2 and gastrointestinal tract bleeding in 1). Cord blood transplantation was identified as the only independent risk factor (relative risk [RR] = 4.98; P = .049) by multivariate analysis. There was no statistical significance of survival after HSCT between the patients with HHV-6 encephalitis and those without HHV-6 encephalitis (the 2-year survival rate was 60% and 52.6%, respectively; P = .617). Four of the 5 surviving patients were unable to return to society because of neuropsychological disorders, including anterograde amnesia and seizures with prominent hippocampal atrophy. Although HHV-6 encephalitis occurring after HSCT is now becoming a curable complication, its sequelae, such as neuropsychological disorders, have a marked influence on the quality of life of long-term survivors. Accordingly, it is necessary to identify risk factors for HHV-6 encephalitis and establish methods for prevention of this complication.

    DOI： 10.1016/j.bbmt.2011.01.014

    PubMed

    researchmap

  • Lack of non-hematological cross intolerance of dasatinib to imatinib in imatinib-intolerant patients with Philadelphia chromosome positive chronic myeloid leukemia or acute lymphatic leukemia: a retrospective safety analysis Reviewed

    Yukio Kobayashi, Hisashi Sakamaki, Shin Fujisawa, Kiyoshi Ando, Kazuhito Yamamoto, Masaya Okada, Kenichi Ishizawa, Tadashi Nagai, Syuichi Miyawaki, Toshiko Motoji, Noriko Usui, Shinsuke Iida, Masafumi Taniwaki, Nobuhiko Uoshima, Taku Seriu, Ryuzo Ohno

    INTERNATIONAL JOURNAL OF HEMATOLOGY   93 ( 6 )   745 - 749   2011.6

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1007/s12185-011-0864-1

    Web of Science

    Scopus

    PubMed

    J-GLOBAL

    researchmap

    Other Link： http://orcid.org/0000-0003-2378-7865

  • Clinical efficacy and safety of biapenem for febrile neutropenia in patients with underlying hematopoietic diseases: a multi-institutional study Reviewed

    Yasunori Nakagawa, Kenshi Suzuki, Takayuki Hirose, Takaaki Chou, Shin Fujisawa, Michiko Kida, Kensuke Usuki, Yoji Ishida, Shuichi Taniguchi, Yasuji Kouzai, Shigeru Tomoyasu, Koji Miyazaki, Masaaki Higashihara, Kiyoshi Ando, Sadao Aoki, Ayako Arai, Nobu Akiyama, Kiyohiko Hatake, Shinichiro Okamoto, Kazuo Dan, Kazuma Ohyashiki, Akio Urabe

    JOURNAL OF INFECTION AND CHEMOTHERAPY   17 ( 1 )   58 - 67   2011.2

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1007/s10156-010-0075-3

    Web of Science

    PubMed

    researchmap

  • Assessment of adherence to imatinib therapy by questionnaire survey in patients with chronic myeloid leukemia

    Hideyuki Kuwabara, Hiroyuki Takahashi, Yukako Hattori, Rika Ohshima, Maki Hagihara, Rika Sakai, Tetsuji Kaneko, Satoshi Morita, Yoshiaki Ishigatsubo, Shin Fujisawa

    Yokohama Medical Journal   62 ( 4 )   495 - 500   2011

    　More details

    Language：Japanese   Publishing type：Research paper (scientific journal)  

    Scopus

    researchmap

  • Erratum: Clinical efficacy and safety of biapenem for febrile neutropenia in patients with underlying hematopoietic diseases: A multi-institutional study (Journal of Infection and Chemotherapy DOI: 10.1007/s10156-010-0075-3) Reviewed

    Yasunori Nakagawa, Kenshi Suzuki, Takayuki Hirose, Takaaki Chou, Shin Fujisawa, Michiko Kida, Kensuke Usuki, Yoji Ishida, Shuichi Taniguchi, Yasuji Kouzai, Shigeru Tomoyasu, Koji Miyazaki, Masaaki Higashihara, Kiyoshi Ando, Sadao Aoki, Ayako Arai, Nobu Akiyama, Kiyohiko Hatake, Shinichiro Okamoto, Kazuo Dan, Kazuma Ohyashiki, Akio Urabe

    Journal of Infection and Chemotherapy   17 ( 1 )   68 - 69   2011

    　More details

    Language：English   Publishing type：Research paper (scientific journal)   Publisher：Japanese Society for Cancer Chemotherapy  

    DOI： 10.1007/s10156-010-0185-y

    Scopus

    researchmap

  • L-asparaginase単剤で全身状態が改善し、SMILE療法、allo-SCTを施行しえたaggressive NK cell leukemiaの一例

    高橋 寛行, 酒井 リカ, 服部 友歌子, 大島 理加, 桑原 英幸, 萩原 真紀, 江中 牧子, 野沢 昭典, 石ヶ坪 良明, 藤澤 信

    臨床血液   51 ( 9 )   1254 - 1254   2010.9

    　More details

    Language：Japanese   Publisher：(一社)日本血液学会-東京事務局  

    researchmap

  • 別クローン由来と考えられるt(15;17)(q22;q12)とt(9;22)(q34;q11.2)を認めた急性前骨髄性白血病(APL)の1例

    高橋 寛行, 服部 友歌子, 大島 理加, 萩原 真紀, 桑原 英幸, 藤澤 信, 酒井 リカ, 石ヶ坪 良明

    臨床血液   51 ( 3 )   222 - 222   2010.3

    　More details

    Language：Japanese   Publisher：(一社)日本血液学会-東京事務局  

    researchmap

  • The therapeutic effect of rituximab on CD5-positive and CD5-negative diffuse large B-cell lymphoma Reviewed

    Rie Hyo, Naoto Tomita, Kengo Takeuchi, Tomohiro Aoshima, Atsuko Fujita, Hideyuki Kuwabara, Chizuko Hashimoto, Sachiya Takemura, Jun Taguchi, Rika Sakai, Hiroyuki Fujita, Shin Fujisawa, Koji Ogawa, Shigeki Motomura, Ritsuro Suzuki, Yoshiaki Ishigatsubo

    HEMATOLOGICAL ONCOLOGY   28 ( 1 )   27 - 32   2010.3

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1002/hon.896

    Web of Science

    PubMed

    researchmap

  • 抗HLAクラスII抗体陽性例に対する再臍帯血移植

    桑原 英幸, 高橋 寛行, 服部 友歌子, 山本 渉, 大島 理加, 萩原 真紀, 藤澤 信, 酒井 リカ, 石ヶ坪 良明

    神奈川医学会雑誌   37 ( 1 )   110 - 110   2010.1

    　More details

    Language：Japanese   Publisher：(公社)神奈川県医師会  

    researchmap

  • Retrospective comparison of mobilization methods for autologous stem cell transplantation in multiple myeloma Reviewed

    Hideki Nakasone, Yoshinobu Kanda, Tomoki Ueda, Kenji Matsumoto, Naomi Shimizu, Jiro Minami, Rika Sakai, Maki Hagihara, Akira Yokota, Kumi Oshima, Yuiko Tsukada, Takayoshi Tachibana, Chiaki Nakaseko, Shin Fujisawa, Shingo Yano, Hiroyuki Fujita, Satoshi Takahashi, Heiwa Kanamori, Shinichiro Okamoto

    AMERICAN JOURNAL OF HEMATOLOGY   84 ( 12 )   809 - 814   2009.12

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1002/ajh.21552

    Web of Science

    PubMed

    researchmap

  • 免疫電気泳動でM蛋白陰性だがVEGF高値で診断したPOEMS症候群

    服部 友歌子, 田口 淳, 松浦 史郎, 今井 昇, 和佐野 浩一郎, 小原澤 英之, 高橋 寛行, 大島 理加, 萩原 真紀, 桑原 英幸, 酒井 リカ, 藤澤 信, 石ヶ坪 良明

    臨床血液   50 ( 9 )   1159 - 1159   2009.9

    　More details

    Language：Japanese   Publisher：(一社)日本血液学会-東京事務局  

    researchmap

  • Features of primary extranodal lymphoma in Kanagawa, a human T-cell leukemia virus type 1 nonendemic area in Japan

    Atsuko Fujita, Naoto Tomita, Hiroyuki Fujita, Kenji Motohashi, Rie Hyo, Etsuko Yamazaki, Michiko Hattori, Shin Fujisawa, Heiwa Kanamori, Koji Ogawa, Shigeki Motomura, Fumio Kodama, Yoshiaki Ishigatsubo

    Medical Oncology   26 ( 1 )   49 - 54   2009.3

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1007/s12032-008-9080-0

    Scopus

    PubMed

    researchmap

  • Diffuse Large B Cell Lymphoma without Immunoglobulin Light Chain Restriction by Flow Cytometry Reviewed

    Naoto Tomita, Kengo Takeuchi, Rie Hyo, Chizuko Hashimoto, Sachiya Takemura, Jun Taguchi, Hiroyuki Fujita, Shin Fujisawa, Koji Ogawa, Shigeki Motomura, Yoshiaki Ishigatsubo

    ACTA HAEMATOLOGICA   121 ( 4 )   196 - 201   2009

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1159/000220332

    Web of Science

    PubMed

    researchmap

  • Long-Term Follow-up of the Randomized JALSG AML 201 Study Comparing High Dose Ara-C Therapy with Conventional Consolidation Therapy in Adult Acute Myeloid Leukemia (AML) Reviewed

    Shuichi Miyawaki, Shigeki Ohtake, Shin Fujisawa, Hitoshi Kiyoi, Katsuji Shinagawa, Noriko Usui, Kohichi Miyamura, Miki Nishimura, Yasushi Miyazaki, Kazuhiro Nishii, Tadashi Nagai, Takahisa Yamane, Masafumi Taniwaki, Masatomo Takahashi, Fumiharu Yagasaki, Yukihiko Kimura, Norio Asou, Sumihisa Honda, Kazunori Ohnishi, Tomoki Naoe, Ryuzo Ohno

    BLOOD   112 ( 11 )   56 - 56   2008.11

    　More details

    Language：English  

    Web of Science

    researchmap

  • Central nervous system relapse of leukemia after allogeneic hematopoietic stem cell transplantation Reviewed

    Kumi Oshima, Yoshinobu Kanda, Takuya Yamashita, Satoshi Takahashi, Takehiko Mori, Chiaki Nakaseko, Katsumichi Fujimaki, Akira Yokota, Shin Fujisawa, Takafumi Matsushima, Hiroyuki Fujita, Tohru Sakura, Shinichiro Okamoto, Atsuo Maruta, Hisashi Sakamaki

    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION   14 ( 10 )   1100 - 1107   2008.10

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1016/j.bbmt.2008.07.002

    Web of Science

    PubMed

    researchmap

  • サリドマイドが奏功し、自家末梢血幹細胞移植後に完全寛解を得た原発性形質細胞性白血病の1例

    酒井 リカ, 橋本 千寿子, 山崎 悦子, 青島 朋裕, 松浦 史郎, 山本 渉, 藤田 敦子, 大島 理加, 兵 理絵, 桑原 英幸, 石ヶ坪 良明, 藤澤 信

    臨床血液   49 ( 9 )   1134 - 1134   2008.9

    　More details

    Language：Japanese   Publisher：(一社)日本血液学会-東京事務局  

    researchmap

  • Discrepant results of ABO type of red cells and serum in a patient with acute myelogenous leukemia

    FUJITA Atsuko, FUJISAWA Shin, OHSHIMA Rika, HYO Rie, KUWABARA Hideyuki, YAMAZAKI Etsuko, TOMITA Naoto, HARANO Hiroshi, ISHIGATSUBO Yoshiaki

    Rinsho Ketsueki   49 ( 1 )   51 - 54   2008.1

    　More details

    Language：Japanese   Publisher：The Japanese Society of Hematology  

    A 42-year-old woman was admitted to our hospital with acute myelogenous leukemia. We conducted blood-type examination, and her serum showed strong agglutination with all B cells but questionable agglutination with A<sub>1</sub> cells, which became stronger with incubation. We considered her blood type as O, but her previously assessed blood type was A. After receiving one cycle of induction therapy, she achieved complete remission and blood group A antigen was proven on her red blood cells. Anti-A<sub>1</sub> in her serum disappeared after induction therapy. We should be aware that blood group antigens are not entirely independent of the environment and are occasionally modified by disease.

    DOI： 10.11406/rinketsu.49.51

    CiNii Books

    researchmap

    Other Link： https://jlc.jst.go.jp/DN/JALC/00309943299?from=CiNii

  • Usefulness of hematopoietic cell transplantation-specific comorbidity index after allogeneic hematopoietic stem cell transplantation

    Katsumichi Fujimaki, Rika Sakai, Shin Fujisawa, Hiroyuki Fujita, Masatsugu Tanaka, Maki Hagihara, Hideyuki Koharazawa, Takuya Miyazaki, Naoto Tomita, Heiwa Kanamori, Atsuo Maruta, Yoshiaki Ishigatsubo

    Gan to kagaku ryoho. Cancer &amp; chemotherapy   35 ( 1 )   87 - 91   2008

    　More details

    Language：Japanese   Publishing type：Research paper (scientific journal)  

    Scopus

    PubMed

    researchmap

  • Thiotepa/cyclophosphamide/TBI as a Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients Aged 50 Years and Over

    Fujimaki Katsumichi, Tanaka Masatsugu, Takasaki Hirotaka, Hyo Rie, Kawano Tomoko, Sakai Rika, Fujita Hiroyuki, Fujisawa Shin, Kanamori Heiwa, Maruta Atsuo, Ishigatsubo Yoshiaki

    Japanese Journal of Medicine   47 ( 5 )   379 - 383   2008

    　More details

    Language：English   Publisher：The Japanese Society of Internal Medicine  

    <b>Objective</b> To reduce the relapse rate for hematological malignancies after allogeneic hematopoietic stem cell transplantation, we employed a myeloablative regimen comprising thiotepa 400 mg/m<sup>2</sup>, cyclophosphamide 3,600 mg/m<sup>2</sup> and total body irradiation 10 Gy.<br> <b>Materials and Methods</b> Subjects comprised 17 patients (median age, 53 years; range, 50-56 years) with hematological malignancies who received allogeneic hematopoietic stem cell transplantation from HLA-identical related (n=6), HLA-mismatched family (n=2) or unrelated donors (n=9). Prophylaxis of acute graft-versus-host disease (GVHD) consisted of short-term methotrexate and cyclosporine (n=4) or short-term methotrexate and tacrolimus (n=13).<br> <b>Results</b> No grade IV regimen-related toxicities as determined by Bearman's criteria were encountered. Acute grade II-IV GVHD developed in 7 patients, with chronic GVHD in 11 patients. With a median follow-up of 39 months, 3 years survival rate after transplantation was 59%. Two patients died due to infection by 100 days after transplantation. Only 1 patient with Philadelphia-positive acute lymphoblastic leukemia experienced relapse. Eight patients died of non-leukemic causes (sepsis, n=2; liver dysfunction, n=2; idiopathic interstitial pneumonia, n=1; bacterial pneumonia, n=1; bronchiolitis obliterans resulting from chronic GVHD, n=1; and disseminated infection with varicella zoster virus, n=1).<br> <b>Conclusions</b> This regimen was tolerable, but a large trial is warranted to confirm the efficacy of this conditioning.<br>

    DOI： 10.2169/internalmedicine.47.0598

    researchmap

    Other Link： http://search.jamas.or.jp/link/ui/2008245502

  • Long-term outcome of L86 and L97 protocols for adult acute lymphoblastic leukemia Reviewed

    Hideyuki Koharazawa, Heiwa Kanamori, Rika Sakai, Chizuko Hashimoto, Sachiya Takemura, Etsuko Yamazaki, Michiko Hattori, Jun Taguchi, Katsumichi Fujimaki, Naoto Tomita, Hiroyuki Fujita, Shin Fujisawa, Hiroshi Harano, Koji Ogawa, Shigeki Motomura, Atsuo Maruta, Yoshiaki Ishigatsubo

    LEUKEMIA & LYMPHOMA   49 ( 11 )   2133 - 2140   2008

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1080/10428190802464711

    Web of Science

    researchmap

  • ダサチニブの慢性骨髄性白血病及びPhiladelphia染色体陽性急性リンパ性白血病に対する臨床第I/II相試験 Reviewed

    坂巻 壽, 谷脇 雅史, 石澤 賢一, 藤澤 信, 森島 泰雄, 飛内 賢正, 岡田 昌也, 安藤 潔, 薄井 紀子, 宮脇 修一, 宇都宮 與, 魚嶋 伸彦, 永井 正, 直江 知樹, 泉二 登志子, 陣内 逸郎, 谷本 光音, 宮崎 泰司, 大西 一功, 飯田 真介, 岡本 真一郎, 芹生 卓, 大野 竜三

    臨床血液   48 ( 9 )   944 - 944   2007.9

    　More details

    Language：Japanese   Publisher：(一社)日本血液学会-東京事務局  

    researchmap

  • Comparison of peripheral T-cell lymphomas and diffuse large B-cell lymphoma Reviewed

    Naoto Tomita, Shigeki Motomura, Rie Hyo, Hirotaka Takasaki, Sachiya Takemura, Jun Taguchi, Shin Fujisawa, Koji Ogawa, Yoshiaki Ishigatsubo, Kengo Takeuchi

    CANCER   109 ( 6 )   1146 - 1151   2007.3

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1002/cncr.22507

    Web of Science

    PubMed

    researchmap

  • Postremission therapy in adult acute myeloid leukemia (AML): A randomized comparison between high dose ara-C therapy and conventional consolidation therapy (JALSG AML 201 study). Reviewed

    Shuichi Miyawaki, Shigeki Ohtake, Shin Fujisawa, Hitoshi Kiyoi, Katsuji Shinagawa, Noriko Usui, Koichi Miyamura, Miki Nishimura, Yasushi Miyazaki, Kazuhiro Nishii, Tadashi Nagai, Takahisa Yamane, Masafumi Taniwaki, Masatomo Takahashi, Fumiharu Yagasaki, Yukihiko Kimura, Norio Asou, Sumihisa Honda, Kazunori Ohnishi, Tomoki Naoe, Ryuzo Ohno

    BLOOD   108 ( 11 )   567A - 567A   2006.11

    　More details

  • Phase II study of CHOP-GR therapy for advanced-stage follicular lymphoma Reviewed

    Naoto Tomita, Fumio Kodama, Rika Oshima, Chizuko Hashimoto, Hideyuki Koharazawa, Sachiya Takemura, Etsuko Yamazaki, Katsumichi Fujimaki, Rika Sakai, Hiroyuki Fujita, Shin Fujisawa, Heiwa Kanamori, Shigeki Motomura, Yoshiaki Ishigatsubo

    LEUKEMIA & LYMPHOMA   47 ( 6 )   1041 - 1047   2006.6

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1080/10428190500472784

    Web of Science

    researchmap

  • DLBCLにおけるbulky massへの寛解後照射の意義

    富田 直人, 児玉 文雄, 本村 茂樹, 伊藤 仁美, 大島 理加, 兵 理絵, 河野 知子, 橋本 千寿子, 竹村 佐千哉, 山崎 悦子, 藤田 浩之, 藤澤 信, 小川 浩司, 金森 平和, 石ヶ坪 良明

    日本リンパ網内系学会会誌   46   102 - 102   2006.6

    　More details

    Language：Japanese   Publisher：(一社)日本リンパ網内系学会  

    researchmap

  • Clinical course of 8 patients with intravascular large B-cell lymphoma diagnosed while alive

    OHSHIMA Rika, TOMITA Naoto, MOTOHASHI Kenji, IEDA Atsuko, HYOU Rie, FUJISAWA Shin, FUJITA Hiroyuki, SAKAI Rika, KOHARAZAWA Hideyuki, KUWABARA Hideyuki, KANAMORI Heiwa, ISHIGATSUBO Yoshiaki

    Rinsho Ketsueki   46 ( 6 )   453 - 457   2005.6

    　More details

    Language：Japanese   Publisher：The Japanese Society of Hematology  

    We retrospectively evaluated the diagnosis and clinical courses of 8 patients with intravascular large B-cell lymphoma (IVL) diagnosed while they were alive. The median age was 67 years old (range 54 to 82). Most complaints at diagnosis were fever or dyspnea. All patients were in clinical stage IV with B symptoms and 4 patients showed performance status 4. The diagnosis of IVL was confirmed by biopsy specimens from the bone marrow in 4, lung in 2, muscle, adrenal gland, and lymph node in 1 case, respectively. Initial bone marrow involvement was found in 6 patients. Chemotherapy was performed in 7 patients. Rituximab was added to chemotherapy in 5 patients. Though 5 patients are alive at the median follow up of 12.3 months, only 1 patient is in remission. Four of 5 patients treated with Rituximab relapsed. In suspicious cases, it is important to bear IVL in mind and examine bone marrow biopsies for an early diagnosis. In addition, it is suggested that Rituximab may play only a temporary role in the treatment of IVL.

    DOI： 10.11406/rinketsu.46.453

    CiNii Books

    researchmap

    Other Link： http://search.jamas.or.jp/link/ui/2005290296

  • A trial of front-line intensive chemotherapy followed by peripheral blood stem cell transplantation in high-intermediate and high risk non-Hodgkin's lymphoma patients

    MOTOMURA Shigeki, HASHIMOTO Chizuko, KODAMA Fumio, MARUTA Atsuo, SAKAI Rika, FUJITA Hiroyuki, TOMITA Naoto, FUJISAWA Shin, HARANO Hiroshi, KOHARAZAWA Hideyuki, FUJIMAKI Katsumichi, KANAMORI Heiwa, ISHIGATSUBO Yoshiaki

    Rinsho Ketsueki   46 ( 5 )   350 - 357   2005.5

    　More details

    Language：Japanese   Publisher：The Japanese Society of Hematology  

    High-intermediate (HI)- and high (H)-risk non-Hodgkin lymphoma was treated with front-line intensive chemotherapy followed by autologous peripheral blood stem cell transplantation (auto-PBSCT). Twenty-eight cases were enrolled after obtaining informed consent, from November, 1998 to October, 2003. Initial treatment was 2 or 3 cycles of CHOP-V regimen, followed by three high-dose therapy, one each of cyclophosphamide, methotrexate and etoposide. The final high-dose therapy was a combination of ranimustine, ifosphamide and etoposide, which was followed by auto-PBSCT. Patients with a bulky mass received involved-field radiation therapy (IF-RT) after auto-PBSCT. Complete remission (CR) was achieved in 16 cases (57%) and partial remission (PR) in 9 cases (32%), after auto-PBSCT. The final responses after IF-RT were CR in 20 cases (71%) and PR in 5 cases (18%). Overall survival of cases with 2 cycles of CHOP-V regimen was 56% after a median observation time of 30 months, compared with 82% in cases with 3 cycles (p=0.0732). The results suggested that the reduction of tumor size with the initial CHOP-V treatment was most important. In all cases, progression-free survival was 64% and the overall survival was 74% after a median observation time of 30 months, which showed a good outcome compared with that of HI- and H-risk group defined by the age-adjusted international prognostic index reported by Shipp et al.

    DOI： 10.11406/rinketsu.46.350

    CiNii Books

    researchmap

    Other Link： http://search.jamas.or.jp/link/ui/2005235625

  • Epstein - Barr virus-associated extranodal NK/T-cell lymphoma following mosquito bites in an elderly patient without prior hypersensitivity

    Naoto Tomita, Heiwa Kanamori, Katsumichi Fujimaki, Shin Fujisawa, Yoshiaki Ishigatsubo

    Leukemia and Lymphoma   45 ( 10 )   2153 - 2155   2004.10

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1080/10428190410001697403

    Scopus

    PubMed

    researchmap

  • Pulmonary embolism and thrombotic thrombocytopenic purpura in acute promyelocytic leukemia treated with all-trans retinoic acid

    Hiroyuki Fujita, Sachiya Takemura, Rie Hyo, Masatsugu Tanaka, Hideyuki Koharazawa, Shin Fujisawa, Heiwa Kanamori, Yoshiaki Ishigatsubo

    Leukemia and Lymphoma   44 ( 9 )   1627 - 1629   2003.9

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1080/1042819031000097401

    Scopus

    PubMed

    researchmap

  • Lymphoblastic lymphoma presenting as a solitary subcutaneous mass

    KOJIMA Mio, TOMITA Naoto, FUJIMAKI Katsumichi, FUJISAWA Shin, KANAMORI Heiwa, ISHIGATSUBO Yoshiaki

    Rinsho Ketsueki   44 ( 1 )   25 - 27   2003.1

    　More details

    Language：Japanese   Publisher：The Japanese Society of Hematology  

    A solitary cutaneous or subcutaneous mass in lymphoblastic lymphoma (LBL) is a rare manifestation. A 15-year-old girl presented with a subcutaneous LBL on her left back. There were no other lesions. Complete remission (CR) was achieved after 2 courses of ACOMP-B (doxorubicin, cyclophosphamide, vincristine, methotrexate, prednisolone, and bleomycin) therapy. Two courses of the chemotherapy and 4 sessions of prophylactic intrathecal methotrexate (15 mg/body) and hydrocortisone (25 mg/body) were added after CR. However, the patient relapsed with bone marrow involvement after 14 months remission. It is necessary to accumulate more experience with this kind of case to find the appropriate treatment strategy for solitary cutaneous or subcutaneous LBL.

    DOI： 10.11406/rinketsu.44.25

    CiNii Books

    researchmap

    Other Link： http://search.jamas.or.jp/link/ui/2003168393

  • Complete cytohenetic response obtained with unrelared donor lymphocyte infusion for relapse of chronic myeloid leukemia in blastic crisis after allogeneic bone marrow transplantation

    FUJIMAKI Katsumichi, MARUTA Atsuo, YOSHIDA Michihiko, YAMAZAKI Etsuko, MATSUZAKI Michio, FUJISAWA Shin, KANAMORI Heiwa, ISHIGATSUBO Yoshiaki

    Rinsho Ketsueki   42 ( 3 )   204 - 208   2001.3

    　More details

    Language：Japanese   Publisher：The Japanese Society of Hematology  

    A 35-year-old man with chronic myeloid leukemia (CML) in blastic crisis (BC) received an allogeneic bone marrow transplant from an unrelated donor in October 1998 after three cycles of chemotherapy. BC relapse developed on day 349 after transplantation. After one cycle of chemotherapy and treatment with interferon, the patient received donor lymphocyte infusion (DLI), and this resulted in a complete cytogenetic response 21 days later. Grade III acute graft-versus-host disease developed on day 25 after DLI, but this was resolved after administration of prednisolone. Disease relapse occurred at extramedullary sites on day 162 after DLI, and the patient died of sepsis after receiving chemotherapy. This case illustrates that unrelated DLI can induce remission successfully in patients with relapse of CML in BC through a graft-versus-leukemia effect.

    DOI： 10.11406/rinketsu.42.204

    CiNii Books

    researchmap

    Other Link： https://jlc.jst.go.jp/DN/JALC/00090873287?from=CiNii

  • Subcutaneous Extramedullar Hematopoiesis in a Patient with Secondary Myelofibrosis Following Polycythemia Vera

    Masatsugu Tanaka, Heiwa Kanamori, Satoshi Yamaji, Aki Mishima, Etsuko Yamazaki, Jun Taguchi, Mami Aoba, Shin Fujisawa, Hiroshimohri, Yoshiaki Ishigatsubo

    Leukemia and Lymphoma   40 ( 42067 )   437 - 440   2001.1

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.3109/10428190109057946

    Scopus

    PubMed

    researchmap

  • Successful Emergency Operation for Subdural Hematoma and Acute Epidural Hematoma in a Patient with Acute Promyelocytic Leukemia

    YAMAJI Satoshi, KANAMORI Heiwa, TANAKA Masatsugu, MISHIMA Aki, KOHARAZAWA Hideyuki, FUJITA Hiroyuki, FUJISAWA Shin, MURATA Takashi, MATSUZAKI Michio, MOHRI Hiroshi, ISHIGATSUBO Yoshiaki

    Rinsho Ketsueki   40 ( 7 )   606 - 609   1999.7

    　More details

    Language：Japanese   Publisher：The Japanese Society of Hematology  

    A 22-year-old woman was admitted with purpura. Acute promyelocytic leukemia (APL) with disseminated intravascular coagulation (DIC) was diagnosed. On the 17th day after treatment with all-<i>trans</i> retinoic acid (ATRA), left subdural hematoma developed. Although coagulation abnormalities were still observed, emergency surgery was perfomed. Acute epidural hematoma was confirmed by computed tomographic scan after the operation. A second operation for drainage was successful. Post-operative intracranial hematoma may be caused by rapid decompression induced by surgery, but DIC could also be involved. This case underscored the need for careful consideration of the indications for surgical treatment of such DIC patients, with close follow-up monitoring for the postoperative development of neurological symptoms.

    DOI： 10.11406/rinketsu.40.606

    CiNii Books

    researchmap

    Other Link： http://search.jamas.or.jp/link/ui/2000020558

  • De novo Acute Myelogenous Leukemia with Trilineage Myelodysplasia Associated with t(8:21)(q22;q22)

    FUJISAWA Shin, TOGAWA Jun-ichi, TANAKA Masatsugu, KOHARAZAWA Hideyuki, AOBA Mami, FUJITA Hiroyuki, MURATA Takashi, KANAMORI Heiwa, MATSUZAKI Michio, MOHRI Hiroshi, ISHIGATSUBO Yoshiaki

    Japanese Journal of Medicine   38 ( 7 )   607 - 611   1999.7

    　More details

    Language：English   Publisher：The Japanese Society of Internal Medicine  

    We describe a rare case of de novo acute myelogenous leukemia with trilineage myelodysplasia (AML/TMDS) associated with t(8;21)(q22;q22). The patient was admitted to our hospital with leukocytopenia. AML/TMDS was diagnosed by excess myeloblasts and morphological findings of bone marrow. The karyotype revealed 45, X, -Y, t(8;21)(q22;q22) in 17 of 20 analyzed mitoses, and also AML1/MTG8 transcripts were detected by the reverse transcription polymerase chain reaction (RT-PCR) method. The patient achieved a complete remission with a combination chemotherapy of daunorubicin, cytarabine, and prednisolone. This case suggests that t(8;21)(q22;q22) may participate in the pathogenesis of AML/TMDS, although this type is usually found as one of the chromosomal abnormalities in de novo acute myelogenous leukemia (AML) with maturation.<br>(Internal Medicine 38: 607-611, 1999)

    DOI： 10.2169/internalmedicine.38.607

    CiNii Books

    researchmap

    Other Link： https://jlc.jst.go.jp/DN/JALC/00086400046?from=CiNii

  • Improvement of quality of life after splenectomy in an HTLV-I carrier with T-cell prolymphocytic leukemia

    Rika Sakai, Atsuo Maruta, Naoto Tomita, Jun Taguchi, Shin Fujisawa, Koji Ogawa, Shigeki Motomura, Fumio Kodama, Hiroshi Mohri, Yoshiaki Ishigatsubo

    Leukemia and Lymphoma   35 ( 5-6 )   607 - 611   1999

    　More details

    Language：English   Publishing type：Research paper (scientific journal)   Publisher：Harwood Academic Publishers GmbH  

    DOI： 10.1080/10428199909169626

    Scopus

    PubMed

    researchmap

  • Chronic Myelogenous Leukemia with ling term Hypoplasia induced by α-Interferon and Hydroxyurea

    MOTOMURA Shigeki, SAKAI Rika, TOMITA Naoto, FUJMAKI Katsumichi, HATTORI Michiko, FUJISAWA Shin, MOHRI Hiroshi, TAKAHASHI Naoki, MARUTA Atsuo, KODAMA Fumio, OKUBO Takao

    Rinsho Ketsueki   39 ( 4 )   302 - 307   1998.4

    　More details

    Language：Japanese   Publisher：The Japanese Society of Hematology  

    A 48-year-old woman was admitted with chronic myelogenous leukemia in November, 1996 and was treated with hydroxyurea (HU), because of marked leukocytosis; WBC 404,000/&mu;<i>l</i>. On January 29, 1997, administration of HU was stopped, and treatment of &alpha;-interferon (IFN&alpha;) was started with 6x10<sup>6</sup>U, every day. However, the WBC count rose from 19,600/&mu;<i>l</i> to 56,800/&mu;<i>l</i>, and the combination of IFN and 2,000 mg of HU was started on February 4. The dose of HU was reduced to 500 mg on February 27, and the IFN administration was reduced to 3 times a week from April 4, because the WBC count was less than 10,000/&mu;<i>l</i>. Pancytopenia was revealed in May. The bone marrow biopsy specimen demonstrated marked hypoplastic changes, and chromosome analysis of bone marrow cells showed Philadelphia chromosome in all 20 metaphases. Treatment was interrupted for 7 months, but hematologic parameters did not recover. There were 9 cases reported in detail with bone marrow hypoplasia induced by IFN. One patient received IFN alone and 8 patients received anti-cancer drugs before treatment of IFN. We concluded that great care must be taken for IFN treatment of CML.

    DOI： 10.11406/rinketsu.39.302

    CiNii Books

    researchmap

  • Therapy Related Leukemia

    FUJISAWA Shin, MARUTA Atsuo, SAKAI Rika, OGAWA Koji, TAGUCHI Jun, TOMITA Naoto, KODAMA Fumio, FUKAWA Hitoshi, NOGUCHI Tahei, MATSUZAKI Michio, MOTOMURA Shigeki, OKUBO Takao

    Rinsho Ketsueki   36 ( 10 )   1163 - 1169   1995.10

    　More details

    Language：Japanese   Publisher：The Japanese Society of Hematology  

    Eleven therapy related leukemias (TRL) who were hospitalized in the Department of Hematology and Chemotherapy, Kanagawa Cancer Center between October 1983 and December 1993 were identified. Six of the patients were males and five were females. Their median age was 62 years (range from 14 to 75). Three patients had previously received treatment for breast cancer and two patients for malignant lymphoma. The other patients had received treatment for lung cancer, urinary bladder cancer, gastric cancer, brain tumor, maxillary sinus cancer and macroglobulinemia, respectively. Seven patients had been treated with chemotherapy and four patients had been treated with chemotherapy and irradiation for the primary tumor. The TRL cases consisted of 8 acute non-lymphoid leukemias, two acute lymphoid leukemias and one hypoplastic leukemia, respectively. The status of primary tumors at the developement of TRL was complete remission in ten patients and partial remission in one patient. Three of the 10 patients who received anti-leukemic therapy entered complete remission and the median survival time was 36 days (from 7 days to 489 days). One patient expired of pneumonia before he received anti-leukemic therapy. TRL patients showed poor response to chemotherapy and had poor prognosis. These data suggest that the use of reduced doses of carcinogenic drugs for primary tumors might be required to prevent the development of TRL.

    DOI： 10.11406/rinketsu.36.1163

    CiNii Books

    researchmap

    Other Link： https://jlc.jst.go.jp/DN/JALC/00082005818?from=CiNii

  • Autopsy Cases of Cytomegalovirus interstitial Pneumonitis Following Bone Marrow transplantation

    SAKAI Rika, MARUTA Atsuo, TAGUCHI Jun, TOMITA Naoto, KODAMA Fumio, HARADA Masaoki, SHIMIZU Akio, NAKAMURA Yoshiyasu, IDA Manichi, KAMEDA Youichi, MOTOMURA Shigeki, OGAWA Kouji, HARANO Hiroshi, FUJISAWA Shin, MATSUZAKI Michio, OKUBO Takao

    Rinsho Ketsueki   36 ( 8 )   735 - 741   1995.8

    　More details

    Language：Japanese   Publisher：The Japanese Society of Hematology  

    We investigated the relevance of cytomegalovirus (CMV) to interstitial pneumonitis (IP) using formalin-fixed and paraffin-embedded lung tissues obtained from 12 autopsy cases who died following bone marrow transplantation (BMT) from May 1985 to March in 1992. The lung tissues were examined by hematoxylin and eosin (H.E.) staining, immunohistochemistry with monoclonal antibodies (DDG9, CCH2) and polymerase chain reaction (PCR) for amplifying human CMV DNA. Eight of 12 cases were clinically diagnosed as IP. The 4 cases showed no signs of IP, and their tissues were used as controls. H.E. staining revealed inclusion bodies in two of the eight and only severe fibrosis in the other six. In 4 of the 6 cases, however, CMV was identified by immunohistochemistry or PCR. We concluded that the relevance of CMV in the genesis of IP is often overlooked by H.E. staining alone. Immunohistochemistry and PCR are useful in examining tissues which are suspected of CMV-IP.

    DOI： 10.11406/rinketsu.36.735

    CiNii Books

    researchmap

    Other Link： http://search.jamas.or.jp/link/ui/1996038504

  • Intermittent-dose Ara-C/daunomycin Therapy Combinated with Cyclosporin-A and G-CSF Led to a Fourth Remission in a Patient with Acute Promyelocytic Leukemia

    MOTOMURA Shigeki, FUJISAWA Shin, ANZAI Seiichiro, FUJIMAKI Katsumichi, HATTORI Michiko, FUKAWA Hitoshi, OKUBO Takao

    Rinsho Ketsueki   36 ( 8 )   762 - 767   1995.8

    　More details

    Language：Japanese   Publisher：The Japanese Society of Hematology  

    A 50-year-old female was admitted with acute promyelocytic leukemia (APL) in August, 1988. She was treated with behenoyl-ara-C, daunomycin, 6-mercaptopurine and prednisolone (BH-AC&middot;DMP), which led to a complete remission. Thereafter, she was treated with 2 courses of BH-AC&middot;DM and discharged from hospital. Intensification therapy was performed twice a year, with 1 course of BH-AC&middot;DM and 5 courses of intermittent-dose ara-C/mitoxantrone which ended in March, 1992. She had a relapse in September, 1993 and was treated with all-trans retinoic acid, which led to a second remission. A second relapse occured in May, 1994, and intermittent-dose ara-C/mitoxantrone, combinated with granulocyte colony-stimulating factor (G-CSF), led to a third remission. However, she had a third relapse in September, 1994. She was treated with a trial of G-CSF (300 &mu;g/body, day 1-7), to stimulate dormant leukemic cells to enter the cell cycle, and cyclosporin-A (78 mg/kg, day 2-5), in order to overcome daunomycin resistance in refractory leukemia, combinated with daunomycin (45 mg/m<sup>2</sup>, day 3-5) and ara-C (1.4 g/m<sup>2</sup>, day 3-7), after obtaining informed consent. The fourth remission needed 46 days after combination chemotherapy because of severe myelosuppression. It was suggested that intermittent-dose ara-C/daunomycin therapy combinated with G-CSF and cyclosporin-A may be useful for relapsed and refractory leukemia.

    DOI： 10.11406/rinketsu.36.762

    CiNii Books

    researchmap

▼display all

MISC

  • Outcomes of Transplant-Eligible Patients with Myelodysplastic Syndrome-Refractory Anemia with Excess Blasts Registered in a Prospective Observational Study: The JALSG-CS11-MDS-SCT

    Noriharu Nakagawa, Ken Ishiyama, Kensuke Usuki, Satoru Takada, Tatsuki Tomikawa, Hiroshi Handa, Yuna Katsuoka, Daiki Hirano, Nobuo Sezaki, Masahiko Sumi, Shin Fujisawa, Yasuhiro Taniguchi, Takuro Yoshimura, Eiichi Ohtsuka, Ken Takase, Youko Suehiro, Shuichi Ota, Tomohiro Kajiguchi, Tomoya Maeda, Masahide Yamamoto, Shigeki Ohtake, Akira Katsumi, Hitoshi Kiyoi, Itaru Matsumura, Yasushi Miyazaki

    BLOOD   138   2021.11

    　More details

    Language：English   Publishing type：Research paper, summary (international conference)  

    DOI： 10.1182/blood-2021-147587

    Web of Science

    researchmap

  • Dasatinib-Based Two-Step Induction Prior to Allogeneic Hematopoietic Cell Transplantation for Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Results of the JALSG Ph+ALL213 Study

    Isamu Sugiura, Noriko Doki, Tomoko Hata, Ryuko Cho, Toshiro Ito, Youko Suehiro, Heiwa Kanamori, Shinichi Kako, Mitsuhiro Matsuda, Hisayuki Yokoyama, Yasuhiro Taniguchi, Maki Hagihara, Yukiyasu Ozawa, Shin Fujisawa, Nobuaki Dobashi, Yoshihiro Hatta, Noboru Asada, Kazuteru Ohashi, Yasushi Onishi, Koh Shiro, Satoshi Nishiwaki, Yoshiko Atsuta, Fumihiko Hayakawa, Shigeki Ohtake, Yasushi Miyazaki

    BLOOD   134   2019.11

    　More details

    Language：English   Publishing type：Research paper, summary (international conference)  

    DOI： 10.1182/blood-2019-123382

    Web of Science

    researchmap

  • 初診時白血球の著しい増加を伴わず慢性骨髄性白血病と診断された2例

    白蓋 万葉子, 宮下 和甫, 畠山 まりか, 大橋 卓馬, 徳永 真由美, 青木 淳, 石井 好美, 中嶋 ゆき, 藤澤 信, 中島 秀明

    臨床血液   60 ( 5 )   524 - 524   2019.5

    　More details

    Language：Japanese   Publisher：(一社)日本血液学会-東京事務局  

    researchmap

  • Corynebacterium blood stream infection among hematological malignancy patients with neutropenia: a case series analysis

    Hiroyuki Takahashi, Hideaki Kato, Ayako Matsumura, Kazuho Miyashita, Sei Samukawa, Yuki Nakajima, Maki Hagihara, Etsuko Yamazaki, Shin Fujisawa, Hideaki Nakajima

    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS   50   S60 - S60   2017.11

    　More details

    Language：English   Publishing type：Research paper, summary (international conference)  

    Web of Science

    researchmap

  • Association of Peripheral Regulatory T Cells with Achievement of Deep Molecular Response in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Treated with Dasatinib - the Final Results of D-First Study

    Chikashi Yoshida, Noriyoshi Iriyama, Yuho Najima, Shin Fujisawa, Hisashi Wakita, Shigeru Chiba, Shinichiro Okamoto, Kimihiro Kawakami, Naoki Takezako, Takashi Kumagai, Kazuma Ohyashiki, Jun Taguchi, Shingo Yano, Tadahiko Igarashi, Yasuji Kouzai, Satoshi Morita, Junichi Sakamoto, Hisashi Sakamaki, Koiti Inokuchi

    BLOOD   128 ( 22 )   2016.12

    　More details

    Language：English   Publishing type：Research paper, summary (international conference)  

    Web of Science

    researchmap

  • Identification of Bone Marrow Involvement of FL: Comparison of PET-CT and Bone Marrow Biopsy.

    Yuki Nakajima, Shin Fujisawa, Chika Nigauri, Teshigawara Haruka, Ayako Matsumura, Taiki Ando, Taisei Suzuki, Eri Yamamoto, Eriko Ogusa, Yoshimi Ishii, Hiroyuki Takahashi, Kazuho Miyashita, Reina Watanabe, Takuya Miyazaki, Kenji Motohashi, Atsuko Fujita, Maki Hagihara, Kenji Matsumoto, Hideaki Nakajima

    BLOOD   128 ( 22 )   2016.12

    　More details

    Language：English   Publishing type：Research paper, summary (international conference)  

    Web of Science

    researchmap

  • Impact of the Difference in Body Mass Index at Transplantation from That at Diagnosis for Graft-Versus-Host Disease-Free, Relapse-Free Survival in Acute Myeloid Leukemia

    Taiki Ando, Etsuko Yamazaki, Haruka Teshigawara, Eriko Ogusa, Yoshimi Ishii, Kazuho Miyashita, Kenji Motohashi, Takuya Miyazaki, Takayoshi Tachibana, Maki Hagihara, Kenji Matsumoto, Masatsugu Tanaka, Chizuko Hashimoto, Hideyuki Koharazawa, Katsumichi Fujimaki, Jun Taguchi, Hiroyuki Fujita, Heiwa Kanamori, Shin Fujisawa, Hideaki Nakajima

    BLOOD   128 ( 22 )   2016.12

    　More details

    Language：English   Publishing type：Research paper, summary (international conference)  

    Web of Science

    researchmap

  • Phase III Randomized Study of Imatinib Therapy in Chronic Phase Chronic Myeloid Leukemia Comparing Standard Dose-Escalation with Progressive Dose-Escalation (JALSG CML207 study)

    Koichi Miyamura, Shigeki Ohtake, Kazunori Ohnishi, Noriko Usui, Chiaki Nakaseko, Hiroyuki Fujita, Shin Fujisawa, Toru Sakura, Hirokazu Okumura, Yoshihiro Hatta, Nobuhiko Emi, Tomoki Naoe

    BLOOD   128 ( 22 )   2016.12

    　More details

    Language：English   Publishing type：Research paper, summary (international conference)  

    Web of Science

    researchmap

  • Development of pulmonary arterial hypertension during oral dasatinib therapy for chronic myelogenous leukemia

    57 ( 8 )   999 - 1003   2016.8

    　More details

  • Qualitative Analysis of Patient-Reported Free Comments on Quality of Life in Patients Who Completed Treatment for Acute Leukemia

    Ayako Mori, Mayumi Tsukagoshi, Saiko Kurosawa, Takehiko Mori, Heiwa Kanamori, Yasushi Onishi, Nobuhiko Emi, Shin Fujisawa, Akio Kohno, Chiaki Nakaseko, Bungo Saito, Tadakazu Kondo, Masayuki Hino, Yuichiro Nawa, Shunichi Kato, Akiko Hashimoto, Yoshihiro Inamoto, Takahiro Fukuda

    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION   22 ( 3 )   S454 - S455   2016.3

    　More details

    Language：English   Publishing type：Research paper, summary (international conference)  

    Web of Science

    researchmap

  • Musculoskeletal pain may be associated with imatinib withdrawal syndrome in chronic myeloid leukemia patients

    Yoshimi Ishii, Maki Hagihara, Ai Kato, Taiki Ando, Megumi Itabashi, Satoshi Koyama, Wataru Yamamoto, Kenji Motohashi, Kenji Matsumoto, Shin Fujisawa

    LEUKEMIA & LYMPHOMA   57 ( 2 )   496 - 497   2016.2

    　More details

    Language：English   Publishing type：Rapid communication, short report, research note, etc. (scientific journal)  

    DOI： 10.3109/10428194.2015.1064531

    Web of Science

    Scopus

    researchmap

  • Emergence of del(20q) in a patient in molecular remission of chronic myelogenous leukemia during imatinib treatment, with reduction following imatinib discontinuation

    Ayumi Numata, Ryoko Kajiyama, Megumi Itabashi, Yoshimi Ishii, Wataru Yamamoto, Kenji Motohashi, Kenji Matsumoto, Maki Hagihara, Yoshiaki Ishigatsubo, Shin Fujisawa

    LEUKEMIA & LYMPHOMA   57 ( 1 )   201 - 202   2016.1

    　More details

    Language：English   Publishing type：Rapid communication, short report, research note, etc. (scientific journal)  

    DOI： 10.3109/10428194.2015.1037763

    Web of Science

    researchmap

  • Body Mass Index Is a Prognostic Factor in Adults with Newly Diagnosed Acute Myeloid Leukemia: A Retrospective Multi-Institutional Study in Japan

    Taiki Ando, Etsuko Yamazaki, Haruka Teshigawara, Fujii Eriko, Yoshimi Ishii, Wataru Yamamoto, Kenji Motohashi, Takayoshi Tachibana, Maki Hagihara, Kenji Matsumoto, Masatsugu Tanaka, Hashimoto Chizuko, Koharazawa Hideyuki, Fujimaki Katsumichi, Jun Taguchi, Naoto Tomita, Hiroyuki Fujita, Heiwa Kanamori, Shin Fujisawa

    BLOOD   126 ( 23 )   2015.12

    　More details

    Language：English   Publishing type：Research paper, summary (international conference)  

    Web of Science

    researchmap

  • The Sil Index Is a Useful Prognostic Indicator for Diffuse Large B-Cell Lymphoma

    Naoto Tomita, Taisei Suzuki, Kazuho Miyashita, Wataru Yamamoto, Kenji Motohashi, Takayoshi Tachibana, Hirotaka Takasaki, Rika Kawasaki, Maki Hagihara, Chizuko Hashimoto, Sachiya Takemura, Hideyuki Koharazawa, Etsuko Yamazaki, Jun Taguchi, Katsumichi Fujimaki, Hiroyuki Fujita, Rika Sakai, Shin Fujisawa, Shigeki Motomura, Keisuke Kawamoto, Hirohito Sone, Jun Takizawa

    BLOOD   126 ( 23 )   2015.12

    　More details

    Language：English   Publishing type：Research paper, summary (international conference)  

    Web of Science

    researchmap

  • Prognostic Impact of Cytogenetic Abnormalities in Adult Patients with Philadelphia-Chromosome (Ph)-Negative Acute Lymphoblastic Leukemia (ALL) Who Underwent Allogeneic Stem Cell Transplant (allo-SCT)

    Hiroaki Shimizu, Takayuki Saitoh, Shinichiro Okamoto, Yoshinobu Kanda, Heiwa Kanamori, Satoshi Takahashi, Kazuteru Ohashi, Kensuke Usuki, Chiaki Nakaseko, Makoto Onizuka, Toru Sakura, Moritaka Goto, Shingo Yano, Shin Fujisawa, Reiko Watanabe, Nobuyuki Aotsuka, Jun Taguchi, Naoto Tomita, Hisashi Wakita, Yasuhito Nannya

    BLOOD   126 ( 23 )   2015.12

    　More details

    Language：English   Publishing type：Research paper, summary (international conference)  

    Web of Science

    researchmap

  • Surveillance Imaging in Patients with Diffuse Large B-Cell Lymphoma

    Ayako Matsumura, Hideyuki Kuwabara, Kumiko Kishimoto, Eriko Fujii, Kazuho Miyashita, Hiroyuki Takahashi, Shiro Matsuura, Yuki Nakajima, Hirotaka Takasaki, Masatsugu Tanaka, Shin Fujisawa, Heiwa Kanamori, Motomura Shigeki, Naoto Tomita

    BLOOD   126 ( 23 )   2015.12

    　More details

    Language：English   Publishing type：Research paper, summary (international conference)  

    Web of Science

    researchmap

  • Effect of the order of TBI and cyclophosphamide administration on the outcome of allogeneic hematopoietic stem cell transplantation

    K. Motohashi, S. Fujisawa, M. Onizuka, S. Kako, E. Sakaida, K. Shono, R. Tatara, N. Doki, T. Mori, T. Sakura, N. Aotsuka, E. Fuji, N. Tomita, N. Kawai, T. Saitoh, K. Usuki, J. Taguchi, R. Watanabe, S. Kobayashi, S. Yano, H. Kanamori, S. Takahashi, S. Okamoto

    Bone Marrow Transplantation   50 ( 11 )   1476 - 1479   2015.11

    　More details

    Publishing type：Rapid communication, short report, research note, etc. (scientific journal)  

    DOI： 10.1038/bmt.2015.142

    Scopus

    PubMed

    researchmap

  • Evaluation of soluble interleukin-2 receptor and serum lactate dehydrogenase in malignant lymphoma

    Naoto Tomita, Masataka Taguri, Chizuko Hashimoto, Hirotaka Takasaki, Katsumichi Fujimaki, Shigeki Motomura, Hideyuki Koharazawa, Sachiya Takemura, Hiroyuki Fujita, Etsuko Yamazaki, Rika Kawasaki, Jun Taguchi, Rika Sakai, Shin Fujisawa, Yukako Hattori, Heiwa Kanamori, Wataru Yamamoto, Hiroshi Harano, Koji Ogawa, Yoshiaki Ishigatsubo

    ANNALS OF HEMATOLOGY   94 ( 11 )   1935 - 1937   2015.11

    　More details

    Language：English   Publishing type：Rapid communication, short report, research note, etc. (scientific journal)  

    DOI： 10.1007/s00277-015-2448-2

    Web of Science

    Scopus

    researchmap

  • Favorable survival after allogeneic stem cell transplantation with reduced-intensity conditioning regimens for relapsed/refractory follicular lymphoma

    S. Yano, T. Mori, Y. Kanda, J. Kato, C. Nakaseko, S. Fujisawa, N. Tomita, R. Sakai, K. Shono, T. Saitoh, N. Aotsuka, N. Kobayashi, T. Saito, S. Takahashi, H. Kanamori, S. Okamoto

    BONE MARROW TRANSPLANTATION   50 ( 10 )   1299 - 1305   2015.10

    　More details

  • Early cytotoxic lymphocyte expansion contributes to a deep molecular response to dasatinib in patients with newly diagnosed chronic myeloid leukemia in the chronic phase: results of the D-first study

    Noriyoshi Iriyama, Shin Fujisawa, Chikashi Yoshida, Hisashi Wakita, Shigeru Chiba, Shinichiro Okamoto, Kimihiro Kawakami, Naoki Takezako, Takashi Kumagai, Koiti Inokuchi, Kazuma Ohyashiki, Jun Taguchi, Shingo Yano, Tadahiko Igarashi, Yasuji Kouzai, Satoshi Morita, Junichi Sakamoto, Hisashi Sakamaki

    AMERICAN JOURNAL OF HEMATOLOGY   90 ( 9 )   819 - 824   2015.9

    　More details

  • R-CHOP therapy alone for limited-stage follicular lymphoma

    Naoto Tomita, Taisei Suzuki, Yasufumi Ishiyama, Kazuho Miyashita, Hiroyuki Takahashi, Ayumi Numata, Satomi Ito, Kenji Motohashi, Takayoshi Tachibana, Hirotaka Takasaki, Rika Kawasaki, Maki Hagihara, Chizuko Hashimoto, Etsuko Yamazaki, Jun Taguchi, Katsumichi Fujimaki, Rika Sakai, Shin Fujisawa, Shigeki Motomura, Yoshiaki Ishigatsubo

    LEUKEMIA RESEARCH   39 ( 6 )   582 - 585   2015.6

    　More details

  • Successful pregnancy and delivery via in vitro fertilization with cryopreserved and thawed embryo transfer in an acute myeloid leukemia patient after allogeneic bone marrow transplantation

    Yuki Nakajima, Hideyuki Kuwabara, Kumiko Kishimoto, Ayumi Numata, Kenji Motohashi, Takayoshi Tachibana, Masatsugu Tanaka, Naoki Yamashita, Yoshiaki Ishigatsubo, Shin Fujisawa

    INTERNATIONAL JOURNAL OF HEMATOLOGY   101 ( 4 )   417 - 420   2015.4

    　More details

  • Biweekly THP-COP therapy for newly diagnosed peripheral T-cell lymphoma patients

    Naoto Tomita, Fumio Kodama, Naoko Tsuyama, Seiji Sakata, Kengo Takeuchi, Daisuke Ishibashi, Satoshi Koyama, Yoshimi Ishii, Wataru Yamamoto, Hirotaka Takasaki, Maki Hagihara, Hideyuki Kuwabara, Masatsugu Tanaka, Chizuko Hashimoto, Etsuko Yamazaki, Hideyuki Koharazawa, Katsumichi Fujimaki, Rika Sakai, Shin Fujisawa, Yoshiaki Ishigatsubo

    HEMATOLOGICAL ONCOLOGY   33 ( 1 )   9 - 14   2015.3

    　More details

  • Dissemination pattern of extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue

    Yoshimi Ishii, Naoto Tomita, Taisei Suzuki, Yasufumi Ishiyama, Kumiko Kishimoto, Eri Yamamoto, Satoshi Koyama, Yukako Hattori, Yuki Nakajima, Kenji Motohashi, Hirotaka Takasaki, Rika Kawasaki, Chizuko Hashimoto, Sachiya Takemura, Katsumichi Fujimaki, Hiroyuki Fujita, Rika Sakai, Shin Fujisawa, Shigeki Motomura, Yoshiaki Ishigatsubo

    LEUKEMIA & LYMPHOMA   56 ( 9 )   2750 - 2752   2015

    　More details

    Language：English   Publishing type：Rapid communication, short report, research note, etc. (scientific journal)  

    DOI： 10.3109/10428194.2015.1010161

    Web of Science

    Scopus

    researchmap

  • Successful Engraftment and Durable Graft-versus-host Disease Control with Haploidentical Peripheral Blood and a Short-term Conditioning Regimen for Primary Graft Failure

    Takayoshi Tachibana, Eri Yamamoto, Rika Kawasaki, Hideyuki Koharazawa, Daisuke Ishibashi, Yuki Nakajima, Masatsugu Tanaka, Kenji Matsumoto, Yoshiaki Ishigatsubo, Shin Fujisawa

    INTERNAL MEDICINE   54 ( 21 )   2749 - 2752   2015

    　More details

  • Effect of High Body Mass Index on the Prognosis of Diffuse Large B-Cell Lymphoma

    Yukako Hattori, Naoto Tomita, Taisei Suzuki, Yasufumi Ishiyama, Kumiko Kishimoto, Satoshi Koyama, Hiroyuki Takahashi, Kazuho Miyashita, Yuki Nakajima, Kenji Motohashi, Hirotaka Takasaki, Rika Kawasaki, Chizuko Hashimoto, Katsumichi Fujimaki, Rika Sakai, Shin Fujisawa, Shigeki Motomura, Yoshiaki Ishigatsubo

    BLOOD   124 ( 21 )   2014.12

    　More details

    Language：English   Publishing type：Research paper, summary (international conference)  

    Web of Science

    researchmap

  • Effects of the Order of Administration of Total Body Irradiation and Cyclophosphamide on the Outcome of Allogeneic Hematopoietic Cell Transplantation

    Kenji Motohashi, Shin Fujisawa, Makoto Onizuka, Shinichi Kako, Emiko Sakaida, Katsumichi Shono, Raine Tatara, Noriko Doki, Takehiko Mori, Toru Sakura, Nobuyuki Aotsuka, Eriko Ogusa, Naoto Tomita, Nobutaka Kawai, Takayuki Saitoh, Kensuke Usuki, Jun Taguchi, Heiwa Kanamori, Satoshi Takahashi, Shinichiro Okamoto

    BLOOD   124 ( 21 )   2014.12

    　More details

    Language：English   Publishing type：Research paper, summary (international conference)  

    Web of Science

    researchmap

  • No Outcome Differences Were Observed Between Supra-Diaphragmatic and Infra-Diaphragmatic Lesions in Limited-Stage Diffuse Large B Cell Lymphoma Treated with R-CHOP Therapy, Whereas the Presence of Gastro-Intestinal Lesions Was Associated with a Favorable Prognosis

    Yuki Nakajima, Naoto Tomita, Megumi Itabashi, Kazuho Miyashita, Reina Watanabe, Takuya Miyazaki, Takayoshi Tachibana, Hirotaka Takasaki, Rika Kawasaki, Masatsugu Tanaka, Chizuko Hashimoto, Etsuko Yamazaki, Jun Taguchi, Katsumichi Fujimaki, Rika Sakai, Hiroyuki Fujita, Shin Fujisawa, Hiroshi Harano, Shigeki Motomura, Yoshiaki Ishigatsubo

    BLOOD   124 ( 21 )   2014.12

    　More details

    Language：English   Publishing type：Research paper, summary (international conference)  

    Web of Science

    researchmap

  • Imatinib-Based Chemotherapy for Newly Diagnosed BCRABL Positive Acute Lymphoblastic Leukemia: Japan Adult Leukemia Study Group (JALSG) Ph+ALL208 Study

    Shin Fujisawa, Keitaro Matsuo, Shuichi Mizuta, Hideki Akiyama, Yasunori Ueda, Yasutaka Aoyama, Yoshihiro Hatta, Kazuhiko Kakihana, Nobuaki Dobashi, Isamu Sugiura, Yasushi Onishi, Tomoya Maeda, Kiyotoshi Imai, Shigeki Ohtake, Yasushi Miyazaki, Kazunori Ohnishi, Tomoki Naoe

    BLOOD   124 ( 21 )   2014.12

    　More details

    Language：English   Publishing type：Research paper, summary (international conference)  

    Web of Science

    researchmap

  • Prognostic Impact of Gender in Diffuse Large B Cell Lymphoma Patients Treated with R-CHOP Therapy

    Hiroyuki Takahashi, Naoto Tomita, Yasufumi Ishiyama, Satoshi Koyama, Kazuho Miyashita, Yuki Nakajima, Yukako Hattori, Kenji Motohashi, Hirotaka Takasaki, Rika Kawasaki, Maki Hagihara, Chizuko Hashimoto, Sachiya Takemura, Katsumichi Fujimaki, Jun Taguchi, Rika Sakai, Hiroyuki Fujita, Shin Fujisawa, Hiroshi Harano, Yoshiaki Ishigatsubo

    BLOOD   124 ( 21 )   2014.12

    　More details

    Language：English   Publishing type：Research paper, summary (international conference)  

    Web of Science

    researchmap

  • Peripheral blood absolute lymphocyte/monocyte ratio as a useful prognostic factor in diffuse large B-cell lymphoma in the rituximab era

    Reina Watanabe, Naoto Tomita, Megumi Itabashi, Daisuke Ishibashi, Eri Yamamoto, Satoshi Koyama, Kazuho Miyashita, Hiroyuki Takahashi, Yuki Nakajima, Yukako Hattori, Kenji Motohashi, Hirotaka Takasaki, Rika Ohshima, Chizuko Hashimoto, Etsuko Yamazaki, Katsumichi Fujimaki, Rika Sakai, Shin Fujisawa, Shigeki Motomura, Yoshiaki Ishigatsubo

    EUROPEAN JOURNAL OF HAEMATOLOGY   92 ( 3 )   204 - 210   2014.3

    　More details

  • Phase II Trial Of Medium-Dose VP-16, Cyclophosphamide and Total-Body Irradiation Conditioning Regimen Before Allogeneic Stem Cell Transplantation For Acute Lymphoblastic Leukemia In Adults

    Tatsunori Goto, Akio Shigematsu, Makoto Onizuka, Shin Fujisawa, Ritsuro Suzuki, Yoshiko Atsuta, Kazuo Hatanaka, Masayoshi Masuko, Toshiro Ito, Naoki Kobayashi, Jun Kato, Koichi Miyamura, Takahiro Fukuda, Yasuo Morishima, Masahiro Imamura

    BLOOD   122 ( 21 )   2013.11

    　More details

    Language：English   Publishing type：Research paper, summary (international conference)  

    Web of Science

    researchmap

  • Prognostic Impact Of Gender In Diffuse Large B Cell Lymphoma Patients Treated With R-CHOP Therapy

    Hiroyuki Takahashi, Naoto Tomita, Rika Kawasaki, Chizuko Hashimoto, Etsuko Yamazaki, Jun Taguchi, Rika Sakai, Shin Fujisawa, Koji Ogawa, Yoshiaki Ishigatsubo

    BLOOD   122 ( 21 )   2013.11

    　More details

    Language：English   Publishing type：Research paper, summary (international conference)  

    Web of Science

    researchmap

  • Successful treatment of a patient with adult T cell leukemia/lymphoma using anti-CC chemokine receptor 4 monoclonal antibody mogamulizumab followed by allogeneic hematopoietic stem cell transplantation

    MOTOHASHI Kenji, SUZUKI Taisei, KISHIMOTO Kumiko, NUMATA Ayumi, NAKAJIMA Yuki, TACHIBANA Takayoshi, OHSHIMA Rika, KUWABARA Hideyuki, TANAKA Masatsugu, TOMITA Naoto, ISHIGATSUBO Yoshiaki, FUJISAWA Shin

    98 ( 2 )   258 - 260   2013.8

    　More details

    Language：English  

    CiNii Books

    researchmap

  • Multicenter validation of scoring system of pre-transplant serum ferritin and disease risk in patients with acute myeloid leukemia and myelodysplastic syndrome after allogeneic hematopoietic stem cell transplant

    Takayoshi Tachibana, Masatsugu Tanaka, Etsuko Yamazaki, Ayumi Numata, Hirotaka Takasaki, Hideyuki Kuwabara, Katsumichi Fujimaki, Rika Sakai, Hiroyuki Fujita, Shin Fujisawa, Atsuo Maruta, Yoshiaki Ishigatsubo, Heiwa Kanamori

    Leukemia and Lymphoma   54 ( 6 )   1318 - 1320   2013.6

    　More details

    Language：English   Publishing type：Rapid communication, short report, research note, etc. (scientific journal)  

    DOI： 10.3109/10428194.2012.730613

    Scopus

    PubMed

    researchmap

  • Successful treatment of a pregnant woman with Philadelphia chromosome-positive acute lymphoblastic leukemia

    NAKAJIMA Yuki, KUWABARA Hideyuki, HATTORI Yukako, OHSHIMA Rika, SAKAI Rika, KITAGAWA Masakazu, TOMITA Naoto, ISHIGATSUBO Yoshiaki, FUJISAWA Shin

    97 ( 3 )   427 - 429   2013.3

    　More details

    Language：English  

    CiNii Books

    researchmap

  • Absolute Monocyte Count in Follicular Lymphoma Patients Treated with Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone

    Reina Watanabe, Naoto Tomita, Kumiko Kishimoto, Satoshi Koyama, Eriko Ogusa, Yoshimi Ishii, Kazuho Miyashita, Shiro Matsuura, Shin Fujisawa, Yukako Hattori, Hirotaka Takasaki, Atsuko Fujita, Rika Ohshima, Hideyuki Kuwabara, Chizuko Hashimoto, Katsumichi Fujimaki, Rika Sakai, Yoshiaki Ishigatsubo

    BLOOD   120 ( 21 )   2012.11

    　More details

    Language：English   Publishing type：Research paper, summary (international conference)  

    Web of Science

    researchmap

  • Serum Ferritin Level As a Prognostic Factor for Patients with Extranodal NK/T-Cell Lymphoma, Nasal Type

    Etsuko Yamazaki, Naoto Tomita, Satoshi Koyama, Kumiko Kishimoto, Eriko Ogusa, Yoshimi Ishii, Hiroyuki Takahashi, Kazuho Miyashita, Shiro Matsuura, Takayoshi Tachibana, Hirotaka Takasaki, Sachiya Takemura, Katsumichi Fujimaki, Rika Sakai, Shin Fujisawa, Yoshiaki Ishigatsubo

    BLOOD   120 ( 21 )   2012.11

    　More details

    Language：English   Publishing type：Research paper, summary (international conference)  

    Web of Science

    researchmap

  • Does the Hematopoietic Cell Transplantation Specific Comorbidity Index (HCT-CI) Predict Transplant Outcomes?: A Prospective Multicenter Validation Study of the Kanto Study Group for Cell Therapy (KSGCT)

    Aya Nakaya, Takehiko Mori, Masatsugu Tanaka, Naoto Tomita, Chiaki Nakaseko, Shingo Yano, Shin Fujisawa, Hisashi Sakamaki, Nobuyuki Aotsuka, Akira Yokota, Yoshinobu Kanda, Toru Sakura, Yasuhito Nannya, Takayuki Saitoh, Heiwa Kanamori, Satoshi Takahashi, Shinichiro Okamoto

    BLOOD   120 ( 21 )   2012.11

    　More details

    Language：English   Publishing type：Research paper, summary (international conference)  

    Web of Science

    researchmap

  • Serum Ferritin Level As a Prognostic Factor for Patients with Extranodal NK/T-Cell Lymphoma, Nasal Type.

    Etsuko Yamazaki, Naoto Tomita, Satoshi Koyama, Kumiko Kishimoto, Eriko Ogusa, Yoshimi Ishii, Hiroyuki Takahashi, Kazuho Miyashita, Shiro Matsuura, Takayoshi Tachibana, Hirotaka Takasaki, Sachiya Takemura, Katsumichi Fujimaki, Rika Sakai, Shin Fujisawa, Yoshiaki Ishigatsubo

    BLOOD   120 ( 21 )   2012.11

    　More details

    Language：English   Publishing type：Research paper, summary (international conference)  

    Web of Science

    researchmap

  • Clinical Significance of Addition of Cytarabine or Thiotepa to TBI/CY Regimen.

    Takayoshi Tachibana, Masatsugu Tanaka, Maki Hagihara, Rika Ohshima, Etsuko Yamazaki, Hideyuki Koharazawa, Jun Taguchi, Naoto Tomita, Katsumichi Fujimaki, Rika Sakai, Hiroyuki Fujita, Shin Fujisawa, Atsuo Maruta, Yoshiaki Ishigatsubo, Heiwa Kanamori

    BLOOD   120 ( 21 )   2012.11

    　More details

    Language：English   Publishing type：Research paper, summary (international conference)  

    Web of Science

    researchmap

  • Retrospective Study of Standard R-CHOP Therapy in Localized DLBCL

    Naoto Tomita, Hirotaka Takasaki, Kazuho Miyashita, Shin Fujisawa, Eriko Ogusa, Shro Matsuura, Kumiko Kishimoto, Ayumi Numata, Atsuko Fujita, Rika Ohshima, Hideyuki Kuwabara, Maki Hagihara, Chizuko Hashimoto, Sachiya Takemura, Hideyuki Koharazawa, Etsuko Yamazaki, Katsumichi Fujimaki, Jun Taguchi, Rika Sakai, Yoshiaki Ishigatsubo

    BLOOD   120 ( 21 )   2012.11

    　More details

    Language：English   Publishing type：Research paper, summary (international conference)  

    Web of Science

    researchmap

  • Clinical significance of minimal residual disease detected by multidimensional flow cytometry: Serial monitoring after allogeneic stem cell transplantation for acute leukemia Reviewed

    Takuya Miyazaki, Hiroyuki Fujita, Katsumichi Fujimaki, Takeshi Hosoyama, Reina Watanabe, Takayoshi Tachibana, Atsuko Fujita, Kenji Matsumoto, Masatsugu Tanaka, Hideyuki Koharazawa, Jun Taguchi, Naoto Tomita, Rika Sakai, Shin Fujisawa, Heiwa Kanamori, Yoshiaki Ishigatsubo

    LEUKEMIA RESEARCH   36 ( 8 )   998 - 1003   2012.8

    　More details

  • Immune-mediated encephalomyelitis following varicella-zoster virus infection after allogeneic stem cell transplantation

    TACHIBANA Takayoshi, TAKASAKI Hirotaka, TANAKA Masatsugu, NUMATA Ayumi, YAMAZAKI Etsuko, SEGAWA Fuminori, FUJISAWA Shin, MARUTA Atsuo, ISHIGATSUBO Yoshiaki, KANAMORI Heiwa

    53 ( 4 )   465 - 468   2012.4

    　More details

  • Prognostic factors in patients aged 50 years or older undergoing allogeneic hematopoietic stem cell transplantation for hematologic malignancy

    TAKASAKI Hirotaka, TANAKA Masatsugu, TACHIBANA Takayoshi, NUMATA Ayumi, FUJIMAKI Katsumichi, SAKAI Rika, FUJISAWA Shin, TOMITA Naoto, FUJITA Hiroyuki, MARUTA Atsuo, ISHIGATSUBO Yoshiaki, KANAMORI Heiwa

    95 ( 3 )   291 - 298   2012.3

    　More details

    Language：English  

    CiNii Books

    researchmap

  • Successful treatment with gemtuzumab ozogamicin and donor lymphocyte infusion for acute myeloid leukemia relapsing after allogeneic stem cell transplantation

    TACHIBANA Takayoshi, TANAKA Masatsugu, TAKASAKI Hirotaka, NUMATA Ayumi, FUJISAWA Shin, MARUTA Atsuo, HARADA Hiroshi, MORI Hiraku, ISHIGATSUBO Yoshiaki, KANAMORI Heiwa

    94 ( 6 )   580 - 582   2011.12

    　More details

    Language：English  

    CiNii Books

    researchmap

  • Allogeneic Hematopoietic Stem Cell Transplantation for Adult AML Patients with Granulocytic Sarcoma

    Hiroaki Shimizu, Takayuki Saitoh, Masatsugu Tanaka, Takehiko Mori, Nobutaka Kawai, Toru Sakura, Yoshinobu Kanda, Chiaki Nakaseko, Shingo Yano, Hiroyuki Fujita, Shin Fujisawa, Shuichi Miyawaki, Heiwa Kanamori, Shinichiro Okamoto

    BLOOD   118 ( 21 )   890 - 891   2011.11

    　More details

    Language：English   Publishing type：Research paper, summary (international conference)  

    Web of Science

    researchmap

  • Standard R-CHOP Therapy in Follicular Lymphoma and Diffuse Large B-Cell Lymphoma

    Naoto Tomita, Hirotaka Takasaki, Shin Fujisawa, Kazuho Miyashita, Eriko Ogusa, Kumiko Kishimoto, Shiro Matsuura, Rika Sakai, Hideyuki Koharazawa, Wataru Yamamoto, Katsumichi Fujimaki, Hiroyuki Fujita, Yoshimi Yamamoto, Jun Taguchi, Hideyuki Kuwabara, Shigeki Motomura, Yoshiaki Ishigatsubo

    BLOOD   118 ( 21 )   708 - 709   2011.11

    　More details

    Language：English   Publishing type：Research paper, summary (international conference)  

    Web of Science

    researchmap

  • Successful treatment with dasatinib and allogeneic peripheral blood stem cell transplant for imatinib-resistant Philadelphia chromosome-positive acute lymphoblastic leukemia relapsing after bone marrow transplant and donor lymphocyte infusion

    Takayoshi Tachibana, Ayumi Numata, Masatsugu Tanaka, Kenji Motohashi, Shin Fujisawa, Hiroyuki Fujita, Rika Sakai, Naoto Tomita, Atsuo Maruta, Yoshiaki Ishigatsubo, Heiwa Kanamori

    Leukemia and Lymphoma   52 ( 7 )   1376 - 1379   2011.7

    　More details

    Language：English   Publishing type：Rapid communication, short report, research note, etc. (scientific journal)  

    DOI： 10.3109/10428194.2011.566395

    Scopus

    PubMed

    researchmap

  • Pretransplant serum ferritin is associated with bloodstream infections within 100 days of allogeneic stem cell transplantation for myeloid malignancies

    TACHIBANA Takayoshi, TANAKA Masatsugu, TAKASAKI Hirotaka, NUMATA Ayumi, ITO Satomi, WATANABE Reina, HYO Rie, OHSHIMA Rika, HAGIHARA Maki, SAKAI Rika, FUJISAWA Shin, TOMITA Naoto, FUJITA Hiroyuki, MARUTA Atsuo, ISHIGATSUBO Yoshiaki, KANAMORI Heiwa

    93 ( 3 )   368 - 374   2011.3

    　More details

    Language：English  

    CiNii Books

    researchmap

  • ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR PATIENTS WITH LIGHT RENAL FAILURE

    K. Oshima, Y. Kanda, Y. Nanya, M. Tanaka, C. Nakaseko, S. Yano, S. Fujisawa, H. Fujita, S. Takahashi, H. Kanamori, S. Okamoto

    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION   17 ( 2 )   S304 - S305   2011.2

    　More details

    Language：English   Publishing type：Research paper, summary (international conference)  

    Web of Science

    researchmap

  • A randomized comparison of 4 courses of standard-dose multiagent chemotherapy versus 3 courses of high-dose cytarabine alone in postremission therapy for acute myeloid leukemia in adults: the JALSG AML201 Study

    Shuichi Miyawaki, Shigeki Ohtake, Shin Fujisawa, Hitoshi Kiyoi, Katsuji Shinagawa, Noriko Usui, Toru Sakura, Koichi Miyamura, Chiaki Nakaseko, Yasushi Miyazaki, Atsushi Fujieda, Tadashi Nagai, Takahisa Yamane, Masafumi Taniwaki, Masatomo Takahashi, Fumiharu Yagasaki, Yukihiko Kimura, Norio Asou, Hisashi Sakamaki, Hiroshi Handa, Sumihisa Honda, Kazunori Ohnishi, Tomoki Naoe, Ryuzo Ohno

    BLOOD   117 ( 8 )   2366 - 2372   2011.2

    　More details

  • Biclonal co-existence of t(15;17) and t(9;22) chromosomal abnormalities in acute promyelocytic leukemia

    TAKAHASHI Hiroyuki, SAKAI Rika, HATTORI Yukako, OHSHIMA Rika, HAGIHARA Maki, KUWABARA Hideyuki, ISHIGATSUBO Yoshiaki, FUJISAWA Shin

    The Japanese journal of clinical hematology   52 ( 1 )   37 - 40   2011.1

    　More details

  • ABVD chemotherapy for Hodgkin lymphoma at a single institute

    OHSHIMA Rika, MOTOMURA Shigeki, HASHIMOTO Chizuko, MIYAZAKI Takuya, ITO Satomi, TAKASAKI Hirotaka, HYO Rie, KOHARAZAWA Hideyuki, TAKEMURA Sachiya, YAMAZAKI Etsuko, FUJIMAKI Katsumichi, TOMITA Naoto, FUJITA Hiroyuki, FUJISAWA Shin, HARANO Hiroshi, KANAMORI Heiwa, ISHIGATSUBO Yoshiaki

    The Japanese journal of clinical hematology   51 ( 12 )   1756 - 1761   2010.12

    　More details

  • Sustained Superior Long-Term Outcomes of Imatinib Therapy In Japanese Patients with Newly Diagnosed Chronic Myelogenous Leukemia In Chronic Phase: Sub-Analysis According to the Mean Daily Dose of Imatinib and the Plasma Trough Levels In JALSG CML202 Study After 66 Months Follow-up Reviewed

    Chiaki Nakaseko, Kazunori Ohnishi, Jin Takeuchi, Shin Fujisawa, Tadashi Nagai, Shigeki Ohtake, Hirohito Yamazaki, Tetsuzo Tauchi, Kiyotoshi Imai, Naoki Mori, Fumiharu Yagasaki, Hideki Akiyama, Yasuhiro Maeda, Noriko Usui, Yoshio Saburi, Takashi Ishida, Hiroshi Kosugi, Koichi Miyamura, Yasushi Miyazaki, Hiroshi Handa, Akira Yokota, Kenji Matsumoto, Katsumichi Fujimaki, Toshimitsu Matsui, Hitoshi Kiyoi, Shuichi Miyawaki, Ryuzo Ohno, Tomoki Naoe

    BLOOD   116 ( 21 )   1400 - 1400   2010.11

    　More details

    Language：English   Publishing type：Research paper, summary (international conference)  

    Web of Science

    researchmap

  • A retrospective analysis of obstetric patients with idiopathic thrombocytopenic purpura : a single center study

    FUJITA Atsuko, SAKAI Rika, MATSUURA Shiro, YAMAMOTO Wataru, OHSHIMA Rika, KUWABARA Hideyuki, OKUDA Mika, TAKAHASHI Tsuneo, ISHIGATSUBO Yoshiaki, FUJISAWA Shin

    92 ( 3 )   463 - 467   2010.10

    　More details

    Language：English  

    CiNii Books

    researchmap

  • Second transplantation for graft failure after allogeneic hematopoietic stem cell transplantation -A retrospective survey by Kanto Study Group for Cell Therapy:&mdash;A retrospective survey by Kanto Study Group for Cell Therapy

    HAGIHARA Maki, KAWAI Nobutaka, TANAKA Masatsugu, FUJISAWA Shin, OHWADA Chikako, WAKITA Hisashi, YOKOTA Akira, KAWAMURA Toshihide, MARUTA Atsuo, SAKAMAKI Hisashi, OKAMOTO Shinichiro, KANAMORI Heiwa, Kanto Study, Group for Cell Therapy, KSGCT, SAKAI Miwa, MORI Takehiko, NAKASEKO Chiaki, AOTSUKA Nobuyuki, UEHARA Taeko, SAKURA Tohru, YOSHIBA Fumio

    Rinsho Ketsueki   51 ( 6 )   390 - 397   2010.6

    　More details

    Language：Japanese   Publisher：The Japanese Society of Hematology  

    We retrospectively surveyed patients who received a second transplantation for graft failure (GF) after allogeneic hematopoietic stem cell transplantation (SCT) in hospitals participating in the Kanto Study Group for Cell Therapy. A second SCT was performed in 21 of 45 patients with primary GF and in 13 of 15 with secondary GF. The median time between the first and second SCT was 49 days (range, 18-1204 days). The diagnosis included 28 patients with hematologic malignancies and 6 with aplastic anemia. Non-myeloablative or reduced-intensity conditioning was performed in 30 patients. Cord blood was frequently used as the source of stem cells followed by related donor peripheral blood, and unrelated bone marrow. Engraftment was achieved in 23 patients (68%). Conditioning regimen including total body or total lymphoid irradiation, was significantly associated with a higher engraftment rate. Overall survival at 5 years in all patients who underwent second SCT was 34%. Prognostic factors for better survival after second SCT were a time to second SCT longer than 90 days, the performance status at second SCT with 0 or 1, and the administration of tacrolimus for GVHD prophylaxis. The major cause of death after second SCT was infection. Although the outcome of a second SCT for graft failure remains poor, these findings suggest that the selection of patients as well as transplant methods, such as conditioning and GVHD prophylaxis, may contribute to survival.

    DOI： 10.11406/rinketsu.51.390

    researchmap

  • Prophylactic impact of tyrosine kinase inhibitor administration after allogeneic stem cell transplantation on the incidence and severity of chronic graft-versus-host disease in patients with Philadelphia chromosome-positive leukaemia

    H. Nakasone, Y. Kanda, H. Takasaki, C. Nakaseko, T. Sakura, S. Fujisawa, A. Yokota, S. Yano, K. Usuki, A. Maruta, D. Abe, T. Hoshino, S. Takahashi, H. Kanamori, S. Okamoto

    BONE MARROW TRANSPLANTATION   45   S122 - S122   2010.3

    　More details

    Language：English   Publishing type：Research paper, summary (international conference)  

    Web of Science

    researchmap

  • ダサチニブの慢性骨髄性白血病及びPh+ALLに対する臨床第1/2相試験の2年追跡成績

    石澤 賢一, 坂巻 壽, 谷脇 雅史, 藤澤 信, 森島 泰雄, 飛内 賢正, 岡田 昌也, 安藤 潔, 薄井 紀子, 宮脇 修一, 宇都宮 與, 魚嶋 伸彦, 永井 正, 直江 知樹, 泉二 登志子, 陣内 逸郎, 谷本 光音, 宮崎 泰司, 大西 一功, 飯田 真介, 岡本 真一郎, 芹生 卓, 大野 竜三

    臨床血液   50 ( 9 )   956 - 956   2009.9

    　More details

    Language：Japanese   Publisher：(一社)日本血液学会-東京事務局  

    researchmap

  • Phase 1/2 clinical study of dasatinib in Japanese patients with chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia

    Hisashi Sakamaki, Ken-ichi Ishizawa, Masafumi Taniwaki, Shin Fujisawa, Yasuo Morishima, Kensei Tobinai, Masaya Okada, Kiyoshi Ando, Noriko Usui, Shuichi Miyawaki, Atae Utsunomiya, Nobuhiko Uoshima, Tadashi Nagai, Tomoki Naoe, Toshiko Motoji, Itsuro Jinnai, Mitsune Tanimoto, Yasushi Miyazaki, Kazunori Ohnishi, Shinsuke Iida, Shinichiro Okamoto, Taku Seriu, Ryuzo Ohno

    INTERNATIONAL JOURNAL OF HEMATOLOGY   89 ( 3 )   332 - 341   2009.4

    　More details

  • ダサチニブのBCR-ABL変異を有するCML及びPh+ALLに対する有効性の検討

    藤澤 信, 森島 泰雄, 坂巻 壽, 岡田 昌也, 石澤 賢一, 谷脇 雅史, 安藤 潔, 飛内 賢正, 宇都宮 與, 泉二 登志子, 直江 知樹, 魚嶋 伸彦, 宮脇 修一, 薄井 紀子, 永井 正, 大西 一功, 陣内 逸郎, 谷本 光音, 飯田 真介, 宮崎 泰司, 岡本 真一郎, 上田 享司, 大野 竜三

    臨床血液   49 ( 9 )   900 - 900   2008.9

    　More details

    Language：Japanese   Publisher：(一社)日本血液学会-東京事務局  

    researchmap

  • ダサチニブの移行期/急性期CML及びPh+ALLに対する臨床第I/II相試験の長期投与成績

    石澤 賢一, 坂巻 壽, 藤澤 信, 岡田 昌也, 安藤 潔, 谷脇 雅史, 森島 泰雄, 飛内 賢正, 薄井 紀子, 宮脇 修一, 魚嶋 伸彦, 永井 正, 直江 知樹, 泉二 登志子, 大西 一功, 飯田 真介, 岡本 真一郎, 芹生 卓, 大野 竜三

    臨床血液   49 ( 9 )   1012 - 1012   2008.9

    　More details

    Language：Japanese   Publisher：(一社)日本血液学会-東京事務局  

    researchmap

  • Lower dose of imatinib provides outcomes similar to the standard dose imatinib in Japanese patients with early chronic-phase CML: The interim analyses of JALSG CML202 study

    Kazunori Ohnishi, Miki Nishimura, Jin Takeuchi, Shin Fujisawa, Tadashi Nagai, Koichi Miyamura, Yukihiko Kimura, Fumiharu Yagasaki, Hideki Akiyama, Noriko Usui, Shigeki Ohtake

    BLOOD   110 ( 11 )   316A - 316A   2007.11

    　More details

    Language：English   Publishing type：Research paper, summary (international conference)  

    Web of Science

    researchmap

  • Clinical feature and prognosis of 60 patients presenting graft failure (GF) after allogeneic stem cell transplantation (SCT)

    Maki Hagihara, Heiwa Kanamori, Fumiaki Yoshiba, Nobuyuki Aotsuka, Masatsugu Tanaka, Takehiko Mori, Chiaki Nakaseko, Shin Fujisawa, Tohru Sakura, Taeko Uehara, Nobutaka Kawai, Takafumi Matsushima, Shinichiro Machida, Hisashi Makita, Atsuo Maruta, Hisashi Sakamaki

    BLOOD   110 ( 11 )   307B - 308B   2007.11

    　More details

    Language：English   Publishing type：Research paper, summary (international conference)  

    Web of Science

    researchmap

  • Air leak syndrome (ALS) following allogeneic stem cell transplantation (SCT): A report of 22 patients from kanto study group for cell therapy (KSGCT) in Japan

    Rika Sakai, Heiwa Kanamori, Shinichiro Okamoto, Fumiaki Yoshiba, Katsumichi Fujimaki, Tohru Sakura, Shin Fujisawa, Nobutaka Kawai, Chiaki Nakaseko, Masahiro Onoda, Takafumi Matsushima, Atsuo Maruta, Hisashi Sakamaki

    BLOOD   110 ( 11 )   335B - 335B   2007.11

    　More details

    Language：English   Publishing type：Research paper, summary (international conference)  

    Web of Science

    researchmap

  • Human Herpesvirus 6 Meningoencephalitis in Allogeneic Hematopoietic Stem Cell Transplant Recipients

    FUJIMAKI Katsumichi, MORI Takehiko, KIDA Aiko, TANAKA Masatsugu, KAWAI Nobutaka, MATSUSHIMA Takafumi, KISHI Kenji, FUJISAWA Shin, SAKURA Tohru, YOKOTA Akira, KANDA Yoshinobu, TAGUCHI Jun, AKIYAMA Hideki, KANAMORI Heiwa, MARUTA Atsuo, OKAMOTO Shinichiro, SAKAMAKI Hisashi

    Int. J. hematol.   84 ( 5 )   432 - 437   2006.12

    　More details

    Language：English  

    CiNii Books

    researchmap

  • Dasatinib (SPRYCEL (R), BMS-354825) phase-I/II study of patients with, chronic myeloid leukemia (CML) resistant or intolerant to imatinib: Results of the CA180031 study in Japan (Phase I portion).

    Hisashi Sakamaki, Shin Fujisawa, Kensei Tobinai, Masafumi Taniwaki, Shuichi Miyawaki, Itsuro Jinnai, Atae Utsunomiya, Mistune Tanimoto, Yasuo Morishima, Masaya Okada, Yasushi Miyazaki, Nobuhiko Uoshima, Taku Seriu

    BLOOD   108 ( 11 )   287B - 287B   2006.11

    　More details

    Language：English   Publishing type：Research paper, summary (international conference)  

    Web of Science

    researchmap

  • Outcome of Involved-Field Radiotherapy for Stage 1 Follicular Lymphoma

    TOMITA Naoto, KODAMA Fumio, MOTOHASHI Kenji, FUJITA Atsuko, HYO Rie, HASHIMOTO Chizuko, TAKEMURA Sachiya, YAMAZAKI Etsuko, TAGUCHI Jun, SAKAI Rika, FUJISAWA Shin, KANAMORI Heiwa, MOTOMURA Shigeki, ISHIGATSUBO Yoshiaki, TAKEUCHI Kengo

    83 ( 4 )   370 - 372   2006.5

    　More details

    Language：English  

    CiNii Books

    researchmap

  • CORD BLOOD TRANSPLANTATION FOR ELDERLY PATIENTS OVER 60 YEARS OLD WITH HEMATOGICAL MALIGNANCIES

    Reo TANOSHIMA, Kenji MOTOHASHI, Atsuko IEDA, Rie HYO, Naoto TOMITA, Shin FUJISAWA, Yoshiaki ISHIGATSUBO, Department of Hematology Yokohama City University Medical Center, Department of Hematology Yokohama City University Medical Center, Department of Hematology Yokohama City University Medical Center, Department of Hematology Yokohama City University Medical Center, Department of Hematology Yokohama City University Medical Center, Department of Hematology Yokohama City University Medical Center, Department of Internal Medicine and Clinical Immunology Yokohama City University Graduate School of Medicine

    Yokohama medical journal   56 ( 3 )   201 - 207   2005.5

    　More details

  • Clinical Significance of Fragmented Red Cells after Allogeneic Bone Marrow Transplantation

    KANAMORI Heiwa, TAKAISHI Yumiko, TAKABAYASHI Maki, TANAKA Masatsugu, YAMAJI Satoshi, TOMITA Naoto, FUJIMAKI Katsumichi, FUJISAWA Shin, WATANABE Shinichiro, MATSUZAKI Michio, ISHIGATSUBO Yoshiaki

    Int J Hematol   77 ( 2 )   180 - 184   2003.2

    　More details

    Language：English  

    CiNii Books

    researchmap

  • Acute Lymphoblastic Leukemia with t(1;9;22)(q32;q34;q11)

    FUJISAWA Shin, KANAMORI Heiwa, TAKABAYASHI Maki, TANAKA Masatsugu, YAMAJI Satoshi, TOMITA Naoto, FUJIMAKI Katsumichi, ISHIGATSUBO Yoshiaki

    75 ( 4 )   443 - 445   2002.5

    　More details

    Language：English  

    CiNii Books

    researchmap

  • Posttransplantation Epstein-Barr Viral Meningitis in a Patient With Chronic Myelogenous Leukemia

    KANAMORI Heiwa, FUJISAWA Shin, YAMAJI Satoshi, TANAKA Masatsugu, TOMITA Naoto, FUJIMAKI Katsumichi, ISHIGATSUBO Yoshiaki

    74 ( 4 )   473 - 474   2001.12

    　More details

    Language：English  

    CiNii Books

    researchmap

  • Feasibility of early tapering and discontinuation of cyclosporine to intensify the graft-versus-leukemia effect in patients with advanced hematologic neoplasms

    FUJIMAKI Katsumichi, FUJISAWA Shin, AOTSUKA Nobuyuki, SAITO Kenji, KANAMORI Heiwa, MATSUZAKI Michio, TAKAHASHI Satoshi, OKAMOTO Shinichiro, SAKAMAKI Hisashi, MARUTA Atsuo

    42 ( 9 )   680 - 684   2001.9

    　More details

  • Successful second transplant from one-locus HLA-mismatched unrelated donor for graft rejection following initial transplant from another unrelated donor in patient with chronic myelogenous leukemia

    TANAKA Masatsugu, KANAMORI Heiwa, KUWABARA Hideyuki, YAMAJI Satoshi, KAMIJO Aki, TAGUCHI Jun, FUJITA Hiroyuki, FUJISAWA Shin, MATSUZAKI Michio, MOHRI Hiroshi, ISHIGATSUBO Yoshiaki

    42 ( 8 )   656 - 658   2001.8

    　More details

  • Sequential analysis of p210 - and p190 - bcr - abl by RT - PCR after allogeneic bone marrow transplantation for p210/p190 - bcr - abl double positive acute lymphoblastic leukemia

    FUJIMAKI Katsumichi, MARUTA Atsuo, YOSHIDA Michihiko, YAMAZAKI Etsuko, MOTOMURA Shigeki, KODAMA Fumio, MATSUZAKI Michio, FUJISAWA Shin, KANAMORI Heiwa, ISHIGATSUBO Yoshiaki

    42 ( 2 )   89 - 93   2001.2

    　More details

    Language：Japanese  

    CiNii Books

    researchmap

  • Follow-up of Residual BCR-ABL Transcripts and Clinical Details in Patients with Chronic Myelogenous Leukemia after Allogeneic Bone Marrow Transplantation

    KOHARAZAWA Hideyuki, MARUTA Atsuo, TANABE Juichi, OKAMOTO Naoyuki, FUJITA Hiroyuki, FUJISAWA Shin, KANAMORI Heiwa, MOTOMURA Shigeki, MOHRI Hiroshi, ISHIGATSUBO Yoshiaki

    35 ( 2 )   65 - 74   2000.4

    　More details

    Language：Japanese  

    CiNii Books

    researchmap

  • Identification of breakpoint cluster regions at 1p36.3 and 3q21 in hematologic malignancies with t(1;3)(p36;q21)

    Seiichi Shimizu, Kazumi Suzukawa, Takao Kodera, Toshiro Nagasawa, Tsukasa Abe, Masafumi Taniwaki, Fumiharu Yagasaki, Hideo Tanaka, Shin Fujisawa, Bertil Johansson, Tomas Ahlgren, Jun Yokota, Kazuhiro Morishita

    Genes Chromosomes and Cancer   27 ( 3 )   229 - 238   2000.3

    　More details

  • Pulmonary Function after Allogeneic Hematopoietic Stem Cell Transplantation

    FUJIMAKI Katsumichi, MARUTA Atsuo, TANABE Juichi, HASHIMOTO Chizuko, KODAMA Fumio, NOMURA Ikuo, MATSUZAKI Michio, FUJISAWA Shin, KANAMORI Heiwa, MOTOMURA Shigeki, ISHIGATSUBO Yoshiaki

    40 ( 12 )   1245 - 1251   1999.12

    　More details

  • Chronic myelocytic leukemia following ulcerative colitis

    FUJISAWA Shin, MOTOMURA Shigeki, FUJIMAKI Katsumichi, MOHRI Hiroshi, OKUBO Takao

    63 ( 3 )   241 - 242   1996.4

    　More details

    Language：English  

    CiNii Books

    researchmap

  • Low-Grade Non-Hodgkin's Lymphoma: Intensive Combined Chemotherapy

    HATTORI Michiko, MOTOMURA Shigeki, TOMITA Naoto, TAGUCHI Jun, TANABE Juichi, SAKAI Rika, FUJISAWA Shin, FUKAWA Hitoshi, KANAMORI Heiwa, MOURI Hiroshi, MARUTA Atsuo, KODAMA Fumio, OKUBO Takao

    37 ( 2 )   101 - 108   1996.2

    　More details

  • Ganciclovir Prophlaxis for Cytomegalovirus Interstitial Pneumonitis after Allogeneic Bone Marrow Transplantation

    SAKAI Rika, MARUTA Atsuo, TAGUCHI Jun, TOMITA Naoto, FUJITA Hiroyuki, KODAMA Fumio, OGAWA Kouji, FUJISAWA Shin, MATSUZAKI Michio, MOTOMURA Shigeki, OKUBO Takao

    37 ( 1 )   14 - 21   1996.1

    　More details

  • Treatment for Elderly Patients with Acute Non-Lymphocytic Leukemia

    FUJISAWA Shin, MARUTA Atsuo, OGAWA Koji, SAKAI Rika, TAGUCHI Jun, TOMITA Naoto, KODAMA Fumio, SASAKI Shin, FUKAWA Hitoshi, MURATA Takashi, HASHIMOTO Yoshimi, HARANO Hiroshi, KATO Haruko, NOGUCHI Tahei, KANAMORI Heiwa, MIYASHITA Hiroko, MATSUZAKI Michio, MOTOMURA Shigeki, MOHRI Hiroshi, OKUBO Takao

    36 ( 2 )   91 - 97   1995.2

    　More details

  • Hypoplastic Leukemia Achieved Long-Term Remission with Low-Dose Cytosine Arabinoside

    FUJISAWA Shin, KANAMORI Heiwa, NOGUCHI Tahei, MARUTA Atsuo, OGAWA Koji, SAKAI Rika, TAGUCHI Jun, TOMITA Naoto, KODAMA Fumio, OOKUBO Takao

    36 ( 1 )   56 - 58   1995.1

    　More details

    Language：Japanese  

    CiNii Books

    researchmap

▼display all